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ABSTRACT 
The role of clinical pharmacy in the treatment of hypertension in Kuwait. 
 
The thesis investigated nicotine levels and their effects on hypertensive subjects and whether 
aspirin could be used in the treatment of hypertension to bring about not only an anti thrombotic effect 
but reduce the systemic blood pressure especially in those individuals who smoke cigarettes. The study, 
which also audits the use of aspirin, was conducted in Kuwait and so provides an insight of  hypertensive 
patients very rarely considered in the literature 
The thesis begins in Chapter One with an extensive literature review which analyses the 
properties and problems that nicotine causes and its ability to cause hypertensive changes along with its 
multitude of other events. The physiological and pathological problems caused by nicotine are reviewed 
on the basis of its chemistry and pharmacological properties using a worldwide perspective rather than 
just focus on Kuwait.  
The second Chapter uses extensive analysis of the literature to determine the pharmacological 
properties of aspirin and its use in cardiovascular disease. The pharmacokinetics and therapeutic effects 
are presented with emphasis to its inhibitory effects on platelet activation which is central to the 
development of serious cardiovascular consequences such as stroke and myocardial infarction. 
The third Chapter returns to consider the literature in detail and why nicotine has specific effects 
on the cardiovascular system in terms of receptor stimulation and how aspirin may be able to reduce 
nicotine‟s cardiovascular effects and concludes with the Aims and Objectives of the thesis. 
The fourth Chapter investigates urinary nicotine levels in smokers from cigarettes available in 
Kuwait to indicate the actual levels which could be achieved by smokers in this study. This established 
that the levels would cause pharmacological effects demonstrating also the effects of passive smoking. 
The number of cigarettes smoked per day has an unpredictable effect on metabolism and urinary output of 
nicotine. 
The fifth Chapter is the major investigational section of the thesis and considers if aspirin ability 
to reduce cardiovascular effects, may be useful in terms of diastolic blood pressure and lipid levels in the 
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blood. The effects were suggestive that aspirin did reduce the blood pressure in hypertensive subjects but 
was not universal and was limited to those suffering from mild - moderate hypertension. It was 
determined that aspirin should be sued at the earliest age possible in these patients. 
The sixth Chapter involved a large scale trial of the effectiveness of aspirin treatment in 
hypertensive patients over a one year period in Kuwait. This used ambulatory blood pressure 
measurements to determine the effectiveness of daytime and nightime changes in blood pressure in 
patients with and without aspirin treatment. The overall conclusion was a reduced relative risk of 
suffering cardiovascular events in mild to moderate hypertension when aspirin (75mg/day) was 
administered. Specifically in smokers, aspirin lowers the systolic daytime BP and diastolic nightime BP.  
To support this work a comprehensive audit is provided of the use of the current use of aspirin 
in Kuwait hospitals  
 
Key words: Kuwait, hospital pharmacy, treatment strategies for hypertension, aspirin, 
smoking, nicotine, blood pressure 
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Chapter One 
Literature review part 1 - nicotine, its chemistry, metabolism and 
pharmacological effects with reference to Kuwait. 
1.0 Introduction  
This study was carried out in the hospitals of Kuwait where the problems of 
cigarettes and cardiovascular disease are seen every day. The structure of the health care 
system has developed over the years and a central feature of the system are the primary 
health centres (PHC) which patients attend on the first signs of any disease. In Kuwait 
cardiovascular diseases are a common presenting factor. The role of clinical pharmacy in 
such settings is in its infancy and as yet has not really made an impact on patient care. The 
topic of cigarettes causing health problems is one that could be addressed by clinical 
pharmacy as smoking cessation has been very successful elsewhere in the world especially 
in the UK where it has become a major role of community pharmacists in promoting and 
helping people to overcome this addictive practice. The strategy was developed by 
National Institute for Health and Clinical Excellence (NICE, 2008) and has produced some 
major reductions in the number of people smoking in the UK. The strategy was entitled 
„Smoking cessation services in primary care, pharmacies, local authorities and 
workplaces, particularly for manual working groups, pregnant women and hard to reach 
communities‟. The role of the community pharmacist was paramount in implementing this 
system. The reduction in smoking of course reduces one of the risk factors for 
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cardiovascular disease which will of course have consequences for both the individual and 
the health care system of the country, for the purposes of this thesis, Kuwait. So what is 
the present structure of Kuwait‟s health care system? 
Kuwait has 77 of these primary health centres (PHCs), staffed by 4 PHC physicians 
for each 10, 000 of the population. Each PHC has a nursing staff which number, between 4 
and 6 for each centre. When a patient is first diagnosed with hypertension a file is started 
which is added to over the years as the disease develops and is treated.  This means that 
every hypertension patient has an accurate and „complete‟ medical file which documents 
the progression of their condition and most importantly the drugs which have been 
prescribed for the condition for example aspirin. In addition to the hypertension treatment 
some of these PHC centres also have obesity clinics which give advice and possibly 
treatment for this condition.  
All hypertensive patients are provided with treatment cards and educational 
material to try and encourage the patient to change their lifestyle and behaviour. Such 
changes are very necessary because the prevalence of cardiovascular disease is the leading 
cause of death in Kuwait followed by motor vehicle and domestic accidents, neoplasms 
and diabetes mellitus (Al-Otaibi et al., 2008). This is shown by a newspaper article in the 
Kuwait Times for the 28
th
 August 2007 (Anon, 2007) which read: 
Heart disease 'main killer' in Kuwait 
KUWAIT: According to a recent study made by the Ministry of Health on the causes of deaths 
in Kuwait, the three main 'killers' which were detected in 2006 are still the three main killers 
for 2007 as well. 
 
In reference to the study, heart disease was the prime cause of deaths in Kuwait wherein the 
study states that 1,497 men and women have died due to heart diseases in 2006 with an 
increase of 100 compared to 2005. 
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The second killer was cancer diseases that were responsible for 677 deaths in 2006 including 
citizens and expatriates. 
 
The third killer, according to the study, was road accidents where 482 were killed in 2006 with 
an increase of 30 people compared to 2005. Notably, Kuwait has a high rating among 
countries with high traffic related deaths worldwide. 
 
Hypertension is generally thought to affect 7% of the population with a significant 
relationship to body mass index (BMI), physical inactivity and smoking. The mortality rate 
from cardiovascular diseases is 6.6% of total deaths suffered in Kuwait. 
It is a truism which is attributed to smokers that once they start smoking they are 
badly addicted to nicotine (Chapman, 1995).This form of addiction is extremely complex 
and in order to help such people in their circumstances it is very important to know about 
the factors which make them addicted, to the pharmacologically active agents contained 
within tobacco smoke. The pharmacological effects of smoking are multiple but one major 
consequence is to increase their blood pressure. This increase can cause changes in the 
cardiovascular system (CVS) and the central nervous system (CNS) both of which have 
serious consequences (Benowitz, 2008). 
The consequences of inhalation of cigarettes or in some cases chewing tobacco 
products are multiple. A summary of all the reported cardiovascular effects are shown in 
Table 1 and its effects on other physiological systems are given in Appendix 1. 
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Table 1.  Reported cardiovascular effects of tobacco products in both men and women 
(Placezek et al., 2004). 
Cardiovascular 
diseases 
  
Abdominal aortic 
aneurysm 
"Death more common in cigarette smokers."  
"The evidence is sufficient 
to infer a causal relationship 
between smoking and 
abdominal aortic 
aneurysm." 
 
Atherosclerosis 
 
"Smoking the most common factor to atherosclerotic 
peripheral vascular disease."  
 
"The evidence is sufficient 
to infer a causal relationship 
between smoking and 
subclinical atherosclerosis." 
Cerebrovascular 
disease 
"Smoking is a major cause of cerebrovascular disease 
(stroke)."  
 
"The evidence is sufficient 
to infer a causal relationship 
between smoking and 
stroke." 
Coronary heart 
disease 
"Smoking is cause coronary heart disease." 
 
"The evidence is sufficient 
to infer a causal relationship 
between smoking and 
coronary heart disease." 
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1.01 Literature Review - History of Nicotine. 
The use of tobacco began with the native people of North and South America. 
Early Europeans visiting the New World observed Native Americans smoking cigars and 
chewing tobacco. When introduced by the Spanish to Europe in the early 1500s, tobacco 
was thought to hold medicinal properties (Orsinii, 2001). For example, smoke was blown 
into all openings of the head to treat diseases of the ear, eyes, nose, and mouth. In fact, the 
tobacco plant was named Nicotiana tabacum in honor of Jean Nicot, who promoted it use 
for its medicinal values. In 1828, two French scientists isolated nicotine as being the active 
ingredient in tobacco (Jain et al., 2003).  
Nicotine, at low to moderate doses, is a central nervous system stimulant. Effects 
include tremors, an increase in behavioural activity, increased alertness, and facilitation of 
memory and release of epinephrine from the adrenal glands (Rusted et al., 1994) In 
addition to these central effects of nicotine, increasing heart rate and blood pressure, it 
inhibits stomach secretions and stimulates bowel activity. At high doses nicotine produces 
convulsions and death. Low dose stimulation of the central nervous system is followed by 
depression at high doses, and death results from failure of respiration due to paralysis of 
muscles involved in breathing (Einstein et al., 1989). 
Chronic use of nicotine leads to changes in the brain and behavior. One of the first 
changes is tolerance, a decrease in the stimulatory effects of nicotine. Tolerance occurs 
rapidly and produces some of the unpleasant effects, including dizziness, nausea and 
vomiting. At low to moderate doses, because nicotine is a cholinergic agonist, it acts by 
stimulating nicotinic acetylcholine receptors. In fact, as the name suggests, nicotinic 
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receptors were named after the drug as it was found that they were selectively and potently 
activated by nicotine (Guillem et al., 2005). 
Nicotine can be absorbed through most of the body's membranes. After nicotine is 
absorbed it is distributed by the blood to a number of sites of pharmacological action. The 
effects of nicotine are observed rapidly, with its distribution half-life is only eight minutes 
it can have a rapid and acute effect (Swan, 1998). 
Of all the many complex constituents of tobacco it is generally assumed that 
nicotine has potentially the most significantly pharmacological effects in man. If a 
consideration is made of nicotine‟s effects then perhaps it provides an explanatory basis on 
which to consider the effect of cigarette use on an individual‟s health. 
Nicotine is considered to be involved in increasing systemic blood pressure of 
smokers. By analyzing the levels of nicotine in detail medicine is in a better position to 
consider the claims made about the various actions of nicotine in the body (Siegmund et 
al., 2008). A major problem exists, if a person's addiction to the nicotine in cigarettes is 
impossible to stop, as may be the case for many individuals (Martin, 2008), and this 
problem centers around the cardiovascular system, see Table 1 (see also Appendix 1 for a 
more comprehensive range of other effects on the body). One major problem is reported to 
be the increase in thrombosis risk in people who smoke. This risk could be due to an 
increase in the development of atherosclerosis, This condition makes the platelets more 
likely to adhere to the endothelium or for more complex reasons which are grouped 
together known as the "atherogenic potential" (Weisberg, 2000; Brain, 2010). 
Consequently, one approach is to target the ''adhesiveness'' or adherence potential of 
platelets by using the drug acetylsalicylic acid (aspirin). The use of this drug is central to 
this thesis. 
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One of the most important uses of aspirin is the reduction in the ability of platelets 
to be activated and so prevent platelet aggregation, this effect can have the property of 
inhibiting aggregates forming (Smith and Willis, 1971) and so prevent the consequences of 
these aggregates breaking up which may result in the formation of thrombus which block 
vessels and so cause embolism classically in lungs. 
In this thesis it will only be the effects of nicotine in cigarette smoke which are 
considered. When cigarette smoke is inhaled the constituents of the smoke are capable of 
being absorbed through the vascularity of any of the mucous membranes of the mouth, 
nose, pharynx or lung. This drug absorption is reported to be rapid and some studies have 
found nicotine in the blood stream within 6-10 seconds of inhalation (Julia, 1991; Lunell et 
al., 2000). Once in the bloodstream, since it is not plasma bound, its effects can be very 
rapid and of course widespread throughout the CVS. 
One important contributory effect within the CVS is to stimulate nicotinic receptors in 
the adrenal medulla. This stimulation causes the rapid release and passage into the adrenal 
blood vessels of both adrenaline and noradrenaline and these agents when in the systemic 
circulation stimulate both α1 and β1 receptors  found on the smooth muscle of the 
heart/blood vessels resulting in both an increase in heart rate and peripheral resistance. 
This double effect will of course raise the systemic blood pressure by increasing both 
contributory factors in the fundamental equation concerning blood pressure, namely: 
BP= cardiac output × peripheral resistance 
This equation shows that if one of the factors of cardiac output is heart rate then an 
increase in β1 receptors stimulation will change this factor in the equation. The peripheral 
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resistance is of course due to the tone of the vascular smooth muscle and if this changes in 
addition to cardiac output the change in blood pressure will be substantial. 
 
1.02 Why should nicotine have such a profound and rapid pharmacological effect?      
Nicotine normally makes up about 5 % of a tobacco plant by weight. Cigarettes 
usually contain between 8 to 20 milligrams (mg) of nicotine, the variation being dependent 
upon the brand.  Of this variable quantity, on average, approximately 1 mg is actually 
absorbed into the body when someone smokes a single cigarette (Gamborne, 2007). Once 
in the bloodstream, nicotine flows almost immediately to the brain. Although nicotine has 
multiple actions throughout body (see Table 1 and see Appendix 1), what it produces in 
the brain is responsible for both the good feelings an individual gets  from smoking, as 
well as the irritability a smoker gets when trying to quit. Within 10 to 15 seconds of 
inhaling, most smokers are in the '' throes of nicotine's effects'' (Siegmund et al., 2008). 
The plasma half life of nicotine in the human body is, as compared with many other 
drugs, relatively brief and it has a half-life of about 60 minutes. However due to repetitive  
smoking of cigarettes the half life effect is more complex than when therapeutic drugs are 
taken and there is of course the urge to smoke due to the cravings it induces in the 
individual and so the plasma concentrations can be kept at a higher level than would be the 
case for therapeutic drugs.  During its presence it is of course capable of undergoing 
metabolism (see Figure 1). This metabolism occurs in the liver and results in metabolites 
which have a longer half than nicotine but they have no pharmacological action. 
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Figure 1. Primary pathways of (S)-nicotine metabolism to (S)-cotinine and cis- and trans-
nicotine-1′-N-oxide in humans Liver (source: Kyerematen, 1991). 
Six hours after smoking of a single cigarette, only about 31 micrograms of the 1 
mg of nicotine inhaled remains in body (Grunenberg, 1994). The elimination half-life of 
nicotine averages 2 hours. The half-life of a drug is very useful in determining the rate of 
accumulation of that drug in the body but of course is made more complicated due to the  
repetitive ''puffing''  and the number of cigarettes smoked  both of which modify the time 
course of decline of plasma levels after the cessation of a period of smoking. Consistent 
with a half-life of 2 hours, an accumulation of nicotine over 6 to 8 hours during regular 
smoking and a persistence of significant levels of nicotine in the blood for 6 to 8 hours  
overnight after cessation of smoking have all been observed ( Benowitz, 1996). 
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Consequently, cigarette smoking represents a situation where the smoker is 
exposed to significant concentrations and possibly the pharmacological effects of nicotine 
for 24 hours a day. It has been reported that there is an apparent acute tolerance to nicotine, 
as determined on the basis of observations of the relationship between venous blood levels 
and effects (Benowitz, 1996). This may be due to distribution disequilibrium between 
venous and arterial blood. It has been found that venous blood levels substantially 
underestimate concentrations of nicotine in arterial blood and at potential sites of action 
(Henningfield et al., 1993). 
True tolerance does, however, develop rapidly, with a half-life of development and 
regression of about 35 minutes. The complex kinetics of tolerance may be another 
determinant of cigarette smoking particularly when the smoker smokes his next cigarette 
(Stolerman et al., 1974). 
1.03 The Chemistry of Nicotine.  
The chemical formula for nicotine is C10H14N2, with a molecular mass of 162.23. 
In chemical nomenclature, nicotine is 3-(1-Methyl-2-pyrrolidinyl) pyridine. Nicotine‟s 
structure was deduced by Pinner, and is shown in Figure 2:- 
 
Figure  2. Chemical structure of nicotine (Martindale online, 2011). 
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Nicotine is a hygroscopic, oily liquid that is miscible with water in its base form. 
As a nitrogenous base, nicotine forms salts with acids that are usually solid and water 
soluble. Nicotine easily penetrates the skin as shown by the physical data, and its use in 
nicotine replacement skin applied patches. The free base of nicotine will burn at a 
temperature below its boiling point, and its vapors will combust at 308 K (35 °C; 95 °F) in 
air despite a low vapor pressure. Because of this, most of the nicotine is thermally 
destroyed when a cigarette is smoked; however, enough is inhaled to provide the desired 
effects. The amount of nicotine inhaled with tobacco smoke is a fraction of the original 
amount contained in the tobacco leaves. 
Nicotine is optically active, having two enantiomeric forms. The naturally-
occurring form of nicotine is levorotatory, with (α) D = –166.4°. The dextrorotatory form, 
(+)-nicotine, has only one-half the physiological activity of (–)-nicotine. It is therefore 
weaker in the sense that a higher dose is required to attain the same effects. The salts of 
(+)-nicotine are usually dextrorotatory (William et al., 1984). 
The amount of nicotine absorbed by the body from smoking depends on many 
factors, including the type of tobacco, whether the smoke is inhaled, and whether a filter is 
used. For chewing tobacco, dipping tobacco and snuff, which are held in the mouth 
between the lip and gum, or taken in the nose, the amount released into the body tends to 
be much greater than with smoked tobacco. Nicotine is metabolized in the liver by 
cytochrome P450 enzymes (mostly CYP2A6, and also by CYP2B6). A major metabolite is 
cotinine (see Figure 1). Other primary metabolites include nicotine N'-oxide, nornicotine, 
nicotine isomethonium ion, 2-hydroxynicotine and nicotine glucuronide. Gluconuration 
and oxidative metabolism of nicotine to cotinine are both inhibited by menthol, an additive 
to mentholated cigarettes, thus increasing the half-life of nicotine in vivo. Cotinine is a 
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byproduct of the metabolism of nicotine which remains in the blood for up to 48 hours. It 
can therefore be used as an indicator of a person's exposure to nicotine (Donald et al., 
2007). 
Additionally considering its function within the plant, nicotine is an alkaloid found 
in the nightshade family of plants (Solanaceae) where it constitutes approximately 0.6–
3.0% of the dry weight of tobacco. Biosynthesis takes place in the roots and accumulates 
in the leaves. It is thought to function as an antiherbivore chemical with particular 
specificity to insects. Consequently, nicotine was widely used as an insecticide in the past, 
and currently nicotine analogs such as imidacloprid continue to be widely used for such a 
purpose (Siegmund et al., 2008). 
1.04 Various actions of nicotine. 
In low concentrations (an average cigarette yields about 1 mg of absorbed 
nicotine), the substance acts as a stimulant in mammals and is the main factor responsible 
for the dependence-forming properties of tobacco smoking. According to the American 
Heart Association   "nicotine addiction has historically been one of the hardest addictions 
to break". The pharmacological and behavioral characteristics that determine tobacco 
addiction are similar to those that determine addiction to drugs such as heroin and cocaine. 
Against this background it is very surprising to read that the nicotine content in cigarettes 
has actually slowly increased over the years, and one study found that there was an 
average increase of 1.6% per year between the years of 1998 and 2005. This was found for 
all major market categories of cigarettes. The detrimental consequences for the average 
smoker can easily be appreciated. 
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As nicotine enters the body, it is distributed quickly through the bloodstream and 
can cross the blood-brain barrier. On average it takes about seven seconds for the 
substance to reach the brain when inhaled the half life of nicotine in the body is around 
two hours (Benowitz et al., 1983).  
As mentioned above, nicotine acts on the nicotinic acetylcholine receptors, 
specifically the ganglion type nicotinic receptor and one CNS nicotinic receptor. The 
former is present in the adrenal medulla and elsewhere, while the latter is present in the 
central nervous system (CNS). In small concentrations, nicotine increases the activity of 
these receptors. Nicotine also has effects on a variety of other neurotransmitters through 
less direct mechanisms (Villegier et al., 2003). By binding to nicotinic acetylcholine 
receptors, nicotine increases the levels of several neurotransmitters - acting as a sort of 
"volume control". It is thought that increased levels of dopamine in the reward circuits of 
the brain are responsible for the euphoria and relaxation and eventual addiction caused by 
nicotine consumption (Nguyen et al., 2003; Pons et al., 2008). A single amino-acid 
difference between brain and skeletal muscle acetylcholine receptors explains why 
nicotine activates the CNS but does not activate skeletal muscles and cause „instant death‟. 
Nicotine addiction is therefore a biological oddity and has some strange effects. 
A further complication is that tobacco smoke contains the monoamine oxidase 
inhibitors (MAOIs) harman, norharman, anabasine, anatabine, and nornicotine. These 
compounds significantly decrease MAO activity in smokers.  MAO enzymes break down 
monoaminergic neurotransmitters such as dopamine, norepinephrine, and serotonin, so its 
inhibition will result in the epinephrine release by adrenal medulla having an even greatest 
effect. 
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Chronic nicotine exposure via tobacco smoking up-regulates alpha4 beta2  nAChR 
in cerebellum and brainstem regions but not habenulopeduncular structures Alpha4 beta2 
and alpha6beta2 receptors,  present in the ventral tegmental area which play a crucial role 
in mediating the reinforcement effects of nicotine. 
Nicotine also activates the sympathetic nervous system, acting via splanchnic 
nerves to the adrenal medulla, stimulates the release of epinephrine. This stimulates 
receptors, and causes cell depolarization and an influx of calcium through voltage-gated 
calcium channels. Calcium triggers the exocytosis of chromaffin granules and thus the 
release of adrenaline/epinephrine into the bloodstream (Nolley et al., 2006). The release of 
epinephrine causes an increase in heart rate, blood pressure and respiration, as well as 
higher blood glucose levels.  
Acetylcholine released by preganglionic sympathetic fibers of these nerves acts on 
nicotinic acetylcholine receptors, causing the release of epinephrine (and norepinephrine) 
into the bloodstream. Nicotine also has an affinity for melanin-containing tissues due to its 
precursor function in melanin synthesis or the irreversible binding between melanin and 
nicotine and this has been suggested to underlie the increased nicotine dependence and 
lower smoking cessation rates in darker pigmented individuals (King et al., 2009).  
Nicotine's mood-altering effects are said to be brought about by complex series of 
actions. It is both a stimulant and a relaxant. First causing a release of glucose from the 
liver and adrenaline from the adrenal medulla, it causes stimulation, of smokers and they 
report feelings of relaxation, sharpness, calmness, and alertness. By reducing the appetite 
and raising the metabolism, some smokers may lose weight as a consequence.  
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When a cigarette is smoked, nicotine-rich blood passes from the lungs to the brain 
within few seconds and immediately stimulates the release of many chemical messengers 
including acetylcholine, norepinephrine, epinephrine, vasopressin, arginine, dopamine, 
autocrine agents, and beta-endorphin. This release of neurotransmitters and hormones is 
responsible for most of nicotine's effects. Nicotine appears to enhance concentration and 
memory due to the increase of acetylcholine. It also appears to enhance alertness due to the 
increases of acetylcholine and norepinephrine. Arousal is increased by the increase of 
norepinephrine. Pain is reduced by the increases of acetylcholine and beta-endorphin 
(Einstein et al., 1989; Margaret, 2004). Anxiety is reduced by the increase of beta-
endorphin. Nicotine also extends the duration of positive effects of dopamine and increases 
sensitivity in brain reward systems. Most cigarettes (in the smoke inhaled) contain 0.1 to 
2.8 milligrams of nicotine.  
Research by Stolerman et al., (1995) suggests that, when smokers wish to achieve a 
stimulating effect, they take short quick puffs, which produce a low level of blood 
nicotine. This stimulates nerve transmission. When they wish to relax, they take deep 
puffs, which produce a high level of blood nicotine, which depresses the passage of nerve 
impulses, producing a mild sedative effect. At low doses, nicotine potently enhances the 
actions of norepinephrine and dopamine in the brain, causing a drug effect typical of those 
of psychostimulants. At higher doses, nicotine enhances the effect of serotonin and opiate 
activity, producing a calming, pain-killing effect. Nicotine is unique in comparison to most 
other drugs, as its profile changes from stimulant to sedative/pain killer in increasing 
dosages and use. Technically, nicotine is not significantly addictive, as nicotine 
administered alone does not produce significant reinforcing properties. However, only 
after co-administration with an MAOI, such as those found in tobacco, as discussed 
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previously, nicotine produces significant behavioural sensitization, a measure of addiction 
potential. This is similar in effect to amphetamine (Okamoto et al., 1994). 
Other research by Bevins and Caggiula, in 1992, showed that nicotine acts on the 
brain to produce a number of effects. Specifically, its addictive nature has been found to 
show that nicotine activates reward pathways - the circuitry within the brain that regulates 
feelings of pleasure and euphoria. Dopamine is one of the key neurotransmitters actively 
involved in the brain, by increasing the levels of dopamine within the reward circuits in the 
brain, nicotine acts as a chemical with intense addictive qualities. In many studies it has 
been shown to be more addictive than cocaine and heroin, though chronic treatment has an 
opposite effect on reward thresholds. Like other physically addictive drugs, nicotine causes 
down-regulation of the production of dopamine and other stimulatory neurotransmitters as 
the brain attempts to compensate for artificial stimulation (Andrew et al., 2004). In 
addition, the sensitivity of nicotinic acetylcholine receptors decreases. To compensate for 
this compensatory mechanism, the brain in turn up regulates the number of receptors, 
convoluting its regulatory effects with compensatory mechanisms meant to counteract 
other compensatory mechanisms. The net effect is an increase in reward pathway 
sensitivity, opposite of other drugs of abuse such as cocaine and heroin, which reduce 
reward pathway sensitivity. This neuronal brain alteration persists for months after 
administration ceases (Nestler et al., 1998). 
  Due to an increase in the reward pathway sensitivity, nicotine withdrawal is said to 
be relatively mild as compared to alcohol or heroin withdrawal. Man is not unique to its 
effects as nicotine also has the potential to cause dependence in many animals such as 
mice where the animals administered nicotine exhibit withdrawal reactions when its 
administration is stopped (Benowitz et al., 1998). Another study in mice found that 
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nicotine exposure in adolescent mice retarded the growth of the dopamine system, thus 
increasing the risk of substance abuse during adolescence (Smith, 2003). 
1.05 Toxicity of nicotine. 
The LD50 of nicotine is 50 mg/kg for rats and 3 mg/kg for mice. In contrast 40–
60 mg (0.5-1.0 mg/kg) can be a lethal dosage for adult humans. Nicotine therefore has a 
higher toxicity in comparison to many other alkaloids such as cocaine, which has an LD50 
of 95.1 mg/kg when administered to mice. It is impossible however to overdose on 
nicotine through smoking alone, though a person can overdose on nicotine through a 
combination of nicotine patches, nicotine gum, and/or tobacco smoking at the same time. 
Applying an extremely high concentration of nicotine onto the skin can result in 
intoxication or even death since nicotine readily passes into the bloodstream from dermal 
contact, via the process of transdermal diffusion.  
The carcinogenic properties of nicotine by itself as compared to when present in 
tobacco smoke, have not been evaluated by the IARC (International Agency Research on 
Cancer), and it has not been assigned to an official carcinogen group. The currently 
available literature indicates that nicotine, on its own, does not promote the development 
of cancer in healthy tissue and has no mutagenic properties. However, nicotine and the 
increased cholinergic activity it causes have been shown to impede apoptosis, which is one 
of the methods by which the body destroys unwanted cells (programmed cell death). Since 
apoptosis helps to remove mutated or damaged cells that may eventually become 
cancerous, the inhibitory actions of nicotine may create a more favorable environment for 
cancer to develop, though this also remains to be proven (Cohen et al., 2001).   
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The teratogenic properties of nicotine have not yet been adequately researched, and 
while the likelihood of birth defects caused by nicotine is believed to be very small or 
nonexistent, nicotine replacement product manufacturers recommend consultation with a 
physician before using a nicotine patch or nicotine gum while pregnant or nursing. 
However women who use nicotine gum (see below) and patches during the early stages of 
pregnancy face an increased risk of having babies with birth defects, as was reported in a 
study that looked at 77,000 pregnant women in Denmark (Wisburg et al., 2000).  The 
study found that women who used nicotine-replacement therapy in the first 12 weeks of 
pregnancy had a 60 percent greater risk of having babies with birth defects, as compared to 
women who were non-smokers. The controversial findings were published in the 
authoritative Journal Obstetrics and Gynecology in 2000 (Wisborg et al., 2000). 
 As an alternative to smoking, many products are available (see Table 2, page 33) 
and of these perhaps nicotine gum which is the most popular is available in 2-mg or 4-mg 
„doses‟. As an alternative, nicotine patches are available which slowly release, 7mg /24 
hours (NiQuitin), 7mg /24 hours (Nicopatch), 5mg /16 hours (Nicorette). „Smokeless 
tobacco‟ is also available which lacks all the other ingredients in smoked tobacco. 
1.06 Metabolism of nicotine and its physiological effects. 
Chemically nicotine is a tertiary amine which consists of a pyridine and a 
pyrrolidine ring (see Figure 1& 2). Nicotine is subjected to a large first pass effect during 
which 80-90% is metabolized. To a lesser extent, the lung is also able to transform it.  The 
major metabolic product of nicotine, which is also pharmacologically active, is cotinine 
(see Figure1). Nicotine-1'-N-oxide is also produced but is a minor metabolite.  Cotinine is 
also rapidly metabolized into trans-3'-hydroxy-cotinine which becomes a major metabolite. 
Consequently, the most commonly found metabolite of nicotine in the blood is trans-3'-
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hydroxy-cotinine, which accounts for almost 40% of the nicotine absorbed from the 
cigarettes , whereas cotinine itself accounts for only about 15% of the quantity of nicotine 
absorbed in smoking. Surprisingly, the levels of cotinine found in various biological fluids 
are used to estimate the total absorption of nicotine in tobacco users. The usefulness of 
cotinine as a quantitative marker of nicotine intake is limited because of an individual‟s 
variability in the percentage conversion of nicotine to cotinine and in the actual rate of 
elimination of cotinine itself. The alternative measurement, because it accounts for a much 
greater percentage of nicotine, would be to measure the levels of trans-3'-hydroxycotinine 
measurement, either alone or in combination with measurement of other metabolites, as it 
is considered to be a better quantitative indicative of nicotine intake but this has only been 
carried out in recent times and the literature usually uses the older methods of assessment 
(Henningfield et al., 2009).  
The elimination of the absorbed Nicotine and its metabolites (cotinine and nicotine 
1-N-oxide) is usually by passage into the urine. At a pH of 5.5 or less, 23% is excreted 
unchanged in the urine. At a pH of 8, only 2% of nicotine and its metabolites are excreted 
in the urine. Consequently, the urinary pH is very important for excretion, as variations in 
property will modify renal clearance.  Nicotine is also secreted into other body fluids, for 
example, saliva. The saliva containing the secreted nicotine passes into the stomach, 
combined with the „trapping of nicotine‟ in the acidic gastric fluid and re-absorption from 
the small intestine, provides a major route for enteric nicotine recirculation. This 
recirculation of nicotine also accounts for the some of the fluctuations in the final decline 
phase of nicotine blood levels after intravenous nicotine infusion or cessation of smoking.         
The ability of nicotine to enter any body fluid is shown by the finding that nicotine 
almost freely crosses over the placental membranes and has been found in both the 
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amniotic fluid and the umbilical cord blood of neonates in mothers who smoke. Nicotine is 
also found in breast milk (Ilett et al, 2003) and even in the breast fluid of non- lactating 
women. It has also been found in cervical mucus secretions clearly demonstrating that 
nicotine does in fact go into every type of body fluid. 
As has been explained above, about 80% of nicotine is metabolised to cotinine by 
liver enzymes. Perhaps surprisingly, nicotine is also metabolized in the lung where it is 
transformed into cotinine and nicotine oxide. Whatever the source of their production, 
Cotinine and other metabolites are excreted in urine. Cotinine has a 24-hour half-life, 
which is greater than the nicotine's half life, so quite usefully it can be tested for to 
determine whether or not someone has been smoking in the past day or two by screening 
his or her urine for cotinine. The remaining un-metabolized nicotine is filtered from the 
blood by kidneys and excreted in the urine. 
Nicotine, because it is a normal constituent of plants has also been found in other 
species and genus of plants. For example, nicotine has also been determined in several 
frequently consumed vegetables from the family Solanaceae i.e., tomatoes, potatoes, 
aubergines, and peppers, as well as in some of their processed products. The edible 
Solanaceae fruits analyzed in a reported study investigation were found to contain 
relatively consistent amounts of nicotine in the range of 2 -7 μg/kg for fresh fruits 
(Siegmund et al., 1999). 
However, these levels are not constant as the nicotine concentrations of the 
investigated tomato varieties decreased significantly with increasing degree of ripening of 
the fruits. Another comparison which has been made of nicotine content is between 
varieties of black tea as compared to green teas. Conflicting results are found in the 
literature concerning nicotine concentrations in black tea (Sheen, 1988; Davis et al., 1991; 
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Domino et al., 1993). Concentrations that were found in the dry tea leaves were said by 
Siegmund et al., (1999) to be surprisingly high, ranging from 163 to 1600 μg kg-1. Large 
variations were found within the types of black tea, whereas the concentrations were more 
or less consistent within the green teas. For an estimation of the dietary nicotine intake 
from tea, the nicotine concentration of the tea leaves is less relevant than that in brewed 
tea. The results showed that nicotine was not efficiently extracted by conventional brewing 
techniques. Even tea with very high nicotine concentrations in the leaves did not show 
high amounts in the brewed tea. If detectable, the extraction yield was in a range of 
20−25%. Perhaps surprisingly, the nicotine content in tea leaves, although it was found to 
be highly variable, was sometimes much larger than in the Solanaceae fruits. But since 
 Davis et al. (1991) found nicotine in some tea samples, reporting rather high nicotine 
concentrations in brewed tea (mean 69 μg L-1) and Domino et al. (1993) failed to detect 
any nicotine in tea the topic stills remains controversial. 
On the basis of the observed concentrations and the respective food consumption 
data for different countries, a distributive analysis of the results suggests that the mean 
daily dietary nicotine intake for the population of the countries for which consumption data 
were available was approximately 1.4 μg / day, 2.25 μg / day at the 95th percentile 
(Tyroller et al., 2000; Zulickenpflug et al., 2006). 
The problem is made more difficult to study since different people metabolize 
nicotine at different rates. Some people even have a genetic defect in the enzymes in their 
liver which are responsible for quick metabolism of nicotine, whereby the mutant enzyme 
is much less effective at metabolizing nicotine than the normal variant. If a person has this 
gene, their blood and brain nicotine levels stay higher for longer after smoking a cigarette. 
Normally, people keep smoking cigarettes throughout the day to maintain a steady level of 
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nicotine in their bodies. Nicotine changes how your brain and your body function. The net 
results are somewhat of a paradox. Nicotine can both invigorate and relax a smoker, 
depending on how much and how often they smoke. Nicotine initially causes a rapid 
release of adrenaline, the "fight-or-flight" hormone and this has multiple actions 
(Zulickenpflug  et al., 2006).  For example, adrenaline stimulates the use some of glucose 
which has been stored to be liberated into the blood. This makes sense if we remind our 
self that the "fight-or-flight" response is meant to help us either defend ourselves from a 
hungry predator or escape from a dangerous situation.  Running away or fighting off an 
aggressor requires plenty of energy to supply the skeletal muscles during their stimulation. 
Nicotine itself may also block the release of the hormone insulin. Since insulin 
helps the cells to take up excess glucose from blood, the nicotine can make people 
somewhat hyperglycemic, having more sugar than usual in their blood. Some people think 
that nicotine also reduces their appetite so that they eat less. This hyperglycemia could be 
one possible explanation, as nicotine blocks the release of insulin which is responsible for 
the breakdown of glucose fulfilling the energy requirement of body. This down-regulation 
of the hormones results in excess concentration of glucose in blood (Stefan et al., 2000). 
Nicotine is also considered to increase the catabolic metabolic rate too which 
means to some extent it is also involved in the breakdown of stored glucose which result in 
burning of more calories,  which over time will cause a reduction in bodyweight. This 
aspect of smoking may result in „the burning of calories‟ but this weight reduction is  not 
considered a health benefit of smoking as physical exercise can achieve more, with far less 
risk to the individual.  Nicotine also has an effect on increasing the level of the LDL 
cholesterol, the result of which causes an accumulation of lipid in the arteries and the 
41 
 
development of atherosclerosis. This pathological change is one of the main contributory 
factors for heart attacks or a stroke (Zulickenpflug et al., 2006).  
The brain is the key player in nicotine's action. Like a computer, our brain 
processes, stores and uses information. In a computer, information travels in the form of 
electricity moving through wires; information transfer is a binary process, with switches 
being either "on" or "off." In our brain, neurons are the cells that transfer and integrate 
information. Each neuron has thousands of inputs from other neurons throughout the brain. 
Each of these signals is included in the calculation of whether or not the neuron will pass 
the signal it receives on to other neurons in the pathway. While signals are conducted 
through individual neurons as electric current, communication between neurons is 
mediated by chemical messengers, called neurotransmitters. Neurotransmitters traverse the 
physical space between two neurons and bind to special protein receptors on the 
postsynaptic cell. Once bound, these receptors set in motion physiological changes within 
the neuron that allow it to send the signal on „down the line‟ (Stefan et al., 2000; Xinan et 
al., 2009). 
Each neurotransmitter has its own specific family of receptors. Nicotine acts by 
binding to or antagonizing a subset of receptors that bind the neurotransmitter 
acetylcholine. Acetylcholine is the neurotransmitter that, depending on what region of the 
brain a neuron is in, stimulates a variety of physiological events such as muscle in the heart 
and respiration and plays a major role in learning and memory. 
Due to its stimulatory properties just like acetylcholine, nicotine can lead to a burst 
of receptor activity in the CNS. However, unlike acetylcholine, nicotine stimulation is not 
regulated by the normal feedback regulatory mechanisms. While neurons typically release 
small amounts of acetylcholine in a regulated manner, nicotine can simultaneously activate 
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cholinergic neurons (which mainly use acetylcholine to communicate to other neurons) in 
many different regions throughout the brain this stimulation leads to an increase in the 
release of acetylcholine from the neurons, leading to heightened activity in cholinergic 
pathways throughout the brain. This cholinergic activity is the „wake-up call‟ that many 
smokers use to re-energize themselves at the beginning and throughout the day. Through 
these pathways, nicotine can improve the reaction time and a person‟s ability to be more 
attentive to a task in hand and so makes an individual feel they can work better.   
Stimulation of cholinergic neurons promotes the release of the neurotransmitter 
dopamine in the reward pathways of our brain. This neural circuitry is supposed to 
reinforce behaviors that are essential to our survival, like eating when we are hungry. 
Stimulating neurons in these areas of the brain brings on pleasant, happy feelings that 
encourage us to do these things again and again. When drugs like cocaine or nicotine 
activate the reward pathways, it reinforces a person‟s desire to use them again because it 
produces feelings of „peace and happiness‟ (Xinan et al., 2009). The release of glutamate, 
by nicotine which is a neurotransmitter involved in learning and memory, enhances the 
connections between sets of neurons. These stronger connections may be the physical basis 
of what we know as memory. When we use nicotine, glutamate release may create a 
memory loop of the good feelings we get and further drive the desire to use nicotine. 
Nicotine also increases the level of other neurotransmitters and chemicals that 
modulate how our brain works. For example, our brain makes more endorphins in response 
to nicotine. Endorphins are peptides that are often called the body's „natural pain killer‟. 
The chemical structure of endorphins in terms of receptor stimulation is very similar to 
that of the classical opiate analgesics such as morphine and codeine. Endorphins can lead 
to feelings of euphoria (Stevenson, 1999). 
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As has been described previously, nicotine is a highly addictive substance. The 
effects on our body can last between 40 minutes to a couple of hours (Zulickenpflug et al., 
2006).  It leads smokers to consume more and more cigarettes or other tobacco products so 
as to reach the same degree of relaxation and euphoric state, thus explaining why a smoker 
graduates from a 3 cigarettes per day to smoking one or two packets a day. Quitting 
smoking is easier said than done, as only 10% of those who attempted to become free of 
the habit have succeeded. (http://www.stopsmokingtoday.com/dyn/127/Nicotine-
Withdrawal.html)  
Eventually many return to their old bad habit. For those who have succeeded it is 
said to take one to two months to „clean out „the „systems‟ from nicotine addiction. 
But this time frame is the most excruciating for nicotine addicts. Since our system 
is adapted to having nicotine on a regular basis, sudden withdrawal or "cold 
turkey" causes our body to function differently in the absence of the drug. Quitters 
experience extreme craving for nicotine, irritability, anxiety and depression 
(Tyrolier et al., 2000). After one month, these physiological cravings are said to 
subside significantly. After a further month, all the nicotine „residues‟ are stated to 
have been completely eliminated. But for many smokers, every day without a 
single cigarette is a struggle and many who try to quit even after just one week, 
return to their smoking habit. This just shows the irresistible and addictive pull of 
nicotine. (See Figure 3) (Shaffer et al., 2010).  
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Figure 3. Diagrammatic representation of how acetylcholine produces its effects by activation the 
cholinergic receptors on posts synaptic neurons (source- Shaffer et al., 2010). 
Nicotine mimics the affects of the neurotransmitter acetylcholine acting primarily 
on the autonomic nervous system.  For example in the adrenal gland there are nicotinic 
receptors which on stimulation liberate adrenaline and noradrenaline. These 
catecholamines of course have many effects, one of which is to stimulate adrenergic 
receptors on the smooth muscles of the vascular system, and due to this can exert a 
hypertensive effect and in extremes this can be dangerous. Nicotine can also cause 
respiratory failure and paralysis at doses of less than 50 mg and smaller amounts can cause 
nausea, dizziness, lowered blood pressure, and heart palpitations (Herraiz & Chaparro, 
2005). A smoker inhales approximately 3mg of nicotine per cigarette. Even this small 
amount constricts blood vessels, increases the heart rate, and acts on the central nervous 
system. It also confers a feeling of well-being and alertness on the smoker. 
People who use tobacco products in any form will develop a physiological 
addiction to nicotine, (Fowler et al., 1998) as due to the increased flow of dopamine, a 
neurotransmitter, nicotine creates pleasurable feelings in the user, along with a desire to 
maintain them. When nicotine levels in the blood drop, smokers will develop withdrawal 
symptoms within 48 to 72 hours after the last cigarette. The symptoms are so unpleasant 
that most smokers will resume smoking in an effort to raise nicotine levels in the blood to 
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the point where the symptoms subside which is the basis of nicotine replacement therapy 
used in patches, lozenges and chewing gum in smoking cessation (see Table 2). 
Table 2. Anti-smoking preparations available in the UK, the type of formulation and 
nicotine content.  
Trade name  Formulation  Nicotine content 
Nicopass  Lozenges  1.5mg per lozenge 
Nicopatch  Patch   7mg , 14mg and 21mg „patches‟ 
Nicorette  Microtab*  2mg  
   Chewing gum  2mg and 4mg 
   Patch   5mg, 10mg and 15mg „patches‟ 
   Invis patches  10mg, 15mg and 25mg „patches‟ 
   Nasal spray  500µg/metered dose spray  
   Inhalator  10mg cartridge in inhaler 
Nicotinell  Chewing gum  2mg and 4mg 
   Mint lozenge  1mg and 2mg  
   TTS patches  10mg, 20mg and 30mg „patches‟ 
NiQuitin  Chewing gum  2mg and 4mg 
   Lozenges  2mg and 4mg  
   Patches  7mg, 14mg and 21mg 
*sublingual   
Finally, nicotine itself is not considered carcinogenic but it may also enhance 
tumour growth caused by carcinogens so acting as a co-carcinogen. However, it is likely 
that it contributes to the increased incidence of heart disease in smokers and this will be 
considered in the next section.   
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1.07 Smoking and the increase of high blood pressure (hypertension). 
There are several ways, it is thought, as to how nicotine in cigarettes can lead to 
hypertension: 
1. Nicotine as a constituent of cigarettes or tobacco has the tendency to constrict blood 
vessels and arteries, which can encourage the formation of plaque and so atherosclerosis. 
This progressively builds up leading to an increased potential for eventually a fissure and 
the atheroma and so promote blood clots on the surface of the vessel. 
2.  As nicotine passes through the cardiovascular system, the endothelial linings of the 
blood vessels are damaged and these hasten the development, within the arterial walls, of 
atherosclerosis. 
3.  As tobacco smoke is inhaled, the smoker also inhales one of the many combustion 
products, namely carbon monoxide which because it irreversibly binds to hemoglobin 
decreases oxygen the carrying capacity of the blood and so this decreases the oxygen 
supply to the heart, brain and every other vital organ (Pons et al., 2008). 
4. Nicotine has the ability to stimulate the production of the epinephrine also known as 
adrenaline, which acts as a vasoconstrictor. 
  Cigarettes are said to contain 4000 chemical compounds and 400 toxic substances 
the exact physiological consequences of which remain unknown. 
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The damaging products of smoking are multiple but the major ones are considered to 
be: 
• Tar, which is a potential carcinogen (Wynder et al., 1953) 
• Nicotine, which is considered addictive and has the capacity to increase cholesterol 
levels and so encourage atherosclerosis. 
• Carbon monoxide, which forms carboxyhaemglobin which decreases the effective 
red cell mass for oxygen transport around the body.  
• Other combustion components e.g. free radicals which can cause chronic 
obstructive pulmonary disorder due to irritation, inflammation and tissue 
destruction 
Based on medical studies, it is said that smoking tobacco or cigarettes can cause 
our blood pressure level to increase by 5 to 10mm Hg during the day. It is actually the 
systolic blood pressure that is largely affected since the systolic blood pressure increases 
by at least 20mm Hg (Chobahian et al., 2003). 
Persons already afflicted with hypertension - for example essential hypertension 
which is the commonest form - are greatly advised to quit smoking as it can cause further 
arteriosclerosis. Hardening of the arteries and can lead to an even greater potential for 
heart attacks. However the situation in complex as there is no direct link between smoking 
and the increase of high blood pressure, rather an association between hypertension 
disorders to cardio vascular diseases (Nguyen et al., 2003). Consequently, nicotine, 
together with cholesterol and other fat deposits contributes to the hardening of the arteries, 
which as the person ages combined with poor blood circulation leads to high blood 
pressure, and an increased risk of blood clots stroke and heart attacks. It is actually the 
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systolic blood pressure that is largely affected since the systolic blood pressure count can 
increase by up to 20 mm Hg (Thomas et al., 2003). 
Consequently people already afflicted with hypertension are greatly advised to quit 
smoking as it can cause further hardening of the arteries and can lead to heart attacks and 
although there is no direct link between smoking and the increase of high blood pressure, it 
is known that a blood pressure rise can result in a secondary hypertensive disorder(s) in a 
range of cardio vascular diseases (Placezek et al., 2004).  This combination along with 
elevated levels of cholesterol and other fats can bring about deposits in the sub-endothelial 
structures of the blood vessels which contributes to the arterial disease, which 
progressively develops through the years, leading to poor blood circulation, induction of a 
higher risk of the formation of blood clots, which may lead to both strokes and heart 
attacks.  
The consequences of cigarette smoking as the most important proven cause of 
premature death have been shown in the United States. About 35 percent of all smokers 
die prematurely of a smoking-related disease. Smokers are three times more likely to die of 
cancer than nonsmokers and it has been found that men who smoke are 10 times as likely 
to experience sudden death from cardiac arrest as are nonsmokers. 
Among women smokers, the mortality rate is five times greater. Furthermore, the 
combination of cigarette smoking and hypertension increases the risk of stroke and heart 
attack considerably (Placezek et al, 2004; King et al., 2009). 
 It has already been discussed that by puffing a cigarette, nicotine immediately 
enters the bloodstream and reaches the brain within six seconds, where more than 15 
percent of it is absorbed. When nicotine reaches the brain, it signals the adrenal glands to 
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release noradrenaline and adrenaline. This direct stimulation of the adrenal gland, because 
of the very rapid passage of the agent from the adrenal medulla into the blood vessels 
increases both the systolic and diastolic pressure. Nicotine is absorbed in the mouth as well 
as the lungs. Therefore, even if we don't inhale, large amounts of nicotine can still 
potentially enter the bloodstream. Here the heart rate increases and so, as it pumps more 
blood, the arteries have to compensate for the blood flow through the body and so this 
elevates the blood pressure and contributes to blood vessel atherosclerosis (Therapeutic 
Letters, 1997). 
It has further been discussed that in addition to directly causing an increase in heart 
and vessel activity, cigarette smoking also contributes to the advance of atherosclerosis, 
hypertension's deadly partner, as nicotine is known to raise the amount of fats and 
cholesterol circulating in the bloodstream by releasing some of the stored body fat (See 
appendix 1 and table 1) and this increase in circulating fats also contributes to the process 
that forms plaque within the artery walls. Cigarette smoking also causes chemical changes 
in the blood itself, causing it to become more viscous, or sticky, which encourages the 
chance for the formation of large blood clots, in the process usually known as thrombosis. 
Emboli from these clots can cause strokes, pulmonary embolism and heart attacks 
(Grobbee et al., 2002) 
 Cigarette smoking may also increase the risk of developing renovascular 
hypertension, a form of secondary hypertension involving the kidneys. Tobacco smoke 
also contains cadmium, a substance known to contribute directly to the development of 
high blood pressure possibly via an effect on the kidneys, because when cadmium is 
inhaled through smoking, it tends to be retained in the kidneys, and so damaging them. 
This damage can further increase the hypertensive state ( Garovic and Textor, 2005). 
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1.08 Summary of Nicotine and its effects on the cardiovascular system. 
Nicotine has been speculated to increase the risk of blood clots by increasing the 
levels of plasminogen activator inhibitor-1, though this has not been actually proven. 
However, what has been more strongly suggested is that the plasma fibrinogen levels are 
elevated in smokers and are further elevated during acute COPD exacerbation (Antonio  et 
al., 2007). Also, Factor XIII, which stabilizes fibrin clots, is increased in smokers. But 
neither of the two previous effects have been absolutely proven to be caused by nicotine. 
Whatever the mechanism(s) of inducing an increased risk of blood clots forming the 
consequences are without question - the clot will at best reduce blood flow in the worst 
case arrest it and then the tissue supplied by the vasculature, loses its source of oxygen and 
nutrients and dies within minutes (Green et al., 2000). 
In the peripheral circulation, arteries going to the extremities are also highly 
susceptible to the vasoconstrictor effects of nicotine as well as the increased risk of clots 
and clogging (UPI, 2001). 
1.09 Basis of the thesis (1). 
After a consideration of the pharmacological effects of nicotine  and its diverse 
properties in the body and its complicated effects on the blood coagulation system it is 
now appropriate to consider the potential of using aspirin to study if some of the nicotinic 
effects can be modified in the presence of this drug. This is a central part of the thesis as a 
study to determine the interaction between nicotine and aspirin has not been the focus of 
much investigational interest in either the wider scientific community or in Kuwait. 
So it is appropriate to consider next the use of aspirin for the use in cardiovascular 
diseases such as hypertension and this will form the basis of the next chapter. 
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Chapter Two 
Literature review part 2 - Aspirin’s use in cardiovascular medicine 
2.01 Literature review - Aspirin’s use in various diseases. 
Aspirin is widely used drug for both its ant-inflammatory and analgesic properties. 
In reality it has multi aspects to its usage (See Table 3). 
Table 3. Aspirin‟s use against various diseases. 
 
Clinical Outcomes 
 
75 to 81 mg 
(n=1224) 
325 mg 
(n=2877) 
P Value               References 
All cause mortality 9.9 10.7 0.566 ( Trutte et al., 1964) 
Cardiovascular 
composite 
11.0 11.7 0.186 (Spranger et al., 1989) 
 
Myocardial infarction 6.5 7.3 0.005 (National Health Institute, 1980) 
 
Stroke 4.1 4.5 0.818 (Escolar et al., 1986) 
 
Cardiovascular 
mortality 
4.0 4.3 0.876 (Ridker et al., 2005) 
 
Diabetes 14 16 0.334 (Eidelman et al., 2002) 
Hypertension 60 63 0.001 (Groeneveld et al., 2003) 
 
Systolic BP 132 133 0,022 (Williams et al., 2003) 
 
Diastolic BP 72 73 0.001 (Stafford,  2000) 
 
Angina 60 57 0.001 (Harpaz et al., 1996) 
 
Percutaneous 
revascularization 
17 21 0.001 (Higashi et al., 2004) 
 
Peripheral artery 
disease (PAD) 
8.1 9.3 0.301 (Baigent et al., 2008) 
 
Congestive heart 
failure (CHV) 
5.3 5.8 0.250 (Quinn et al., 2004) 
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  Aspirin was the first discovered member of the class of drugs which were later to 
be called the non-steroidal anti-inflammatory drugs (NSAIDs). Not all NSAIDs are 
salicylates, although they all have similar pharmacological effects as they inhibit the 
enzyme cyclo-oxygenase as their primary mechanism of action. Today, aspirin is one of 
the most widely used medications in the world, with an estimated 40,000 metric tons of it 
being consumed each year (Michael et al., 2007). 
Aspirin is also more correctly known as acetylsalicylic acid (ASA) as it is a 
derivative of salicylic acid.  It is often used as an analgesic to relieve minor aches and 
pains, as an antipyretic to reduce fever and as an anti-inflammatory medication. Its 
structural formula is shown below (Figure 4). 
                                                                   
Figure  4.  Aspirin structural formula (source - Jinno Laboratory, 1996). 
Aspirin causes its antiplatelet effect by inhibiting the production of thromboxane 
A2, by the irreversible acetylation of the enzyme cyclo-oxygenase, as shown in Figure 5, 
below. 
Thromboxane  production under normal circumstances is highly controlled as it is a 
very potent pro-aggregatory agent which binds platelets together to repair endothelial or 
more severe damage to blood vessels. Consequently , when ASA is used as a long-term 
treatment at a low dose, a dose below that usually used for analgesia, the low dose 
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selectively block the production of thromboxane and so prevents heart attacks, strokes, and 
blood clot formation in people at high risk for developing these platelets + blood 
coagulation factor complexes. It has also been established that low doses of ASA may be 
given immediately after a heart attack to reduce the risk of another heart attack or of the 
death of cardiac tissue (Danchin et al., 2006).  
 
Figure 5. Flow diagram for the generation of Thromboxane (TxA2) from arachidonic acid 
and its subsequent metabolism to TxB2.  Aspirin blocks an enzyme called cyclo-
oxygenase (shown on the diagram as COX) which is involved with the ring closure and 
addition of oxygen to arachidonic acid converting to prostaglandins ( Rapoport, 2008). 
Aspirin is the salicylate ester of acetic acid. The compound occurs as a white, 
crystalline powder or tabular or needle-like crystals. It is a weak acid with a pKa of 3.5. 
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Aspirin is slightly soluble in water and is freely soluble in alcohol and  each gram of 
aspirin contains approximately 760 mg of salicylate (Brik, 2004). 
 
Figure  6. The acid dissociation reaction of aspirin. (Jinno Laboratory,1996). 
The synthesis of aspirin is classified as an esterification reaction. Salicylic acid is 
treated with acetic anhydride, an acid derivative, causing a chemical reaction that turns 
salicylic acid's phenol group into an acetyl group, (R-OH → R-OCOCH3). This process 
yields aspirin and acetic acid, which is considered a byproduct of this reaction. Small 
amounts of sulfuric acid (and occasionally phosphoric acid) are almost always used as a 
catalyst. This method is so straightforward that it is commonly employed in undergraduate 
teaching labs for the purposes of showing medicinal substance synthesis. The mechanism 
of synthesis is shown in figure 7.  
 
Figure  7.  Synthesis of aspirin via esterification (reaction between alcohol and carboxylic 
for formation of ester) method (Paterson et al., 2008). 
Formulations containing high concentrations of aspirin often smell like vinegar. 
This is because aspirin can decompose through hydrolysis in moist conditions, yielding 
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salicylic acid and acetic acid (Rapoport, 2008). Aspirin is stable in dry air, but readily 
hydrolyzes to acetate and salicylate when exposed to water or moist air. It will then exude 
this strong vinegar-like odor. The addition of heat will speed the rate of hydrolysis. In 
aqueous solutions, aspirin is most stable at pH of 2-3 and least stable at pH‟s below 2 or 
greater than 8 (Brik, 2004). 
As an effective treatment, low dose aspirin has been prescribed by doctors since the 
1890‟s. Although it has practical benefits, some are concerned about its long term use, 
especially if used in a person who has been diagnosed with high blood pressure or other 
cardiovascular disease(s). To receive the drug they have to be informed that they will need 
to take it throughout their lifetime to maintain control of their symptoms (Awtry et al., 
2000). 
2.02 A brief history of aspirin and its use to prevent platelet aggregation.     
Why is low dose aspirin 75mg or 100mg rather than the normal 300mg dose 
preferred? Where does the use of this low dose actually come from?  How was it 
discovered? A brief look at the history of Aspirin will give us a sense of appreciation for 
advantages of aspirin, which is balanced by also mentioning its disadvantages.  
A daily aspirin dose of 75gm is an example of a normal prescribed amount for low 
dose aspirin therapy. Cyclo-oxygenase (COX), which catalyzes the production of 
prostaglandins is the target of the drug. However prostaglandins are molecules produced 
normally in cells to carry out many physiological effects. One of these functions is to make 
the lining of the stomach thick enough to stop stomach acid from irritating and penetrating 
through and so prevent ulcers from forming in the stomach wall. Prostaglandins have 
many other basic functions include inhibiting blood clotting, the 6 oxo derivative, known 
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as prostacyclin, is a very powerful vasodilator and a platelet anti-aggregatory agent and 
has a role in kidney function. They are also involved with bronchiolar airway tone and 
may reduce inflammation in some inflammatory states and in one very special case bring 
about the closure of the ductus arteriosus.  
This thesis is however concerned with the role this drug may play in cardiovascular 
disease. For example when repairing tissue injury, it is necessary for a fresh blood supply 
to get to the injured area. Prostaglandins facilitate this process by dilating these blood 
vessels and at the same time they may encourage an inhibition of blood clotting 
(prostacyclin), to a degree which is enough to keep the blood flowing into the damaged 
area. Inflammation is also reduced by the action of this type of prostaglandin, which works 
in a similar sense, but can produce mixed reactions as the body needs it to modulate 
infections and other problems (Chandrasekharan et al., 2002). 
However with more serious injuries, the body chemistry changes so that the 
prostaglandin E comes into action at the injured site, as in the case of an open wound, 
where the blood needs to form a blood clot. To do this the prostaglandins and thromboxane 
causes platelets to stick together by facilitating adhesion to the blood vessel wall and then 
other prostaglandins induced aggregation swelling and as a consequence inflammation 
develops and progressively increases. This can be dangerous if we have an imbalance and 
the prostaglandins E are in excess which has been linked to one of the causes of high blood 
pressure (Thomas et al., 2003). 
 Aspirin is prescribed at a low dose for its effectiveness in ''thinning'' the blood and 
stopping clotting from excessive thromboxane production and prostaglandin E, which can 
cause blood clots to block vital oxygen supply to the tissues and if this is in the heart, then 
this will lead to a heart attack. In addition, low dose aspirin can be prescribed for people 
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suffering from high blood pressure, as well as other cardiovascular problems, for example 
post myocardial infarction to decrease the risk of future platelet activation and clotting. 
2.03 Mechanism of action of aspirin. 
Correlation between inhibitory and anti-inflammatory activity of aspirin. 
For many decades after its discovery the real mechanism of action of aspirin like 
that of many other anti-inflammatory drugs remained unknown. It was known however 
that as compared to the anti-inflammatory effects which had been produced by steroids, 
these drugs were different in terms of potency and side effects. They were also different in 
terms of the analgesia they produced which was different from those produced by opiates.  
Even today aspirin like drugs have not the same analgesic action as opiates such as 
morphine. This did not really matter as these aspirin like analgesic drugs have been found 
to be very effective for low or moderate severity clinical pain but are not, and probably 
never will be able to be, effective against high intensity pain such as postoperative pain, 
osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and for some types of the more 
severe types of headache (Beaver, 1965). 
Aspirin like drugs were found to be effective in experimental models involving the 
induction of a previous inflammatory state and blocked the delayed stretching response 
induced with an intraperitoneal injection of phenylbenzo-quinone or dilute acetic acid in 
mice. Aspirin-like drugs were not found effective against nociception (mechanical, thermal 
and chemical stimuli) which are detected by nerve endings called nociceptors, which are 
found in the skin and on internal surfaces such as the periosteum or joint surfaces. The 
concentration of nociceptors varies throughout the body, mostly found in the skin and less 
so in deep internal surfaces. All nociceptors are free nerve endings that have their cell 
bodies outside the spinal column in the dorsal root ganglia and are named according to 
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their appearance at their sensory ends. Nociceptors have a certain stimulatory threshold, 
that is, they require a minimum level of stimuli before they trigger a signal. Once this 
threshold is reached a signal is passed along the axon of the nerve into the spinal cord of 
short duration which may be induced by stimuli such as pinching or stimulating the tail or 
toes of mouse, rat or guinea pig (Vane, 1964). 
It has also been suggested by Guzman et al. (1964) and Lim et al. (1964) how the 
peripheral analgesic activity of aspirin-like drugs may have worked. Many biochemical 
effects of aspirin-like drugs had been previously extensively documented but theories 
based on these effects have now been discounted. However such theories included the 
uncoupling of oxidative phosphorylation and the induced inhibition of dehydrogenase 
enzymes, particularly those dependent on pyridine nucleotides (Guzman et al. 1964; Lim 
et al., 1964).  
 Some aminotransferases and decarboxylases were also found to be inhibited by 
these aspirin-like drugs. The inhibition of these enzymes hampered many important body 
functions as several of these enzymes involved in protein and RNA biosynthesis. 
Consequently it was through such mechanism the side effects of the drugs were thought to 
exert themselves. 
 One major theory was that because the drug could affect Oxidative phosphorylation 
which is a metabolic pathway that uses energy released by the oxidation of nutrients to 
produce adenosine triphosphate (ATP) it could bring about its side effects this way. During 
oxidative phosphorylation, electrons are transferred from electron donors to electron 
acceptors such as oxygen, in redox reactions. These redox reactions release energy, which 
is used to form ATP. All of these inhibitory actions of aspirin were for some time the basis 
of the explanation of the therapeutic action of aspirin. There was a problem with such 
theories because the inhibitions of many important enzymes were all observed only when 
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high concentration of these drugs had been taken. Due to this problem of specificity the 
correlation between the ability of these drugs to inhibit particular enzymes and their ant-
inflammatory activities was a real problem in explaining their mode of action. The most 
serious problem of these theories was that they could not provide valid reason why 
inhibition of any of these enzymes should produce the anti-inflammatory, analgesic and 
antipyretic effects of aspirin. In other words, if aspirin was involved in inhibition of many 
enzymes then how could these drugs show a relatively potent anti-inflammatory action. By 
controlling the potency of aspirin by lowering the dose, many of its side effects could be 
reduced, because many of these enzymes were only inhibited when there was a high 
concentration of salicylates (Whitehouse, 1965). 
 
Aspirin inhibits prostaglandin production. 
Aspirin may also cause an anaphylactic-like reaction when people are first exposed 
to the drug. These reactions are not the same as the immune system response that occurs 
with "true" anaphylaxis. However, the symptoms, risk for complications, and treatment are 
the same for both types of reactions. It means that histamine and SRS-A (slow reacting 
substance of anaphylaxis) are involved with this effect of aspirin as are perhaps, other 
possible mediators or stimulators of anaphylaxis (Vane, 1971).  
Anaphylaxis is a severe, whole-body allergic reaction to a „chemical‟ that has 
become an allergen. After being exposed to a substance such as bee sting venom, the 
person‟s immune system becomes sensitized to it. On a later exposure to that allergen, an 
allergic reaction may occur. This reaction happens very quickly after the exposure, is 
severe, and involves the whole body. Tissues in different parts of the body release 
histamine and slow-reacting substance (SRS-A), which is a mixture of the leukotrienes - 
LTC4, LTD4 and LTE4. Mast cells can secrete these agents during the anaphylactic 
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reaction, all of which are capable of inducing inflammation. It can be produced by 
basophiles. These leukotrienes exhibit a prolonged, slow contraction of smooth muscle and 
they have a major bronchoconstrictor role in asthma, a view suggested three decades 
before by Brocklehurst (1962).  
 As compared to histamine, the leukotrienes are 5000 times more potent and have a 
slower onset but longer duration of action. This causes the airways to constrict and leads to 
other symptoms. Leukotriene substances were detected as SRS-A by Piper and Vane who 
conducted their studies on isolated lungs perfuse with Krebs solution from sensitized 
guinea pigs (Piper and Vane, 1969). During the detection of these substances, Piper and 
Vane used the technique which was described as a continuous bioassay with a cascade 
bioassay system which was developed by Vane (1964). He used this system with blood or 
artificial salt solution to demonstrate the nature of the products released in anaphylaxis and 
also the speed of their release (Vane, 1964). 
During anaphylaxis in addition to histamine and slow-release substance (SRS-A), 
being produced there were found to be other substances produced such as prostaglandins 
which were mainly PGE2 and some PGF2. 
 It was also observed that another material, known originally as RCS (rabbit aorta 
contracting substances) was produced which were also known as ephemeral substances 
(short lived or transitory substances), and which were identified in the cascade bioassay 
assay tissues. It has also found that RCS had a half-life of about 20 minutes in lung 
perfusate only when it was cooled to few degrees above its freezing point. At normal 
laboratory temperatures the RCS was very short lived – a matter of seconds – and even 
under ideal controlled conditions it decomposed within 20 minutes, which was then called 
an ephemeral substance. This RCS was chemically identified and characterized by 
Hamberg et al., (1975) as Thromboxane. This new molecule had never previously been 
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found and which because it came from platelets, alternatively known as thrombocytes, and 
had within the molecule an oxane ring, which was given the name, Thromboxane A2. This 
was the agent which had been present in RCS and it when its synthesis could be prevented 
with aspirin then this provided the first foundation of establishing the relationship between 
aspirin and prostaglandin system. 
 In some further research involving RCS, by Palmer et al., (1973) and Hamburg et 
al., (1975) they found that RCS was also released by the peptide, bradykinin, This 
suggested that aspirin has the ability to minimize, some of the effects of bradykinin by 
blocking off or inhibiting the release of RCS (Hamberg et al., 1975). The experimental 
evidences presented by Palmer et al., (1973) and Hamburg et al., (1975) confirmed that the 
release of RCS from isolated guinea pig lungs, in which anaphylaxis had been induced by 
sensitizing the animal to egg albumen, RCS production was blocked by aspirin. These 
experiments also indicated that when aspirin inhibited the releasing of RCS, it also caused 
the reduction in production of prostaglandins (Crutchely et al., 1977). 
The amount of prostaglandin which can be decreased as a result of its inhibition by 
aspirin, is rather complex.  The enzyme cyclo-oxygenase catalyzes the production of 
prostaglandins in response to a variety of mechanical, electrical, chemical or 
immunological stimuli. The study of pharmacological mediators released from isolated 
lungs during anaphylactic reaction has proven that aspirin also acted like these mediators 
and blocked the production of prostaglandin (PG). The concept that aspirin inhibition of 
PG synthesis was correct was the finding that aspirin‟s injury of the wall of stomach was 
prevented if prostaglandins were added to the mucosa.  Clearly, if the production of PG 
was blocked by aspirin the protection of the stomach wall had been lost and so that is why 
it damaged the stomach walls, which was, and still is, one of the major side effects of 
aspirin (Hamberg et al., 1975).  
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In one of the experiments which were conducted by Samuelsson and Anggard 
(1965), they had detected the production of PGE2 and PGF2 in the supernatant of broken 
cell homogenate from guinea pig lungs rather than from ram seminal vesicles which was 
the site from where the synthetase enzyme had been obtained in all their previous studies.  
These experiments proved that there was not only one tissue that can contain/produce the 
enzymes which stimulated the production of prostaglandins, rather, in many other tissues 
the enzyme was also present. Today, all tissues of the body are thought to contain this 
enzyme system. 
The work on lung homogenates had established that if aliquots of the supernatant 
from these homogenates were incubated with arachidonic acid, the precusor of all the 
prostaglandins and thromboxanes of the 2 series, at 37
◦
C the metabolites could be collected 
after 30 min of incubation. The production of the prostaglandins was measured using 
bioassay with especial interest being paid to the production of PGF2. When various 
concentrations of anti-inflammatory drugs such as aspirin, indomethacin or sodium 
salicylate were added their effect on prostaglandin synthesis could be assessed.  The 
experiments clearly proved that a concentration-dependent inhibition of PG synthesis 
occurred in the presence of these anti-inflammatory drugs. Indomethacin was found to be 
the most potent in blocking the production of prostaglandins whereas other drugs such as 
sodium salicylate were less potent in their inhibitory action. Aspirin was potent with a little 
higher concentration as compared to indomethacin. In similar experiments the effect of 
opiate analgesic drugs e.g.; morphine, a steroidal ant-inflammatory drug (hydrocortisone) 
and H1-antihistamine (mepyramine) were also tested to determine their effects on 
prostaglandin synthesis. Here it was found that these drugs had very little or no effects on 
the PG‟s synthesis (Anggard and Samulesson, 1965). 
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At the same time as the above experiments were reported, Smith and Willis studied 
the effect of aspirin on platelets. In their experiment they collected the blood samples of 
three people one hour before taking 600mg of aspirin and then one hour after taking of 600 
mg of aspirin orally. Platelets were isolated, washed and incubated with the enzyme 
thrombin. The thrombin in addition to being involved with blood coagulation, where the 
enzyme is involved in the conversion of a substance called fibrinogen to fibrin, also 
stimulates platelets to contract. The experiment was tested in the presence of various 
substances. It was found that there was a major difference between the ability of platelets 
to make PGs before and after their exposure to aspirin. In contrast there were no 
significant changes in concentration of any other substances found in platelets. This shows 
that platelets activity to form the clots or stick together to form a clot is due to „hyper 
secretion of prostaglandin‟, and as a result of aspirin exposure the production of PGs had 
been decreased which showed the anti-clotting potential action of aspirin (Smith & Willis, 
1971). 
 The great importance of this last study was that it showed for the first time the 
action of aspirin on platelets, a cell type which is central to this thesis. 
 Ferreira also demonstrated in the same year that aspirin and aspirin-like drugs 
blocked the production of prostaglandin (PG) in the perfused, isolated dog spleen 
preparation (Ferreira et al., 1971). Finally in the same momentous year, 1971, Collier and 
Flower also studied the ability of aspirin in blocking the prostaglandin (PG) which has 
been produced by human seminal fluid. These researchers also proved the diversity of 
tissues producing the same range of prostaglandins and the blocking by aspirin of their 
synthesis, irrespective the type of tissues (Collier & Flower, 1971). 
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Inhibition of cyclo-oxygenase and correction 
Cyclo-oxygenase (COX) is an enzyme that is responsible for the formation of 
important biological mediators called prostanoids, including prostaglandins, prostacyclin 
and thromboxane. Pharmacological inhibition of COX can provide relief from the 
symptoms of inflammation and pain. Non-steroidal anti-inflammatory drugs, such as 
aspirin and ibuprofen, exert their effects through inhibition of COX. The names 
"prostaglandin synthase (PHS)" and "prostaglandin endoperoxide synthesize (PES)" are 
still occasionally used to refer to COX (Hemler et al., 1976). 
COX converts arachidonic acid to prostaglandin H2 (PGH2), the precursor of the 
series-2 prostanoids. The enzyme contains two active sites: a heme with peroxidase 
activity, responsible for the reduction of PGG2 to PGH2, and a cyclo-oxygenase site, where 
arachidonic acid is converted into the hydroperoxy endoperoxide prostaglandin G2 (PGG2). 
The reaction proceeds through H atom abstraction from arachidonic acid by a tyrosine 
radical generated by the peroxides active site. Two oxygen molecules then react with the 
arachidonic acid radical, yielding PGG2 (Smith, 1986). Different tissues express varying 
levels of COX-1 and COX-2. Although both enzymes act basically in the same fashion, 
selective inhibition can make a difference in terms of side-effects. COX-1 is considered a 
„constitutive enzyme‟, being found in most mammalian cells. COX-2, on the other hand, is 
undetectable in most normal tissues. It is an „inducible enzyme‟, becoming abundant in 
activated macrophages and other cells at sites of inflammation. In 1975 it was shown to be 
„up regulated‟ in various carcinomas and to have a central role in tumorigenesis (Roth et 
al., 1975). 
The main way to inhibit COX is to use drugs. The now „classical drug inhibition of 
prostaglandin and thromboxane synthesis‟ has the effect of reduced inflammation, as well 
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as antipyretic, antithrombotic and analgesic effects. Aspirin specifically acetylates the 
hydroxyl group of serine residue located 70 amino acids from the C-terminus of the 
enzyme (Roth et al., 1975). The acetylation of the enzyme by aspirin places a bulky 
substituent on Ser530 which inhibits the binding of arachidonic acid and its conversion to 
endoperoxides (Raz et al.,1988).The acetylation which is achieved by aspirin is an 
irreversible process of COX inhibition and  it takes place only in one direction as it can 
never be reversed via deacetylation. This means for the production of more PGs, new 
enzyme has to be synthesized. When this enzymes was acetylated in its pure isolated, it has 
been found that only COX enzyme not its hydro peroxide ability is blocked. The inhibition 
of enzyme by aspirin is also its concentration depending activity (De Witt et al., 2002). 
When the aspirin concentration is low, aspirin rapidly i.e. within a few minutes, 
specifically acetylates the COX. But if the concentration of aspirin are higher for a longer 
period of time, it behaves entirely differently from the low concentration as with a higher 
concentration over long period of time, aspirin non-specifically acetylates a variety of 
protein and nucleic acids.  
After it was established that aspirin irreversibly acetylated COX, major attention 
was given towards the synthesis of COX. It has been found that synthesis of COX could be 
stimulated by growth factors, tumour promoters, interleukin-1, lipopolysaccharides and 
tumour necrosis factor (TNF) (Raz et al., 1988). The synthesis of COX by Interleukin-1 is 
induced by exerting its effects via transcriptional phase rather than translation phase (Raz 
et al., 1988).The induction of COX gene expression is rapid and using serum factors it 
takes place after approximately two hours in mouse 3T3 (fibroblast derived) cells in which 
PGs are essential for cell division. The report of ''Simmons'' described the final stages of 
the theory which related the activation of COX, as it reported that a distinct COX gene 
65 
 
could be induced with mitogens like growth factors, tumour promoters and 
lipopolysaccharides, the inhibition of which could be inhibited with glucocorticoids. This 
gene expression elaboration with PGs is best expressed by COX-2 during inflammatory 
reactions rather than COX-1 which produce PGs and these PGs involved in physiological 
processes such as protection of the stomach mucosa, platelet aggregation and kidney 
function. 
Both COX-1 and COX-2 are isoenzymes and are 60% homologous between amino 
acid structures of COX-1 and COX-2 .Aspirin binds to the active site of COX-2 which is 
Ser 516 in the same the way it binds to Ser530 the active site of COX-I. The only 
difference between both isoenzymes is that the active site of COX-2 is slightly larger than 
the active site of COX-1 (Simmons et al., 1991). Any anti-enzyme activity can cause a 
reduction in the production of both prostaglandins and thromboxanes. This inhibitory 
effect shows the way aspirin acts to produce analgesia, antipyrexia, and reduces the 
clotting formation ability of platelets (Vane et al., 1998).  
The effect of aspirin on platelets is irreversible and to meet the „new situation‟; the 
body has to produce new COX enzyme which in turn produces PG for forming the clots in 
injured and wounded conditions. Platelets cannot produce new COX, which may explain 
why aspirin is effective for the life of the platelet which is generally considered to be 8 -10 
days. In contrast other cells, for example the mast cells, a nucleated resident cell found in 
many types of tissues which contain many granules rich in histamine and heparin, can 
synthesis new COX. Although best known for their role in allergy and anaphylaxis, mast 
cells play an important protective role as well as being intimately involved in wound 
healing and with  defence against pathogens. It has also been observed, in one very 
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important experiment, that aspirin decreased the clinical symptoms of induced anaphylaxis 
(Piper and Vane, 1969). 
Prostaglandins and thromboxanes have a variety of effects on the body which are 
not only limited to sending impulses of pain to the brain, modulation of the hypothalamic 
thermostat and inflammation but also responsible for the aggregation of platelets that 
facilitate the formation of blood clots. It has been proven that one of major reasons for a 
heart attack is the increased risk of blood clot formation. Aspirin is found to inhibit the 
aggregation of platelets, and in this way brings about the anti-clotting effect for which 
aspirin is now famous (Roth et al., 1975). However, this effect is not without its risks. 
 As one of the major side effects of aspirin is the ability to inhibit platelet function 
so severely that excessive bleeding may occur. The newer NSAIDs called COX-2 selective 
inhibitors were developed to specifically inhibit COX-2 with the hope that although they 
would still reduce the platelet effect, whilst reducing the risk of causing the gastrointestinal 
side effects such as gastro-intestinal haemorrhage (Silverstein et al., 2000). The early 
success has been met with removal from the market due to problems with side effects. 
 Finally, using the more recent technique of X-analysis has elucidated the structure 
of cyclo-oxygenase in a much better way than was previously possible. This has provided 
additional information about the formation of PG by this enzyme.  X-rays of COX shows 
the positions of atoms in tiny crystals of enzyme. The analysis showed the presence of a 
tunnel running in the middle of the enzyme. The arachidonic acid must pass through this 
tunnel to reach the core of the enzyme where its oxidation results in its conversion into 
prostaglandin ( Fiorucci et al., 2003).When aspirin is taken, it passes into the tunnel of 
COX where it occupies the same active site where the precursor of PG formation, 
arachidonic acid, is itself attached i. In this way the active site of COX enzymes is blocked 
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by aspirin and acts as a gate effectively blocking the access of arachidonic acid. The 
researchers further showed that this gate where aspirin can attached itself is present in two 
positions in the enzyme, either fully or partially closed and the position of the gate in both 
enzymes COX-1,COX-2 is different. The X- analysis, highlighting these differences, was 
said to be very helpful to bring about the improvement in NSAIDs (Chandrasekharan et 
al., 2002). 
2.04 Absorption of aspirin 
 Aspirin is rapidly absorbed from the stomach and the proximal small intestine in 
monogastric animals. The rate of absorption is dependent upon many factors such as: the 
quantity and nature of the stomach contents, gastric emptying times, tablet disintegration 
rates and gastric pH. In contrast to man, who is a „monogastric animal‟, in cattle with their 
many stomachs absorption is slow. In man, approximately 70% of an oral dose will be 
absorbed in the stomach, which may reflect the fact that the gastric mucosa is permeable to 
the non-ionized form of aspirin, which passes through the stomach wall by a passive 
diffusion process. Optimum absorption of the salicylate in the human stomach occurs in 
the pH range of 2.15 to 4.10.  Absorption in the small intestine occurs at a significantly 
faster rate than in the stomach. After an oral dose of 650 mg Aspirin, the plasma 
acetylsalicylate concentration in man usually reaches a level between 0.6 and 1.0 mg% in 
20 minutes after ingestion and drops to 0.2 mg% within an hour. Within the same period of 
time, half or more of the ingested dose is hydrolyzed to salicylic acid by esterases in the 
gastrointestinal mucosa and the liver. The total plasma salicylate concentration reaches a 
peak between one or two hours after ingestion, averaging between 3 and 7 mg%. Many 
factors influence the speed of absorption of ASA in a particular individual at a given time; 
tablet disintegration, solubility, particle size, gastric emptying time '' psychological state'' 
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physical condition, nature and quantity of gastric contents, all affect absorption (Levy, 
1961). 
There are some factors that influence the absorption of a drug and the major two 
are: Firstly, ionization (the unionized drugs are absorbed better, ionization is affected by 
the pH) and secondly, the surface area of the gastric lining.  
In the stomach where the pH can range from between 1.5-3.5 the aspirin (which is 
acidic) will not ionize, and because of that, the absorption of aspirin in the  stomach is 
much better than in duodenum. In the duodenum the pH is 6.8 so the aspirin will ionize, 
therefore the absorption is not as good. However, because the surface area is very large, 
the time of absorption is greater, so the aspirin although is it absorbed better in the 
stomach, achieves a greater concentration because of its absorption in the duodenum. This 
is shown by small intestinal absorption studies of aspirin at pharmacological 
concentrations in the unanesthetized rat by using a single-pass perfusion technique. The 
rate of aspirin absorption remained linear with its concentration (0.5mM to 10 mM). 
Intestinal aspirin absorption increased as the concentration of hydrogen ions, sodium 
taurocholate, and ascorbic acid in the perfusate increased. Aspirin absorption did not 
change after ethanol addition. At pH 3.5 or 6.5, intestinal absorption of aspirin was greater 
than gastric absorption of the compound. Aspirin was not absorbed by the stomach at pH 
6.5. These experiments indicate that aspirin can be absorbed to an appreciable extent in its 
ionized form by the small intestine but not by the stomach. 
Once absorbed the aspirin is quickly metabolised. Aspirin is partially hydrolyzed to 
salicylic acid where it is distributed widely throughout the body. The highest levels may be 
found in the liver, heart, lungs, renal cortex and plasma. The amount of plasma protein 
binding is variable, depending on species, serum salicylate and albumin concentrations. At 
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lower salicylate concentrations, it is 90% protein bound, but only 70% protein bound at 
higher concentrations. Salicylate is excreted into milk, but levels appear to be very low. 
Salicylate will cross the placenta, and foetal levels may actually exceed those found in the 
mother (Levy, 1961a and b) 
The excretion of salicylate occurs with first-order kinetics with a half-life between 
2 and 19 hours, depending on the dose of aspirin administered. Salicylate is metabolized in 
the liver primarily by conjugation with glycine and glucuronic acid via glucuronyl 
transferase. Minor metabolites formed include gentisic acid and 2, 3-dihydroxybenzoic 
acid, and 2, 3, 5-trihydroxybenzoic acid. Gentisic acid appears to be the only active 
metabolite, but because of its low concentrations, it appears to play a therapeutically 
insignificant role. The rate of metabolism is determined by both first order kinetics and 
dose-dependent kinetics depending on which metabolic pathway is looked at. Generally, 
steady-state serum levels will increase to levels higher (proportionally) than expected with 
dosage increases. Salicylate and its metabolites are rapidly excreted by the kidneys by both 
filtration and renal tubular secretion. Significant tubular reabsorption occurs, which is 
highly pH dependent. Salicylate excretion can be significantly increased by raising urine 
pH to 5-8. Salicylate and metabolites, in cases of overdose and poisoning by aspirin, may 
be removed using peritoneal dialysis or more rapidly by using haemodialysis. About 50–
80% of salicylate in the blood is bound by plasma proteins while the rest remains in the 
active, ionized state. The level of protein binding is concentration-dependent. Saturation of 
binding sites leads to more free salicylate and increased toxicity. The volume of 
distribution is 0.1–0.2 litres/kg. Acidosis increases the volume of distribution because of 
enhancement of tissue penetration of salicylates (Zommermann, 1981). 
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Figure  8.  Aspirin metabolism in the liver (Barsom et al., 2005). 
As much as 80% of therapeutic doses of salicylic acid are metabolized in the liver. 
Conjugation with glycine forms salicyluric acid and with glucuronic acid forms salicyl 
acyl and phenolic glucuronide (see Figure 8). These metabolic pathways have only a 
limited capacity. Small amounts of salicylic acid are also hydroxylated to gentisic acid. 
With large salicylate doses, the kinetics switch from first order to zero order, as metabolic 
pathways become saturated and renal excretion becomes increasingly important.  
Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), free 
salicylic acid (10%), salicylic phenol (10%) and acyl (5%) glucuronides, and gentisic acid 
(< 1%). When small doses (less than 250 mg in an adult) are ingested, all pathways 
proceed by first order kinetics, with an elimination half-life of about 2 to 4.5 hours. When 
higher doses of salicylate are ingested (more than 4g), the half-life becomes much longer 
(15–30 hours) because the biotransformation pathways concerned with the formation of 
salicyluric acid and salicyl phenolic glucuronide becomes saturated (Barsom et al., 2005). 
Renal excretion of salicylic acid becomes increasingly important as the metabolic 
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pathways become saturated, because it is extremely sensitive to changes in urinary pH. 
There is a 10 to 20 fold increase in renal clearance when urine pH is increased from 5 to 8. 
The use of urinary alkalinization exploits this particular aspect of salicylate elimination in 
cases of over dosage or poisoning (Proudfoot,1983). 
2.05 Interference of Laboratory Tests by aspirin 
  Aspirin is used in patients with cardiovascular disease and some of these have 
diabetes. It is of concern to note that the aspirin can modify the results of blood sugar 
determinations in such patients. These difficulties arise when aspirin is being used at high 
doses, as aspirin may cause false-positive results for urinary glucose if using the traditional 
cupric sulfate method (Benedict‟s solution) and false-negative results if using the more 
modern method of glucose oxidase (Tes-Tape).  Furthermore, urinary ketones measured by 
the ferric chloride method (Gerhardt) may be affected if salicylates are in the urine 
(reddish-color produced) (Saeid et al., 1996). 
If the more sophisticated hydroxyindoleacetic acid (5-HIAA) determinations by the 
fluorometric method are being used to assess the 5HT profile in patients then these tests 
may also be interfered with by salicylates in the urine. Finally falsely elevated 
vanillylmandelic acid (VMA), used to assess catecholamine turnover, may be seen with 
most methods used if salicylates are in the urine. In contrast, falsely lowered VMA levels 
may be seen if using the Pisano method.  
 Finally, aspirin also causes complications in the assessment of xylose when 
urinary excretion of this sugar may be decreased if aspirin is given concurrently and 
aspirin can also cause falsely elevated serum uric acid values if a colorimetric method is 
used for its measurement (Caraway et al., 1972).  
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2.06 The therapeutic difficulties caused by the rapid metabolism of aspirin. 
Once aspirin has been taken by the oral route and absorbed is goes via the hepatic 
portal vein to the liver. The liver inactivates the aspirin by deacetylation by the process of 
first pass metabolism. One recent suggestion to overcome this problem is that a trans-
dermal 'Patch' may be suitable as this would minimize first metabolism and so exert its 
therapeutic effect more rapidly (Shamsher, et al., 2010) How such aspirin could be 
formulated to achieve such an effect when it does not compare in potency to drugs usually 
used in trans-dermal patches such as nicotine, female sex steroids, opiate - like analgesics 
e.g. buprenorphine, is not at all clear (Nestlert et al., 1998).  
 
 Aspirin also has a unique usefulness among the family of NSAIDs in that it is 
widely considered to be able to reduce the risk of cardiovascular disease. Low doses (100-
300mg per day) can reduce by 30% the risk of myocardial infarction and stroke among 
patients who already have a history of these disorders. Similarly lower doses of between 
75mg - 150mg per day were also said to be showing promise in reducing the risk of 
cardiovascular disease in patients with a pre-existing condition (Raming et al., 1996) but 
this is still an area that requires further research. The prevention of cardiovascular disease 
is thought to be related to thromboxane inhibition in platelets leading to a reduced risk of 
potentially dangerous blood clots forming in the cardiac and cerebral blood vessels.              
In 1995 the American cancer society epidemiologists (Wannamethee et al., 1995) 
found that while low dose aspirin use had no effect on cancers of most organ systems, the 
risks were greatly reduced for fatal cancers of the oesophagus, stomach, rectum and colon. 
These four digestive tract cancers were approximately 40% lower among men and women 
who used aspirin 16 times per month or more for at least one year compared to those who 
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used no aspirin. Very recently (Rothwell et al., 2012) the use of aspirin was again 
suggested to be useful in preventing cancer occurrence. Time will tell if such effects are 
more commonly found in the future.  Aspirin has also been shown to decrease the 
incidence of gastrointestinal cancer and gall bladder disease, to improve diabetes, 
premenstrual syndrome (PMS) symptoms, and pregnancy outcomes.  
However, aspirin has a proven clear benefit in people with a current or past history 
of heart attack, angina, ischemic stroke, transient ischemic attack, peripheral artery disease 
(claudication), as well as people with a 10-year risk of having a coronary event of at least 
6% to 10%. Aspirin is likely to have a benefit in people with a moderate to high risk of 
heart attack or ischemic stroke (stroke caused by blockage of arteries that supply blood to 
the brain).  
In contrast he benefits of aspirin may not outweigh the risks in people who have a 
low risk of heart attack or ischemic stroke. The benefits of aspirin have been studied in a 
wide range of patients and these will now be considered in some detail below (Placezek et 
al., 2004). 
2.07 Prevention of heart attack or stroke 
 Several large trials, primarily among men, have shown that aspirin can prevent a 
first heart attack in people who have no signs or symptoms of cardiovascular disease. This 
is called primary prevention. However, these trials could not detect the effects of aspirin 
on the risk of stroke and death related to cardiovascular disease. In one trial of women, 
aspirin reduced the risk of a first stroke and also decreased the risk of a first heart attack 
among those aged 65years and over (Ridker et al., 2005). However, the risk of a first heart 
attack or stroke in healthy men and women is quite low. As a result, the benefit of reducing 
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the risk of a first heart attack must be weighed against potential risks, such as 
gastrointestinal bleeding and other side effects.  
Expert groups have recommend aspirin to prevent heart attack or stroke for healthy 
men and women when the benefits outweigh the risks, and this includes people with a 10-
year risk of a coronary event of at least 6% to 10%. The recommended daily dose of 
aspirin for prevention of heart attack and stroke is generally between 75mg and 100 mg, as 
shown in Table 3 (Harpaz et al., 1996).  
2.08 The problems and consequences which occur during a heart attack 
The heart, like all other organs and tissues in the body, requires a constant supply 
of blood. The blood supply to the heart is rather unusual as oxygen extraction is of a very 
high order and blood flow to the cardiac muscle only occurs during diastole. If the vessels 
are compromised for any reason, but primarily atherosclerosis, then blood flow decreases 
and oxygen availability is less. The structure of the coronary arteries is complex but their 
passage through the cardiac muscle and its restriction of flow during systole means that 
any decrease in the vascular lumen diameter for a given heart rate may cause problems. Of 
course, when the heart rate rises or the pressure increases then the flow is compromised to 
an even greater extent.  
 One consequence of a sudden restriction of flow is to cause myocardial infarction 
(M I) which is commonly known as a "heart attack". The cessation in the coronary arteries 
prevents blood flow and so causes serious oxygen depletion and this causes either damage 
or death to the cardiac muscle which the particular vessels supplies. In the majority of 
cases in which MI occurs there is an underlying condition of coronary heart disease (CHD) 
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whether this be genetic or related to aging and lifestyle including diet (Amarenco et al., 
2010). 
2.09 Atherosclerotic plaque ruptures and clot formation 
In the development of atherosclerosis, lipid containing plaque builds up in the sub-
endothelial space. This deposition, as it increases in size may displace the endothelium into 
the lumen of the vessel. This protrusion, by effectively decreasing the lumen diameter, 
reduces the blood flow. These endothelial covered projections in the artery wall may 
sometimes develop cracks – i.e. fissures, in their normally perfectly smooth surfaces. If 
that happens, the platelets within the blood stream rapidly detect such changes, rapidly 
adhere and secrete thromboxane to aggregate more platelets in the bloodstream so forming 
a platelet aggregation on which blood coagulation is facilitated (Delud, 2005). 
Normally, blood coagulation within a vessel is a „good thing‟, because endothelial 
damage is caused by events which usually mean potential blood loss and so bleeding in an 
uncontrolled manner is prevented. Unfortunately, when clots form inside the coronary 
artery damaged by atherosclerosis, they develop is such a way that they may partially or 
completely block the flow of blood. This is what happens during a heart attack (Penz et al., 
2005). When a blood clot forms within a coronary artery, the area of heart muscle fed by 
that artery no longer receives enough blood flow. This lack of blood flow has serious 
consequences as cardiac muscle cannot suffer an oxygen debt and so dies. The death of 
heart muscle in such circumstances is termed an "infarction." 
 In some cases aspirin can be life-saving for people who are actively having a heart 
attack. Healthcare providers recommend that anyone who believes they may be having a 
heart attack should  immediately take 162mg  to 325 mg of aspirin (one half to one whole 
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adult aspirin tablet). This will prevent platelet involvement and so reduce the risk of the 
platelets contributing to an even greater effect (Harpaz et al., 1996). 
2.10 Coronary heart disease 
In people with coronary heart disease, sometimes called coronary artery disease or 
simply, coronary disease, the coronary arteries become narrowed by the fatty deposits due 
to atherosclerosis. These plaques inside the coronary arteries limit blood flow to the heart 
muscle, which may cause pain or tightness in the chest especially on exertion when oxygen 
demand increases. This pain or tightness is called angina pectoris, commonly referred to as 
"angina". Aspirin is recommended for people who have a history of several conditions 
(Harpaz, et al., 1996). 
 As already described, most heart attacks develop when a cholesterol-laden plaque, 
in a coronary artery, fissures and once this occurs platelets detect the fissure and adhere. 
There is then a rapid release of thromboxane which causes aggregation of more platelets to 
produce a surface on which coagulation can occur. The thrombus which forms can actually 
rupture and the relatively small plaques, which produce only partial blockages, are the 
ones most likely to rupture. When they do rupture, they attract even more platelets to their 
surface. Platelets and the associated thrombus, then builds up on the ruptured plaque. The 
thrombus grows because blood coagulation is stimulated by the platelets contributing 
factors for the clotting process and the growth may be such as to cause a blockage in the 
artery. If the blockages completely stop the flow in a vessel then it deprives a portion of 
the heart muscle of oxygen. As a result, the muscle cells die. This sequence of events is 
usually described as heart attack.   
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 In these cases aspirin is recommended because by effectively inhibiting platelets 
ability to produce thromboxane. Only a tiny amount of aspirin is needed to inhibit all the 
COX in the platelets in the blood stream. In fact, small doses are better than high doses to 
achieve the degree of selectivity which is required. But since the thrombus grows minute 
by minute, time is of the essence (Penz, et al., 2005). 
Aspirin is also recommended for percutaneous coronary intervention (angioplasty) 
and post surgically for the treatment of coronary bypass grafted patients (CABAG). For 
this condition most health care providers recommend that people in this group take 
between 75mg and 100 mg of aspirin daily (Harpaz, et al., 1996). For heart disease, studies 
have shown that taking low doses of aspirin and maintaining a diet low in fat and high in 
fiber such as grains, fruits and vegetables can reduces the risk of cardiovascular 
complications (Lichtenstein et al., 2006). 
  Aspirin has benefits in people who are actually having or have recently had an 
ischemic stroke or transient ischemic attack (TIA). The recommended dose for this group 
can be between 81mg to 325 mg per day. (see table 2 – Escolar et al., 1986) 
2.11 Aspirin used to treat gastrointestinal tract (GTI) problems  
 When cholesterol-saturated bile accumulates and becomes lodged in the cystic 
duct, gallstones are formed. During acute cholecystitis, usually a bacterial inflammation 
associated with gallstones, the production of prostaglandins is increased as part of the 
normal inflammation and repair processes. This process involves much pain, increased 
fluid secretions, muscle contraction and decreased bile, all of which exacerbate and 
perpetuate the inflammation. Several studies have been conducted to show that 
prostaglandin inhibitors such as aspirin and non-steroidal anti-inflammatory drugs can 
78 
 
prevent the formation of gallstones, as well as reduce the biliary pain associated with it 
(Truitte and Morgan, 1964).  
2.12 Aspirin and pregnancy induced hypertension 
Many studies have concluded that low dose aspirin reduces the risks of pregnancy 
induced hypertension, toxaemia and severe low birth weight (Steve et al., 1998; Robert et 
al., 2008). In another study by another group aspirin was also thought to be helpful in cases 
of hypertension induced by pregnancy (Diejomaoh et al., 2002). This hypertension is 
responsible for significant prenatal morbidity and mortality. In further studies conducted in 
this area, low dosages of aspirin were effective in reducing this type of hypertension to the 
extent of 65%.  It can be reasonably concluded that although aspirin is not a first line of 
defense against such causes of hypertension, it plays an additional role in preventing the 
health problems caused by this disease (Randall , 2000: Williams et al., 2003). 
2.13 Pharmacological properties of Aspirin and its major metabolites   
 Aspirin due to its rapid metabolism can also have active metabolites which may 
bring about some of its pharmacological actions. The table below shows the effect of the 
major metabolite namely, salicylic acid expressed as salicylate. 
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Pharmacological  Property          Salicylate          Aspirin 
 
     Analgesic                 + +             + 
     Antipyretic                 + +             + 
     Anti-inflammatory                   +            + + 
     Anti-platelet                   -            + + 
Table 4. Properties of aspirin and its principle metabolite on analgesia, antipyretic, anti-
inflammatory and antiplatelet actions (Murnion, 2010).  
2.14 The use of aspirin in hypertension – considerations that aspirin may alter 
systemic blood pressure in the hypertensive state. 
 A relatively recent study has shown that systemic blood pressure is affected by 
taking low dose aspirin which is further related to time. More recent findings have 
suggested how low aspirin dosage may facilitate the control of blood pressure. 
 If a patient has been diagnosed with hypertension, it has been suggested by some 
physicians that they should take low dose aspirin each day to potentially reduce the risk of 
a heart attack. Aspirin has been shown in some studies to have a positive effect not only on 
blood pressure but also on the endothelial cells that line both the chambers of the heart and 
the coronary blood vessels (Randall, 2000; Williams et al., 2003). 
 The actual use of aspirin for this purpose is interesting to consider. If someone has 
hypertension and takes low dose aspirin, it is recommended that they take the aspirin at 
night. This has not always been the case as baseline blood pressure readings through home 
monitoring were not always made before changes, to the timing of the dose aspirin, were 
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made. The literature shows a positive association between the dose timing of aspirin and 
hypertension in terms of overall coronary „health‟ (Larry et al., 1997). In fact, according to 
the British Hypertension Society, small dosage of aspirin should be routinely given to 
persons above 50 years of age. Various studies indicate that people of this age had a lower 
risk of Coronary Heart Disease (CHD) if their blood pressure was also under control 
(Aronow et al., 1989). 
 Very importantly, in another study, which was called the hypertension optimal 
study (HOT), this current time conducted in a Chest Hospital in Kuwait, the country in 
which this current study was to be carried out, revealed that taking the aspirin before 
bedtime decreased the cardiovascular risk by 15% and reduced the chances of myocardial 
infarction by as much as 36% (Al-Shammari et al., 2005: Al-Otaibi et al., 2008). However 
there were drawbacks and the major one, as perhaps could be expected based on previous 
evidence, was that aspirin contributed to increased chances of gastric bleeding by as much 
as 65%. For this reason aspirin is best taken with or after food (BNF, 2011) Due to its 
inhibition of prostaglandins in some individuals it also may cause respiratory problems and 
allergic reactions. 
 This study and others were the first studies to reveal that taking aspirin before 
bedtime as opposed to upon waking in the morning was “an effective strategy to lower 
blood pressure and cost effective way to individualize treatment regimes in pre-
hypertensive patients," said lead investigator Prof. Ramon C. Hermida, Director of 
Bioengineering and Chronobiology at the University of Vigo in Spain. He also went on to 
say that "These findings therefore have vital treatment implications for these at-risk 
patients throughout the world'' (Hermida et al., 2003). 
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 Although researchers are unsure as to the reasons for the critical nature of the 
timing of the dose of aspirin to pre-hypertensive patients, being in the evening rather than 
the morning, suggestions have been made that it slows down the production of ''hormones'' 
and other substances in the body that cause clotting. Many of those are produced while the 
body is at rest. The thinking behind such an idea has provided the basic concept for the 
research carried out for the research in this thesis.  
 In addittion, Professor Ramon C. Hermida had important conclusions about the 
timing of the dose of aspirin.  
"These results show us that we cannot underestimate the impact of the body's 
circadian rhythms” (Hermida et al., 2003). 
They also stated : 
 "The beneficial effects of time-dependent administration of aspirin have, until now, 
been largely unknown in people with prehypertension. Personalizing treatment 
according to one's own rhythms gives us a new option to optimize blood pressure 
control and reduce risk of cardiovascular disease down the line." 
 This recorded effect is perhaps not simply related to aspirin‟s analgesic effects as 
men who used acetaminophen (in the UK known as Paracetamol) six to seven days a week 
for pain control actually increased their risk of incident hypertension by 31% as compared 
with non-users (P=0.05 for trend) while for other non-steroidal anti-inflammatory drugs 
the increase in relative risk was 33% (P=0.02 for trend) (Hart et al., 1996; Guillem et al., 
2005). 
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 The effect of aspirin is seemingly complex. Somewhat surprisingly, men who used 
aspirin for pain relief, 300mg, on a nearly daily basis had a 26% increase in risk for new-
onset hypertension compared to non-users (P<0.001 for trend). In contrast aspirin has 
escaped any suggestion of cardiovascular toxicity and has been used for its ability to 
prevent heart attacks via its effects on platelets. For example, since early 2005 the Food 
and Drug Association (FDA) of the United States of America has required all NSAIDs to 
carry warnings about cardiovascular risks associated with prolonged, high dose use of the 
drugs. But aspirin was exempted from that labeling requirement because the FDA said ''It 
has clearly been shown to reduce the risk of serious adverse cardiovascular events in 
certain patient populations''. 
 Patients who take aspirin to prevent heart attack should continue to take aspirin 
unless advised to stop doing so by their cardiologists. However, there are many people 
who use these medications on a regular basis and do not realize there are potential side 
effects (Lipton et al., 1987). Consequently, physicians should ask all their patients about 
their use of these medications and determine if there are alternatives to use. For example, 
physical therapy for those with arthritis or back pain may reduce symptoms and need for 
medication (Henningfield et al., 2009). For individuals with recurrent headaches, the cause 
of the headaches should be explored. If the headaches can be prevented, then medication is 
not needed. The prospective analysis of the problems of headaches included only men with 
a mean age 64.6, who had with no history of hypertension or blood pressure-lowering 
medication use at baseline (Forman et al., 2007). They completed a questionnaire on 
frequency of use and number of '' pills'' consumed per week of acetaminophen, NSAIDs, 
and aspirin. The questionnaire did not actually specify the types of NSAIDs. This was a 
great pity since different NSAIDs may have had different effects. 
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 However, Dr. Forman reported that the data from the cohort's female counterpart in 
the previous Nurses' Health Study (Forman et al., 2005) showed "the majority of NSAIDs 
used were principally ibuprofen followed by Naprosyn." On a follow-up questionnaire four 
years later, 1,968 men reported a new diagnosis of hypertension. Despite similar baseline 
blood pressure across medication use groups, the researchers found significant increases in 
hypertension incidence with more frequent analgesic use. Among the findings: For 
acetaminophen, elevated risk was found for six to seven days per week of use (1.34, 95% 
CI 1.00 to 1.79, P=0.01 for trend). For NSAIDs, significantly elevated risk for daily or 
near daily use (RR 1.38, 95% CI 1.09 to 1.75 P=0.002). For aspirin, the  risk was greatest 
when used two or three times a week (RR 1.36, 95% CI 1.14 to 1.61) and actually 
decreased with increased use, so that when taken six to seven days a week the RR was 
1.26, 95% CI 1.14 to 1.40 P<0.001).  
 When the data were analyzed by number of tablets/capsules consumed the results 
were similar to the findings based on the frequency of use. Interestingly, the body mass 
index (BMI) did appear to have an effect on the relationship between hypertension and 
analgesic use. For acetaminophen, the risk of the incidence of hypertension was greater 
among users with a BMI less than 25, whereas the association dropped out for ''heftier'' 
men (BMI>25) (P=0.01 for interaction), For NSAIDs, risk of hypertension was greater 
among overweight and obese men but dropped into non significance for BMI less than 25 
(P=0.01 for interaction), for aspirin, the BMI did not appear to modify the aspirin-
hypertension association (P=0.94 for interaction).  
The mechanisms by which analgesics impact on blood pressure may include: 
A-  An inhibition of vasodilatory prostaglandins. 
B-  An increase of renal tubular sodium reabsorption with NSAIDs. 
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C-  An increase in cellular oxidative stress with acetaminophen, and,  
D-  An impairment of endothelial function with both acetaminophen and NSAIDs.  
The researchers concluded that the "contribution of non-narcotic analgesics to the 
hypertension disease burden merits further study," if not more caution in their use. 
2.15 Benefits and harms of low-dose aspirin in well-treated hypertensive patients on 
different baseline cardiovascular risks. 
The use of aspirin in subjects without existing and proven cardiovascular diseases is 
controversial. In the intensively treated patients of the Hypertension Optimal Treatment 
(HOT) Study, randomization to low-dose aspirin (75 mg daily) versus placebo 
significantly reduced cardiovascular events (-15%) and myocardial infarction (-36%), but 
increased major bleedings (+65%). The analyses of the HOT Study data aimed at 
identifying subgroups of hypertensive with different benefit-to-harm ratios from aspirin, in 
order to provide recommendations about the use of aspirin in hypertension.  
2.16 Low-Dose Aspirin Therapy. 
 Aspirin, the common pain reliever, has been available for almost a century.  Its 
recent history has been proved to prevent a first and second heart attack in people who 
have coronary artery disease. Furthermore, when taken during and after a heart attack, 
aspirin can reduce the chances of dying. It can also reduce the risk of having a stroke in 
those who have had a previous stroke or a transient ischemic attack (TIA) - a temporary 
interruption of blood flow to the brain, which is often a warning sign of an impending 
stroke. It has been well documented that aspirin reduces the risk of heart attack in people 
with known CAD. It is also now understood that aspirin lowers the risk of having 
symptoms for people who have a higher risk for the disease. People who are at higher risk 
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for coronary artery disease or who already have coronary artery disease benefit the most 
from aspirin therapy.Instructions on how to take aspirin in appendix 2. 
So, exactly how much aspirin should be taken? To answer this simple question is 
not easy and some may say „This is where it gets confusing‟. Aspirin comes in a wide 
range of dosages and in many forms. The optimum dose of aspirin has not been 
established. Using aspirin correctly gives us the best chance of getting the greatest benefits 
with the fewest unwanted side effects. Some doctors recommend taking low-dose aspirin 
(at least 75 mg/day), because a low dose seems to be as effective in preventing heart 
attacks as higher doses. However, one low-dose aspirin preparation which is available in 
the USA which contains 81 mg and this compares with a one adult-strength aspirin 
contains about 325 mg. Some doctors recommend taking 100 mg every other day. Also, 
some drug companies combine aspirin at different strengths, of different salts and they 
contain other ingredients, such as caffeine. These formulas should not be used for daily 
aspirin therapy. 
2.17 Low-dose aspirin suppresses aggregation of blood platelets in both sexes. 
 The study by Hopkins et al., in 2006 showed that low-dose aspirin suppressed 
clumping of blood platelets in both sexes. A once-daily tablet of low-dose aspirin helped to 
lower the potential for clot-forming blood cells - in both men and women - to stick 
together in narrowed blood vessels (Hopkins et al., 2006). A daily dose of 81mg 
acetylsalicylic acid, has been found to prevent platelet clumping (See Table 4). However, 
while the drug‟s overall effects on blood cell function were the same for men and women, 
the investigators found that women‟s platelets reacted somewhat more „strongly‟ to aspirin 
before the start of therapy, and remained so even after treatment.  
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 This study by Hopkins et al., appeared in the Journal of the American Medical 
Association (JAMA) online on March 21, 2006 In this paper they  challenged the 
conclusions from several other then recent studies, including the Federal Women‟s Health 
Study, which showed low-dose aspirin had no effect in preventing heart attacks in women, 
even though it worked in men (Becker et al., 2006).   Previous results, the researchers said; 
 “were not likely caused by the failure of aspirin to prevent platelets from clumping 
together and forming blood clots in women, but rather due to family history. Aspirin has 
been proven by all previous studies to lower the risk of stroke and, as the latest findings 
show, it also reduces platelet aggregation that can lead to potentially fatal clots in blood 
vessels.” 
 The controversy therefore still remains and the true effect on women is yet to be 
established. 
2.18 Practical study on how platelet aggregation can be effected by aspirin in both 
sexes. 
Using an electrical measure of how well platelets stick together, researchers found 
that in aspirin-treated men, clumping decreased by 15.1 ohms.  The decrease was 
statistically the same in aspirin-treated women, at 17.3 ohms.  In this test, an ohm is the 
measure of electrical resistance caused by platelets as they impede the flow of electricity in 
a wire probe inside a test tube filled with blood. 
Moreover, platelet aggregation was largely suppressed in at least three other key 
pathways related to their function when platelets were stimulated with substances that 
normally trigger clot formation (Katzung et al., 2006; Benowitz, 2008). Each of these tests 
involved mixing whole blood, or platelet-rich plasma, from aspirin-treated men and 
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women with various concentrations of each of the main chemical compounds involved in 
the pathways; collagen, adenosine diphosphate, and adrenaline - to see how platelets 
responded. For example, in aspirin-treated men, platelet clumping went down by 14.6 
ohms when 1 microgram of collagen per milliliter was added to whole blood, and 
decreased by 2.4 ohms when exposed to a higher dose of 5 micrograms per milliliter.  In 
treated women, reductions were the same, at 14.9 ohms and 2.42 ohms, respectively.   
When 10 micromoles per liter of adenosine diphosphate were added to whole 
blood, platelet aggregation decreased the same amount, 0.19 ohms in men and 0.21 ohms 
in women.  Addition of 2 micromoles per liter of epinephrine to platelet-rich plasma 
produced significantly greater reductions in platelet clumping in treated women, a drop of 
36.9 percent, while it was less of a reduction for men, at 31.5 percent.  Again, the 
researchers say, these changes would have been zero if aspirin had had no effect. 
Further analysis of these results highlighted two main factors: 
A- Platelet reactivity levels before therapy starts. 
B- Gender, as having played a significant role in predicting the effects of aspirin 
therapy on platelet clumping.   
Other factors, such as age, race or known risk factors for heart disease, including 
smoking, obesity and high blood pressure, were not found to be good predictors of 
aspirin‟s beneficial effects (Henningfield, et al., 2009). 
More than 500 men and 700 women participated in the Kuwaiti study, which was 
called the Genetic Study of Aspirin Responsiveness (GeneSTAR).  Conducted solely at the 
Kuwait Chest hospital from June 2004 to November 2005, the study enrolled participants 
from across the country who ranged in age from 21 to 80 years, 31% were non-kuwaiti and 
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the rest were Kuwaiti.  None had previous histories of heart problems, such as a heart 
attack, but all were considered to be at slightly increased risk of heart disease because of a 
family history. 50% of women participants were postmenopausal. 
Blood testing was conducted both before and after treatment.  In total, more than 
200 different tests of platelet reactivity were performed and analyzed in the study.  
Because whole blood contains other cells that can affect platelet aggregation, testing was 
repeated using a purified version of test samples made up of strictly platelet-rich 
plasma. At the start of the experiment, laboratory tests of blood platelets in women were 
found four times more likely than in men to aggregate when exposed to arachidonic acid, a 
pro-aggregation inducing chemical in the pathway that is most suppressed by aspirin.  
While taking aspirin, participants maintained a strict and consistent dietary and exercise 
regimen, with no smoking or consumption of foods that by themselves affect platelet 
activity, such as caffeine, chocolate, wine or grapefruit juice.  Physical examinations and 
pill counts were conducted to ensure that all participants adhered to the study protocol.  
Because aspirin reaches its maximal effect in the body at five days, the researchers say a 
longer study testing period was not required to determine the drug‟s effects on platelet 
function. 
2.19 Studies utilizing aspirin which have found that long-term heart attack survival 
rates rise when ''cardiac drugs'' are used. 
 The use of medicines to fight cardiovascular disease has been a primary focus of 
research in this area for the past several decades, as combinations of interventions and 
medicinal therapy have gradually begun to increase long-term survival rates. Two recent 
studies presented at the American College of Cardiology's 56th Annual Scientific Session 
look at the measurable impact of the use of aspirin and other maintenance therapies. One 
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study by Dr Zipes, (2006) demonstrated that lower doses of therapies may prove to be just 
as beneficial while also the lowering side effects induced by the drugs. 
 Today cardiovascular disease is the leading worldwide cause of death, and a major 
focus of research is to find better ways to help these patients through prevention, 
immediate intervention and long-term treatment regimens. As we continue to discover the 
benefits of these therapies, we expect to see continued and measurable improvements in 
overall survival and quality of life. This is demonstrated in a study by Jolly et al., (2009) 
entitled „Effects of Aspirin dose on Ischemic Events and Bleeding after Percutaneous 
Coronary Intervention (PCI): Insights from the PCI-CURE Study‟. After patients with 
acute coronary syndromes (ACS, a group of symptoms related to acute ischemia, or chest 
pain related to arterial damage) undergo percutaneous coronary interventions (PCI, 
including stenting), a significant concern among cardiologists is the risk of major internal 
bleeding. Aspirin (ASA) acts as an anti-platelet agent which prevents clotting 
complications, but high dose levels can cause potentially serious bleeding. While PCI trials 
have traditionally used high-dose ASA (more than 200 mg) in combination with other 
medicines to prevent thrombosis and ischemic events, a sub-analysis from a clinical trial 
presented by researchers at McMaster University in Hamilton, Ontario suggests that low-
dose aspirin may be just as effective as high doses to prevent thrombosis while reducing 
the risk of major bleeding in patients who have undergone PCI.  
 As a sub-analysis of the PCI-CURE study, researchers compared the safety and 
efficacy of varying doses of aspirin: low (less than 100 mg), intermediate (101-199 mg) 
and high (more than 200 mg). A total of 2,658 patients with ACS undergoing PCI were 
divided according to the most commonly used dose, and each dose group was evaluated 
for event rates relating to cardiovascular (CV) death, MI or stroke as well as major 
bleeding (Levine et al., 1987). 
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The researchers found similar rates of CV death, MI or stroke in all of the aspirin dose 
groups at 30 days and 8 months. While the incidence of major bleeding was not 
significantly different between the groups at 30 days, the rate of major bleeding was 
noticeably reduced with low-dose aspirin after 8 months, an important factor in the 
practice of aspirin dosing for patients in this population. In this large observational 
analysis, low-dose aspirin appeared to be just as effective as high-dose aspirin in 
preventing recurrent cardiac events in ACS patients after PCI, while reducing the long-
term risk of major bleeding (Tlisara et al., 2003; Henningfield et al., 2009). These data are 
intriguing, since low-dose aspirin is most commonly prescribed in Europe, but in the 
United States, higher doses are most commonly used.'' Our data suggests that lower doses 
may be safer, but this finding needs confirmation in a dedicated randomized trial," said 
Shamir R. Mehta, Associate Professor of Medicine at McMaster University and the 
principal investigator in many of the relevant studies.  
As we continue to make progress in the area of cardiovascular medicine, including 
new technologies, better therapies and ultimately improved patient survival, researchers 
are taking a look back to determine the major factors that have contributed to growing 
survival rates in cardiovascular patients (Lipton et al., 1987). This was a reference to a 
large observational study conducted by researchers from Brigham Womens Hospital in 
Boston  which suggests the value of the use of maintenance therapies, and in particular, the 
increasing use of statins, beta-blockers, and angiotensin-converting enzyme-inhibitors 
(ACEI) or angiotensin-II-receptor blockers (ARB) after a heart attack. To determine the 
actual impact of the increasing use of cardiovascular medicines, the research team 
retrospectively studied Medicare and pharmacy assistance programs records from 1995 
through 2004 to identify nearly 22,000 patients who had been hospitalized due to a heart 
attack and survived more than 30 days after discharge. These patients were followed from 
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the index date (30 days after discharge) until they either died or were still alive at the end 
of the study period.(Henningfield et al., 2009). Of the 21,848 patients in the study, about 
half eventually died during the 74,982 person-years of follow-up (Tlisara et al., 2003). 
After adjusting for demographics and comorbidities, the post-heart attack mortality rates 
showed significant decline from 1995 to 2004 (adjusted HR=.97), corresponding to a three 
percent reduction in mortality each year. After introducing the therapy variables, the team 
found strong indications that the improvement in mortality after heart attack may be 
explained primarily by the increasing use of these drugs.  
 
Aspirin use - summary 
 Long-term prognosis in elderly patients with MI has improved considerably over 
time, and this literature review supports evidence that this can be attributed to the 
increasing use of cardiovascular medicines, including aspirin, after discharge from MI. As 
the rate of heart risks continues to increase among the general population, treatment 
regimens that include the use of cardiovascular medicines will have considerable benefits 
in overall long-term survival rates. 
Basis of the thesis (2). 
 So, in conclusion, the use of low dose aspirin in a range of cardiovascular 
conditions is both promising and yet remains somewhat controversial. This thesis will 
examine one aspect of such medication in Kuwait namely the use of aspirin in 
hypertensive patients to determine if its addition to established anti-hypertensive 
medication can bring about an improvement in their condition. 
Chapter Three 
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Nicotine’s cardiovascular actions and the problems they may cause - 
Background to the thesis – Aims and Objectives 
3.01 Smoking and hypertension. 
Smoking can temporarily raise blood pressure and can increase the risk of blood 
vessels becoming hardened (arteriosclerosis) which because they cause an increase in 
peripheral resistance may lead to high blood pressure (See Table 1) (Placzek et al, 2004; 
Benowitz et al., 2008).  
Cigarettes and cigars both contain variable amounts of nicotine. This nicotine by 
acting on nictotinic receptors in the adrenal medulla causes the release of adrenaline which 
by acting on alpha receptors causes narrowing of the arterioles/arteries in the body, which 
in turn raises the systemic blood pressure. Consequently, it has been considered that 
smoking can cause such elevations of blood pressure, and so is potentially dangerous for 
the individual.  Smoking and hypertension are both risk factors for heart failure. In 
other words, both raise the chances of developing ''heart attacks''. Each of these factors – 
smoking and hypertension- is bad in its own right but when combined, the development of 
heart failure is accelerated. 
 Smoking can also increase the chances of developing a stroke.  Smoking promotes 
arteriosclerosis, which means hardening of blood vessels and an effective narrowing of the 
arterioles, so as a consequence, these can cause a reduction in blood flow. When this 
affects the blood vessels that form the coronary vessels, the left circumflex and descending 
coronary arteries, it can also lead to significant alterations of blood flow to the cardiac 
muscle which ultimately may result in tissue necrosis and ultimately destruction of 
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sections of the heart muscle supplied by the compromised arterial vessels (Benowitz et al., 
2004).  
It has also been universally considered that smoking offers no advantages to an 
individual whatsoever and certainly no medical benefit of smoking has ever been 
discovered. In contrast, it has been found to be a major contributor to many severe and 
chronic medical conditions and diseases such as chronic obstructive pulmonary disease 
(COPD), functional anaemia, heart failure and cancers. To ensure a good state of health, 
all health authorities around the world try to promote the idea that every smoker should be 
both advised and helped to stop smoking as a matter of urgency. After stopping smoking, 
it has been observed that the chances of developing heart failure start reducing 
immediately. By the end of the first year after stopping, the chances of developing heart 
failure are said to be reduced by 50% (Katzung et al., 2006) 
One major problem smokers face is the carbon monoxide content in cigarette 
smoke which is one of the more important components of smoke as it is considered a 
potentially lethal gas. It is damaging effect centers on its interaction with hemoglobin in 
the red cell mass. Carbon monoxide interferes with the process of oxygen which has been 
breathed in attaching itself to hemoglobin and forming a compound called oxyhemoglobin 
which is necessary for the oxygen to be released into the tissues of the heart and other 
organs. Carbon monoxide preferentially, because it has a greater affinity, attaches itself to 
hemoglobin instead of the oxygen. This attachment is irreversible for the entire life of the 
red cell, 120 days, so it produces an effective reduction in oxygen carrying capacity which 
because of the stimulation of the oxygen sensor in the kidney which causes the release of 
erythropoietin which in turn stimulates the formation of new red cells in the bone marrow. 
These new cells add to the existing cell mass and so actually increase blood viscosity. This 
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increase in viscosity requires the heart to work harder to pump the same volume of blood 
and so this can compromise the load on the heart, increase the oxygen requirement of the 
cardiac muscle whilst at the same time the coronary vessels are compromised by 
atherosclerosis and arteriosclerosis which results in oxygen starvation of the myocardium. 
This anoxia is potentially damaging and of course can result in the muscle suffering anoxia 
and death (Benowitz et al., 2004; Katzung ,2006; Henningfield et al., 2009). 
If these effects were not serious enough, another finding is that cigarettes have a 
problematic effect on blood pressure which is because some of the other constituents of the 
smoke, for example the high number of free radicals, can accelerate the rate of 
advancement of atherosclerotic arterial disease much more rapidly and so cardiovascular 
disease occurs much more quickly in smokers than non-smokers (Xinan et al, 2009). 
Other problems associated with smoking and high blood pressure can be the effects 
on the brain. The brain constantly requires high levels of oxygen supply because it has a 
high rate of usage. If the arteries in the brain have a high level of plaque formation and this 
will decrease the effective „flow rate into the brain‟ this will reduce tissue oxygen 
availability. There is also the problem that these atherosclerotic changes increases the 
potential for blood clots for be initiated in the cerebral vessels. Since atherosclerotic 
disease can advance rapidly the possibility of clot formation in smokers increases their risk 
of suffering a stroke and as a consequence of this, death. These increased risks are 
dependent on a number of factors including: the number of cigarettes which are actually 
smoked by an individual per day, the depth of inhalation and the type of cigarettes smoked 
as all these factors modify the actually level of nicotine in blood. As these levels rise on a 
consistent basis then the chances of hypertension will progressively increase.  
3.02 Absorption and metabolism of nicotine. 
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Numerous studies have shown that smoking or chewing tobacco increases blood 
pressure and blood pressure falls when an individual stops smoking. Nicotine is easily 
absorbed from the respiratory tract, and also through tissues within the oral cavity and can 
even pass through the intact skin as is shown by transdermal drug delivery systems.  
The routes of metabolism of the absorbed nicotine, by whatever route it gains 
access, are well documented. Approximately 80% to 90% of nicotine is metabolized in the 
liver, kidneys and lungs. The lungs metabolize a major portion of inhaled nicotine. The 
major metabolites of nicotine are cotinine and (see above) nicotine-N-oxide. The half-life 
of nicotine after inhalation or injection administration is about 2 hours. The kidney 
eliminates both nicotine and its by-products. The most important aspect about elimination 
of nicotine via the kidney is that its excretion is pH dependent. The rate of urinary 
excretion of nicotine is dependent on the pH of the urine. Excretion is reduced when the 
urine is alkaline and its excretion is increased when urine is acidic. Nicotine is also 
excreted in the milk of lactating women who smoke. Mammary milk of heavy smokers 
may contain 0.5 mg of nicotine per liter of milk (Herraiz et al., 2005). 
Absorption of nicotine through cellular membranes depends on the pH within the 
tissue. If the pH is acidic, nicotine is ionized and does not easily pass through cellular 
membranes. At physiological pH (pH = 7.4), 31% of nicotine is not ionized and easily 
passes through membranes (Walsh, et al., 2008; Wullner et al., 2008) 
Tobacco smoke has an acidic pH, and this acidity only allows a little absorption in 
the mouth. Inhalation is therefore necessary to allow nicotine to be absorbed by the huge 
surface area of alveolar epithelium. In the lungs, nicotine is quickly absorbed into the 
systemic circulation. This absorption is easy because the blood flow is high in the lung 
capillaries: a volume equal to the total blood volume of the body flows through each 
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minute. So, the rate of nicotine progressively increases when a cigarette is smoked. 
Absorbed nicotine in the systemic circulation is then rapidly distributed among all the 
organs and it reaches the brain within only ten seconds.      
3.03 Active form of nicotine. 
The active form of nicotine is a cation whose charge is located on the nitrogen of 
the pyrrolidine ring not on the pyridine ring (see Figure 1 page 19). This active form is 
very close in structural terms to acetylcholine (chemical formula CH3COOCH2CH2N+ 
(CH3)3 and its systematic name, 2-acetoxy-N,N,N-trimethylethanaminium.). It has been 
demonstrated that nicotine mimics the effects of acetylcholine, which is one of the major 
neurotransmitters of the brain. Acetylcholine can bind to two different kinds of receptors: 
nicotinic receptors, which derive their name from being activated by nicotine, and 
muscarinic receptors, which derive their name from being activated by muscarine. 
Nicotine and muscarine are thus specific agonists of the two kinds of cholinergic receptors 
- namely nicotinic and muscarinic (Nguyen et al., 2003). 
Nicotine competitively binds to nicotinic cholinergic receptors. The binding of the 
agonist to the nicotinic receptor triggers off a conformation change of the architecture of 
the receptor, which opens an ion channel for a few milliseconds. This channel is selective 
for cations, especially sodium. The opening of the ion channel leads to a brief 
depolarization. (see Figure 9 (a) and (b) below) Then, the channel closes and the receptor 
transitionally becomes refractory (a) and (b) to agonists. This is the state of desensitization. 
Then, the receptor usually goes back to a state of rest, which means that it is closed and is 
again sensitive to the agonists. In case of continuous exposure to agonists, even in small 
doses, this state of desensitization will last a longer time, where it is known as - long-term 
inactivation (Pons et al., 2008). 
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3.04 Operating cycle of a nicotinic receptor.    
Figure 9 a. Processes involved in nicotine stimulation of a nicotinic receptor. 
 
In physiologically normal conditions after the opening of the channel by its binding of the 
neurotransmitter acetylcholine, the receptor becomes desensitized before it goes back to 
the state of rest or it is regenerated.  
 
Figure  9b. Operating cycle of a nicotinic receptor. (Website, 2011)   
If the receptors are exposed „continuously‟ to nicotine in tobacco the nicotine 
molecules „substitute‟ for acetylcholine and this high concentration then over stimulates 
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the nicotinic receptors. Then, the receptor is subjected to long-term inactivation and its 
effective regeneration is prevented by nicotine (Prinz, 1988). 
3.05 Nicotine causes a ‘pleasurable effect’ in the smoker. 
As explained above nicotine causes the stimulation of nicotinic receptors. If this 
stimulation is excessive then the chronic activation of these receptors is balanced by a 
down-regulation in the number of active receptors. This effective reduction of the number 
of active receptors reduces the psychotropic effect of nicotine. Due to the additional 
phenomenon of tolerance, the smoker needs to smoke more and more cigarettes to keep a 
constant stimulatory effect.  
Nicotine activates the complex arrangement of the dopamine systems within the 
brain. Dopamine is a neurotransmitter which is directly responsible for mediating many 
effects in brain, one of which is the „pleasure response‟. Nicotine triggers the production of 
dopamine in the nucleus accumbens. A prolonged exposure of these receptors to nicotine 
reduces the efficiency of dopamine by cutting down the number of available receptors. 
Consequently, more and more nicotine is needed to give the same pleasurable effect 
(Kenny et al., 2006). 
 After a brief period of abstinence, overnight for instance during the hours of sleep, 
the brain concentration of nicotine declines due to its metabolism and excretion and this 
effective reduction in concentration allows a part of the nicotinic receptor population  to 
recover their sensitivity. The return to an active state raises the ability of the 
neurotransmission to function and this is what the smoker feels to be an „abnormal state‟ 
and because of this the smoker feels uncomfortable, and so to return to the more 
pleasurable state it induces him to smoke again. It is said that the first cigarette of the day 
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is the most pleasant because the sensibility of the dopamine receptors is maximal. Then, 
the receptors are soon desensitized the pleasurable feelings „wear off‟.  This is best 
summarized as the vicious circle of smoking.  
3.06 Chemical changes induced by nicotine – potential carcinogenic effects. 
 Nicotine is mainly transformed in the liver, but is can also occur in the lungs and 
the kidneys. The primary metabolites of nicotine are nicotine N-oxide and cotinine (see 
figure 10 below), which are some of the products of the hepatic oxidation of nicotine 
by cytochrome P-450.  
 
Figure 10. The structures of the nicotine metabolites – nictotine N oxide and cotinine, as 
compared against cytochrome P 450. (Guillem et al., 2005) 
 A very worrying aspect of nicotine and its metabolites is that it is considered by 
many to be a strong carcinogen. In fact, nicotine can undergo several kinds of metabolic 
transformation such as the pyrrole ring opening. The methyl group on this open ring 
structure can then become a very powerful alkylating agent when removed from the cycle 
(Guillem et al., 2005).  
 An additional potential carcinogenic effect may be caused by the amine function of 
nicotine which may react with nitrogen monoxide or with nitrous acid in order to form a 
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"nitrosonium" type molecule. This compound may then be transformed by the body, which 
means oxidized and opened. This opening leads to two isomers, two "nitrosamino" type 
molecules (R2N-N=O) where one of the two R group is a methyl (Oshida et al., 1994). 
This reaction occurs as shown in Figure 11. 
 Figure 11. The pathway of metabolism of nicotine during the transformation of the 
molecule to form the open pyrrole ring structure which may act as an alkylating agent. 
(Oshida et al., 1994) 
 
A = 4 (N-methyl-N-nitrosamino)-1-(3-pyridyl)-butan-1-one       
B = 4 (N-methyl-N-nitrosamino)-4-(3-pyridyl)-butanal  
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In acidic medium, the oxygen of the "nitrosamino" group is protonated and the 
double bond moves to the central nitrogen, which becomes positively charged. This new 
molecule is a methyl source. The "nitrosamino" group can then react with another amine, 
which removes the positive charge from the nitrogen. If the amine that reacts is a part of 
the structure of the DNA, then the irreversible alkylation of the DNA occurs as shown in 
Figure 12.   
Figure 12. The pathway of metabolism of nicotine during the transformation of the 
molecule to form the "nitrosamino" group which can react with another amine (Richard, 
1994).   
 
This alkylation is potentially really damaging and may help in the development of cancer 
as it prevents the normal development of the cell. (Leoppky , 1994; Villegier et al., 2003 ) 
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3.07 Other pharmacological effects of nicotine and its metabolites. 
As nicotine enters the body, usually by the pulmonary circulation, it is distributed 
quickly through the bloodstream and can rapidly cross the blood-brain barrier. On average 
it takes about seven seconds for the substance to reach the brain when it has been inhaled 
in the form of cigarette smoke. The half life of nicotine in the body is around two hours 
(Cohen et al., 2001 ; Benowitz et al., 2004 ; Hukkanen et al. 2005 ;  Nolley et al., 2006). 
The amount of nicotine actually absorbed by the body from smoking cigarettes depends on 
many factors, including. 
A- The type of tobacco and its nicotine content – or even added content. 
B- How the smoke is inhaled and the depth of actual inhalation. 
C- Whether a filter is used on the cigarette  
 For chewing tobacco, dipping tobacco, sinus and snuff, which are held in the 
mouth between the lip and gum, or taken in the nose, the amount released into the body 
tends to be much greater than smoked tobacco. 
3.08 Nicotine metabolism. 
 Once absorbed the nicotine is metabolized in the liver by cytochrome P450 
enzymes (mostly CYP2A6, and also by CYP2B6). A major metabolite is cotinine (See 
figure 10). (Green et al., 2000). Other primary metabolites include nicotine N'-oxide, 
nornicotine, nicotine isomethonium ion, 2-hydroxynicotine and nicotine glucuronide. It is 
interesting to note that the processes of gluconuration and oxidative metabolism of 
nicotine to cotinine are both inhibited by menthol, which is used as an additive to 
„mentholated cigarettes‟, thus actually increasing the half-life of nicotine in vivo.  
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 Nicotine acts on the nicotinic acetylcholine receptors, specifically the ganglionic 
type nicotinic receptor and one CNS nicotinic receptor. The former is present in the 
adrenal medulla and elsewhere throughout the gangalia of the autonomic nervous system, 
while the latter is present in the central nervous system (CNS). In small concentrations, 
nicotine increases the activity of these receptors. Nicotine also has complex effects on a 
variety of other neurotransmitters for example: acetycholine, serotonin, dopamine, 
norepinephrine, L-dopa through less direct mechanisms (Hjern et al., 2001). 
 By binding to nicotinic acetylcholine receptors, nicotine increases the levels of 
several neurotransmitters - acting as a sort of "volume control". It is thought that increased 
levels of dopamine in the reward circuits of the brain are responsible for the euphoria and 
relaxation and eventual addiction which is caused by nicotine consumption. Nicotine has a 
higher affinity for acetylcholine receptors in the brain than those in the skeletal muscle 
which is very fortunate as the stimulation of these receptors at what are toxic doses of 
nicotine can induce unwanted contractions and eventually respiratory paralysis. Nicotine's 
selectivity in these two receptor types is thought to be due to a particular amino acid 
difference on these receptor subtypes (Fratiglioni et al., 2000).  
            In addition to the nicotine in tobacco smoke there are also other perhaps less 
expected constituents. For example it contains a range of molecules which are able to 
inhibit monoamine oxidase and these include: harman, norharman, anabasine, anatabine, 
and nornicotine. These compounds significantly decrease MAO activity in smokers 
(Gillbert et al., 2001; Jean, 2001). Since MAO enzymes break down monoaminergic 
neurotransmitters such as dopamine, norepinephrine, and serotonin, nicotine can affect a 
multiplicity of physiological systems (Aggarwal et al., 2006). 
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 Nicotine also activates the sympathetic nervous system, acting via splanchnic 
nerves to the adrenal medulla, which when stimulated releases epinephrine. Acetylcholine 
released by preganglionic sympathetic fibers of these nerves acts on nicotinic acetylcholine 
receptors, causing the release of epinephrine (and norepinephrine) into the bloodstream. 
By binding to the ganglion type nicotinic receptors in the adrenal medulla nicotine 
increases the release of  epinephrine (adrenaline), which acts as a stimulating agonist 
throughout the body. By binding to nicotinic receptors it causes cell depolarization and an 
influx of calcium through voltage-gated calcium channels. Calcium triggers the exocytosis 
of chromaffin granules and thus the rapid release of epinephrine and norepinephrine into 
the bloodstream. The release of epinephrine (adrenaline) causes an increase in heart rate, 
blood pressure and respiration, as well as higher blood glucose levels (Suemaru et al., 
2008). 
 Nicotine also has an affinity for melanin-containing tissues due to its precursor 
function in melanin synthesis or its irreversible binding of melanin and nicotine. This has 
been suggested to underlie the increased nicotine dependence and lower smoking cessation 
rates in darker pigmented individuals (Aguilar et al., 2005). 
 In contrast to the brief half life of nicotine, cotinine one of the metabolites of 
nicotine, remains in the blood for up to 48 hours. It can therefore be used as a very useful 
indicator of a person's exposure to nicotine and can be used as a check to see if an 
individual is in fact currently taking nicotine containing products. 
3.09 Stimulant, relaxant and addictive effects of nicotine. 
 There are many reports of how nicotine's mood-altering effects are experienced in 
different people as it can be both a stimulant and a relaxant (Okamoto et al., 1994).  
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 First by causing a release of glucose from the liver and epinephrine (adrenaline) 
from the adrenal medulla, it causes stimulation. Users report feelings of relaxation, 
sharpness, calmness and alertness. By reducing their appetite and raising the overall 
metabolic rate, some smokers may lose weight as a consequence (De Luca et al., 2004) 
and when they cease smoking the well documented problem of weight gain has been 
reported. 
 When a cigarette is smoked, nicotine rich blood passes from the lungs to the brain 
and within seven seconds gains access to the brain where it immediately stimulates the 
release of many chemical messengers including: acetylcholine, norepinephrine, 
epinephrine, vasopressin, arginine, dopamine, autocrine agents, and beta-endorphin. This 
release of a complex range of neurotransmitters and hormones is responsible for most of 
nicotine's effects. Amongst many other effects nicotine appears to enhance concentration 
and memory due to the increase of acetylcholine release (Aguilar et al., 2005). It also 
appears to enhance alertness due to the increases of both acetylcholine and norepinephrine.  
 Arousal is increased by the increase of norepinephrine. Pain is reduced by the 
increases of acetylcholine and beta-endorphin. Anxiety is reduced by the increase in the 
release of beta-endorphin. Nicotine also extends the duration of positive effects of 
dopamine and increases sensitivity in brain reward systems. Research suggests that, when 
smokers wish to achieve a stimulating effect, they take short quick puffs, which produce a 
low level of blood nicotine.  This stimulates nerve transmission. When they wish to relax, 
they take deep puffs, which produce a high level of blood nicotine, which depresses the 
passage of nerve impulses, producing a mild sedative effect. At low doses, nicotine 
potently enhances the actions of norepinephrine and dopamine in the brain, causing a drug 
effect typical of those of psychostimulants. At higher doses, nicotine enhances the effect of 
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serotonin and opiate activity, producing a calming, pain-killing effect. Nicotine is unique 
in comparison to most drugs, as its profile changes from stimulant to sedative/pain killer in 
increasing dosages and use, another drug that behaves in a similar way is ethanol (Suemaru 
et al., 2008). 
 Theoretically, nicotine is not significantly addictive, as nicotine administered alone 
does not produce significant reinforcing properties. However, after co-administration with 
an MAOI, such as those found in tobacco, nicotine produces significant behavioral 
sensitization, which is a measure of addiction potential. This is similar in effect to 
amphetamine (De Luca et al., 2004).   
 Modern research shows that nicotine acts on the brain to produce a number of 
effects. Specifically, its addictive nature has been found to show that nicotine activates 
reward pathways the circuitry within the brain that regulates feelings of pleasure and 
euphoria. (Reuters Health, 2001)  
 Dopamine is one of the key neurotransmitters actively involved in the brain. 
Research has shown that by increasing the levels of dopamine within the reward circuits in 
the brain, nicotine acts as a chemical with intense addictive qualities. In many studies it 
has been shown to be more addictive than cocaine and heroin, though chronic treatment 
has an opposite effect on reward thresholds (Fratiglioni et al., 2000; Aguilar et al., 2005; 
Fallon et al., 2005). 
 In a similar way to other physically addictive drugs, nicotine causes down-
regulation of the production of dopamine and other stimulatory neurotransmitters as the 
brain attempts to compensate for artificial stimulation. In addition, the sensitivity of 
nicotinic acetylcholine receptors decreases. To compensate for this „compensatory 
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mechanism‟, the brain in turn „up regulates‟ the number of receptors, convoluting its 
regulatory effects with such compensatory mechanisms is meant to counteract other 
compensatory mechanisms. The nett effect is an increase in reward pathway sensitivity, 
opposite of other drugs of abuse such as cocaine and heroin, which reduce reward pathway 
sensitivity. This neuronal brain alteration persists for months after administration ceases. 
Due to an increase in reward pathway sensitivity, nicotine withdrawal is relatively mild 
compared to alcohol or heroin withdrawal. 
  It is interesting to note that nicotine also has the potential to cause dependence in 
many animals other than humans. Mice which have been administered nicotine exhibit 
withdrawal reactions when its administration is stopped. A study found that nicotine 
exposure in adolescent mice retards the growth of the dopamine system, thus increasing 
the risk of substance abuse during adolescence (Alok, 2005; Lampl et al., 2007; Tfelt, 
2008).  
3.10 Nicotine and its effects on the cardiovascular system. 
Nicotine via „indirect mechanism‟ has very powerful effects on arteries throughout 
the body. Nicotine is clearly a stimulant, as it raises blood pressure by releasing 
vasoconstrictors which increases total peripheral resistance, increasing the work load on 
the heart to effectively pump through the „constricted arteries and arterioles‟. It also causes 
the body to release its stores of fat and cholesterol into the bloodstream (Steiner et al., 
2003; Oldstein et al., 2006; Lampl et al., 2007). 
 Nicotine also has a series of complex effects on the blood coagulation system. It 
has been speculated that nicotine increases the risk of blood clots by increasing 
plasminogen activator inhibitor-1, though this has not been actually proven. Plasma 
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fibrinogen levels are certainly elevated in smokers and are further elevated during acute 
COPD exacerbation, which may be one of the consequences of cigarette smoking.  Also 
Factor XIII, which stabilizes fibrin clots, is increased in smokers. But neither of these two 
effects has been shown to be a direct cause blood clot formation in smokers (Hukkanen et 
al., 2005).  However, peripheral circulation in arterioles going to the extremities is also 
highly susceptible to the vasoconstrictor effects of nicotine and this combined with the 
potential increased risk of alterations of factors within the blood coagulation or fibrinolytic 
system is a serious cause for concern (Gaciong, 2003).  
 The effects of nicotine need to be taken into account when considering the renin-
angiotensin-aldosterone system which is a series of reactions designed to help regulate 
blood pressure. When blood pressure falls, for systolic, to 100 mm Hg or lower, the 
kidneys release the enzyme renin into the bloodstream, renin splits angiotensinogen, from 
a large plasma protein that circulates in the bloodstream. This angiotensinogen is then 
acted upon by by angiotensin-converting enzyme (ACE) to produce a peptide which is 
called angiotensin I. This is then quickly converted into angiotensin II, primarily via the 
ACE found in the pulmonary bed. Angiotensin II is extremely potent on many 
physiological systems including causing the muscular walls of small arteries (arterioles) to 
constrict via stimulation of angiotensin receptors, so potently increasing blood pressure. It 
also triggers the release of the hormone aldosterone from the adrenal cortex which causes 
the kidneys to retain salt (sodium) and excrete potassium. It liberates antidiuretic hormone 
from the pituitary gland, and so conserves circulating volume as it causes sodium to be 
retained, thus increasing blood volume and blood pressure (Hersh et al., 2002). 
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3.11 Background to the use of aspirin in cardiovascular disease. 
 In terms of cost, availability, and usefulness, aspirin is one of the greatest triumphs 
of medical science. First isolated from willow bark hundreds of years ago, aspirin is now 
available as a simple over-the-counter formulation. Aspirin is effective as an analgesic, an 
anti-inflammatory, and has actions against platelets that provide protection against heart 
attack and stroke. While there is as no clear definitive study which proves that aspirin has a 
beneficial effect on blood pressure reduction, its protective benefits are said to be so large 
that routine, daily administration of aspirin is now recommended by the American Heart 
Association as a standard component of maintaining a healthy heart (Baigent et al., 2009). 
 Aspirin is a type of chemical called a "salicylate”. Simple salicylates have been 
used as pain and fever reducers since the time of the ancient Greeks, more than 1,500 years 
ago. While aspirin has a large number of potential actions in the body, those related to 
„heart health‟ are straight-forward and well-understood. In the body, the major effect is 
thought to be via the inhibition of thromboxane formation and so preventing platelet 
adhesion and aggregation and so limiting platelet plugs and stimulation of coagulation 
(Wolff et al., 2009). Since a large number of heart attacks and strokes are directly caused 
by small, ''spontaneously'' forming blood clots, the ability of aspirin to prevent the 
formation of these small clots means that heart attacks and strokes become less likely. 
Aspirin may help to prevent blood clots forming via its action of inhibiting platelets 
adhesion onto atheromatous plaques. A clot in an artery may stop blood flowing to the 
tissues 'downstream'. If a blood clot forms in an artery in the heart or brain, it may cause a 
heart attack or stroke (Wolff et al., 2009). 
 The usual dose to prevent thrombus formation is 75 mg each day. This is a 
significantly less than the dose for pain relief which is 300mg. Taking more than the 
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recommended does not make the aspirin work any better as to achieve its selective effect 
on thromboxane production  it is said a greater dose reduces the production of prostacyclin 
which acts as an „anticogulant prostanoid‟.  The higher doses also increase the risk of side-
effects developing. If low-dose aspirin is taken to prevent blood clots to achieve analgesia 
for for other purposes for example, headaches, paracetamol is the drug of choice, rather 
than a higher dose of aspirin (Bachert et al., 2005). 
 People with known cardiovascular diseases usually suffer diseases of the heart or 
vasculature, and in practice, this means those diseases caused by the formation of vascular 
atheroma. The consequences of atheroma are well known and include: heart attack, angina, 
stroke, transient ischemic attack (TIA) and peripheral vascular disease (Eccles et al., 
2003). Everybody has potentially some risk of developing atheroma that may cause one or 
more of the above cardiovascular diseases. However, certain ''risk factors'' increase the risk 
for individual. These include: high blood pressure, high cholesterol level, smoking, lack of 
exercise, obesity, an unhealthy diet, excess alcohol, a strong family history, certain ethnic 
groups, and being male. All these factors are compounded if a person also has diabetes as 
they have an increased risk of developing cardiovascular diseases for factors other than 
those listed above. If someone has diabetes he/she will normally be advised to 
continuously take low dose aspirin. 
 Although it is usually for atheromatous disease that aspirin is taken, it is not 
exclusively for this disease. For example, in atrial fibrillation (AF), people have an 
increased risk of forming a blood clot which can cause a stroke, so some people with AF 
take warfarin to prevent blood clots forming and some also take aspirin (Hashkes et al., 
2003). 
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 For people with existing cardiovascular diseases, and those at high risk of 
developing cardiovascular diseases, there is said to be great benefits from taking aspirin. 
Several studies involving thousands of people have proved that the risk of having a heart 
attack or stroke is much reduced in these people if they take aspirin. For example, the risk 
of having a non-fatal heart attack is reduced by about a third. The risk of having a non-
fatal stroke is reduced by about a quarter. The risk of dying is reduced by about a sixth 
(Bosetti et al., 2006).  
 There is a small risk of developing serious side effects, when taking aspirin but the 
benefits far outweigh the small risk. However, for healthy people with a low health risk, 
even the small risk of side effects from aspirin is perhaps not always acceptable. The side 
effects of aspirin may sometimes be over emphasized since most people do not have any 
side effects with low dose aspirin. Consequently the benefits of taking aspirin usually 
outweigh the small risk of developing side effects.  
 As a rule, 75mg of aspirin is usually the preferred dose of drug to prevent thrombus 
formation. Sometimes an alternative such as lower doses, 25mg of aspirin, is used if there 
is a problem with using aspirin. Sometimes, aspirin plus another antiplatelet drug are taken 
together. For example, after having a stroke a combination of low-dose aspirin plus 
dipyridamole is often prescribed for up to two years. In this situation, after two years the 
dipyridamole is stopped and the antiplatelet treatment is continued with low-dose aspirin 
alone. The use of dipyridamole is interesting since its effects are not due to the inhibition 
of prostaglandin formation but rather an inhibition of adenosine uptake and cGMP 
phosphodiesterase activity. It has little effect by itself and so should always be given in 
combination with aspirin. In such formulations it can be administered at a dose as low as 
25mg of aspirin (Menezes et al., 2006). 
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3.12 Effects on Platelets.  
 Aspirin acetylates a serine hydroxyl group near the active site, of the cyclo-
oxygenase enzyme which prevents arachidonate binding. The inhibition by aspirin is 
irreversible as its acetylates the active site. However, in most body cells re-synthesis of 
PGH2 synthesis would restore cyclo-oxygenase activity (see figure 13) but this is 
impossible in platelets which do not have a re-synthesis capability (Baron et al., 2003). 
 Thromboxane A2 is an extremely potent stimulatory factor in the process of blood 
platelet aggregation, which is essential to the role of platelets in thrombus formation prior 
to blood clotting actually occurring. Many people take a daily aspirin for its anti-clotting 
effect, attributed to inhibition of thromboxane formation in blood platelets. This effect of 
aspirin is long-lived, because platelets cannot make supplies of the inhibited enzyme since 
they lack a nucleus and so the ability to make new enzyme is impossible. Since they only 
'live' for 8-10 days this inhibition is usually not a major problem since new platelets are 
produced on a continuous basis  
 
Figure  13.  Aspirin acetylates the hydroxyl group of the cyclo-oxygenase which inhibits 
the binding arachidonate and so inhibiting the generation the hydroperoxides which are 
then converted to thromboxane and prostanoids.  
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Two isoforms of PGH2 synthesis are designated COX-1 and COX-2 (Cyclo-oxygenase 1 
& 2) (see Figure 13). COX-1 is constitutively expressed at low levels in many cell types. 
(Baron et al., 2003 ; Andrew et al., 2004). COX-2 expression is highly regulated as the 
transcription of the gene for COX-2 is stimulated by growth factors, cytokines, and 
endotoxins. COX-2 expression may be enhanced by cAMP, and in many cells PGE2 is 
produced as a result of COX-2 activity which itself leads to changes in cAMP levels. 
 Though both cyclo-oxygenase isoforms catalyze PGH2 formation, differing 
localization within a cell, and localization of enzymes that convert PGH2 into particular 
prostaglandins or thromboxanes, may result in COX-1 and COX-2 yielding different 
ultimate products (see fig. 13) (Akhmedkhanov et al., 2002). COX-1 is essential for 
thromboxane formation in blood platelets, and for maintaining integrity of the 
gastrointestinal epithelium. Inflammation is associated with up-regulation of COX-2 and 
increased formation of particular prostaglandins. COX-2 levels increase in inflammatory 
diseases such as arthritis (Moysich et al., 2002). 
 An increased COX-2 expression is seen in some cancer cells. Angiogenesis (blood 
vessel development), which is essential to tumor growth, requires COX-2. Over expression 
of COX-2 leads to increased expression of vascular endothelial growth factor (VEGF). 
Regular use of NSAIDs has been shown to decrease the risk of developing colorectal 
cancer. (Baron et al., 2003; Andrew et al., 2004). 
3.13 Aspirin and its site of action. 
 Aspirin‟s ability to suppress the production of prostaglandins and thromboxanes is 
due to its irreversible inactivation of the cyclo-oxygenase (COX) enzyme. Cyclo-
oxygenase is required for prostaglandin endoperoxide, thromboxane and prostanoid 
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synthesis (Sanda et al., 2009). Aspirin covalently acetylates a serine residue at COX 
enzyme active site where arachidonic acid has to attach itself for a cyclization process in 
presence of molecular oxygen for converting itself to PG endoperoxides (see Figure.13). 
Aspirin is different from other NSAIDs, for example, diclofenac and ibuprofen, which are 
reversible inhibitors of the active site of COX-2 whereas aspirin is irreversible. This 
irreversible inhibition blocks the production of prostaglandins, molecules which have both 
positive and negative effects in the body. Prostaglandins, also, have protective effects 
against the development of stomach ulcers, but they can also mediate inflammation as well 
as the pain response. Therefore, ibuprofen and aspirin both inhibit COX-1 and COX-2, but 
in different ways. Ibuprofen does not covalently bind to COX enzymes and competes with 
the enzyme natural substrate, this is called „ reversible inhibition‟. On the other hand, 
aspirin forms a covalent bond to a serine residue in the enzyme, and this bond cannot be 
broken, this is ''called irreversible inhibition'' (Anggard et al., 1965). 
                                                          
                  ( a )                                                                             ( b )  
                                                                 
                     ( c )                                                                       ( d )                         
Figure 14. (a) Structure of serine residue present at the active site of COX-2           
                  (b)  Structure of aspirin 
                  (c)  Structure of tyrosine residue present at the active site of COX-2 
                  (d)  Structure of ibuprofen (Mehta et al., 2005). 
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 The mechanism of both residues of amino acids serine and tyrosine (Figure 14) 
with aspirin and ibuprofen is the same because the reactive site of both enzymes is the 
same and that is the   - OH group. Although the reaction of binding with tyrosine is slow 
due to the aromatic ring, here the electron donating effect of –OH decrease the availability 
of electron or free radical for esterification reaction and also the „big structure‟ causes 
steric hindrance which also decreases the binding to tyrosine. The platelet prostaglandin 
G/H synthase-1 (cyclooxygenase-1) is depicted as a dimer. The arachidonic acid substrate 
gains access to the catalytic site (red area) through a hydrophobic channel that leads into 
the core of the enzyme. (Figure 15a) aspirin blocks the access of arachidonic acid to the 
catalytic site by irreversibly acetylating a serine residue at position 529 in platelet 
cyclooxygenase-1, near but not within the catalytic site. (Figure 15b) interpolation of the 
bulky acetyl residue prevents metabolism of arachidonic acid into the cyclic endoperoxides 
PGG2 and PGH2 for the lifetime of the platelet. Because PGH2 is normally metabolized 
by thromboxane synthase into thromboxane A2, aspirin prevents the formation of 
thromboxane A2 by the platelets until new platelets are generated. Nonsteroidal anti-
inflammatory drugs, such as ibuprofen, are reversible, competitive inhibitors of the 
catalytic site (Figure 15c) whose use results in the reversible inhibition of thromboxane A2 
formation during the dosing interval. Prior occupancy of the catalytic site by ibuprofen 
prevents aspirin from gaining access to its target serine (Francesca et al., 2001).    
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Figure 15.  Effect of Aspirin Alone and of Ibuprofen plus Aspirin on Platelet (source: 
Francesca et al., 2001). 
 
 
3.14 Aspirin induced bronchospasm   
Cysteinyl-leukotrienes (LTs) are derived from arachidonic acid via the 5-
lipoxygenase (LO) pathway (Figure 16). The cellular biosynthesis of LTs involves 5-LO 
activating protein, which transports arachidonic acid into the cytosol to be acted on by the 
enzyme 5-LO. The sequential catalytic action of 5-LO on arachidonic acid yields LTA4, 
which is further hydroxylated to LTB4 or is converted into the first of the cysteinyl LTs, 
LTC4, by LTC4 synthesis (Figure 16). LTC4 is exported to the extracellular space where it 
forms LTD4, which in turn is cleaved to form the 6-cysteinyl analog of LTC4 known as 
LTE4. The cysteinyl LTs exert their biological action by binding to two types of G-
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protein-coupled 7-transmembrane receptors, cyseinyl-leukotrienes (LT1) and CysLT2 
(Kathrina et al., 2005). 
 
 
Figure 16.  Leukotriene synthesis (Sala et al., 2009). 
Aspirin-induced bronchoconstriction is thought to be caused by the shunting of the 
arachidonic acid metabolism away from the cyclooxygenase (COX) pathway toward the 
lipoxygenase (LO) pathway (Hopkines et al., 1989). This results in the increased 
production of cysteninyl–leukotriene (LTs) with the resultant bronchoconstriction. 
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Consistent with this finding, bronchoconstriction in patients with aspirin induce asthma 
(AIA) can be inhibited by cysteninyl– leukotriene (LT) receptor antagonists (Delanay et 
al., 2007; Dorsh et al., 2007; Chan et al., 2009). 
Provocations with aspirin in (AIA) patients produces airflow obstruction 
accompanied by the release of cysteinyl LTs into the urine and blood alcohol level (BAL) 
fluid. LTC4 synthesis is the rate-limiting enzyme for the synthesis of cysteinyl LTs. 
Bronchial biopsy studies have revealed an over expression of LTC4 synthesis in patients 
with AIA as compared to aspirin-tolerant asthma (ATA) patients (Guitton et al., 2003; 
Benowitz et al., 2004; Hukkanen et al., 2005; Gorelick, 2009).  
 The gene for LTC4 synthesis has been localized to chromosome 5q, telomeric to 
other candidate genes, including interleukin (IL)-3, IL-4, IL-5, and granulocyte 
macrophage colony-stimulating factor, which also have been implicated in asthma 
pathogenesis. A genetic variant of LTC4 synthesis gene promoter has been described, 
which is over expressed in the AIA population. However, 30% of patients with AIA do not 
have a predisposing variant of the LTC4 synthesis gene, whereas 25% of the control 
subjects do have it without any consequence to their health (Moysich et al., 2002). 
Although this will not explain the pathophysiology of AIA in all patients in the population, 
such a finding is common in conditions with multifactorial inheritance and is predictable 
on the basis of nonmendelian low inheritance of AIA. The normal expression of 5-LO in 
patients with AIA precludes 5-LO as a contributing factor in the pathogenesis of AIA. 
 Over expression of the LTC4 synthesis in the bronchial wall may be the single 
most important determinant of acute respiratory reactions to aspirin in subjects with AIA. 
In addition, the removal of the prostaglandin (PG) E2 brake in all subjects by NSAIDs, as 
described later, leads to exaggerated cysteinyl LT synthesis only in AIA patients due to the 
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altered threshold activity of LTC4 synthetase in their bronchial wall. Some common 
medicines for example and their advantages over aspirin have been described to provide a 
clear view on the limitations of aspirin in treating high blood pressure (Vane et al., 2003 ; 
Paul-Clark et al., 2004 ; McCarthy et al., 2006). 
3.15 Diuretic effect of aspirin.   
Diuretics are meant to remove sodium (ions) and with then the necessary osmotic 
equivalent of water from the body which is responsible for the increase of blood volume in 
the body. As far as it is known aspirin does not have a reported diuretic action in man  
3.16 The audit the current effective of aspirin and hypotensive agents as compared 
with aspirin. 
Beta-blockers help to reduce blood pressure by reducing heart rate, which is 
completely different from the reported effects of aspirin. Similarly, there are ACE, alpha 
blockers, and calcium blockers which have specific purposes in reducing blood pressure. 
All the above-mentioned medicines are prescribed to target known factors in the systems 
which elevate blood pressure. So, the perhaps on the available evidence the answer to the 
question „will aspirin lower blood pressure‟ is a guarded “no”. But, it may be prescribed to 
have an effect on elements within the blood, namely clotting factors and platelets which 
may facilitate the actual effectiveness of antihypertensive drugs.  In a report almost ten 
years ago it was thought that aspirin achieved such an „antihypotensive effect‟ (Dargan et 
al., 2002).   
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3.17 Aims and objectives. 
So, taking all these factors into consideration the basis of our thesis can be determined. 
Aim: To determine if the use of aspirin in cardiovascular disease is beneficial to those 
people who suffer hypertension in Kuwait especially those who smoke cigarettes 
Objectives: 
1. To undertake a series of experiments investigating nicotine levels and their effects in 
hypertensive subjects (Chapter 4) 
2. To investigate the effectiveness of aspirin in reducing risks (Chapter 5) 
3. To investigate the ambulatory blood pressure of hypertensive patients and their 
treatment with aspirin (Chapter 6) 
4. To audit the curative effect of aspirin and a range of cardiovascular drugs in the state of 
Kuwait hospitals (Appendix 1) 
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Chapter Four 
An experimental investigation of nicotine levels in smokers. 
Experimental investigation of nicotine levels and their effects in hypertensive       
subjects the objectives of which is to use the urinary levels as an index as to what levels of 
nicotine can be currently found in smokers in Kuwait (see page 104) 
4.01 Background. 
The relation of nicotine and circulatory diseases is extremely complex because of 
its (nicotine) ability to stimulate a rise in blood pressure, act as a vasoconstrictor, as well 
as increasing the utilization of  stored body fats and so stimulating the appetite so amongst 
many other things, the smoker feels hungry (Dominguezdes et al., 1981).   
Another of the very important aspects induced by nicotine, which has been 
observed in the blood of smokers, is the enhanced ability of their blood to clot. Central to 
blood clotting is the role of an important regulatory protein known as named as 
plasminogen activator inhibitor-1, stimulation of which prevents the normal activation of 
plasminogen which breaks down the fibrin formed in the coagulation process in a very 
precise negative feedback mechanism which enables the clot to be dynamically modified 
during the complex process and blood coagulation and dissolution by the process of 
fibrinolysis induced by plasmin formed from plasminogen. The suggestion has been made 
that nicotine has the ability to trigger the faster release of plasminogen activator inhibitor-1 
and also increasing the production of fibrinogen. A combination of these two prominent 
procoagualant effects will potentially cause an increased risk of clotting to occur and an 
inability of the plasminogen-plasmin  system to be activated which would normally  bring 
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about the resolution of the clot. This is not just a hypothetical possibility as this change of 
a faster rate of blood clotting has frequently been observed in blood of smokers (Linberg et 
al., 1998). The situation is even more complex since plasma fibrinogen levels which are 
elevated in smokers are further elevated during acute COPD exacerbation which as has 
been described above occurs due to cell damage caused by the constituents of cigarette 
smoke (see above).  
Furthermore, the problems of coagulation are made worse by the finding that 
Factor XIII, which stabilizes monomeric fibrin into cross linked polymeric fibrin, is also 
increased in smokers the greater activity of which may increase the stability of any clot 
which is formed. This would make it more difficult to resolve by the plasminogen-plasmin 
system. All these potential blood clotting problems can influence the way in which blood 
flow can be compromised and this may feed back to cause elevations in the systemic 
arterial pressure due to restrictions of flow caused by thrombi formations.  
In addition to the serious coagulation problems, the arteries which supply the 
extremities are also highly susceptible to the vasoconstrictor effects of nicotine as well as 
the increased risk of blood clots and cessation of flow. A transient increase in blood 
pressure, followed by bradycardia, paroxysmal atrial fibrillation, or cardiac standstill have 
all been observed in smokers (Johnson et al., 1995). Many of these effects reflect problems 
with the blood vessels of the heart and nicotine contributes both to the atherosclerotic 
process and to acute coronary events by several mechanisms. Nicotine could promote 
atherosclerotic disease by its actions on lipid metabolism and enhanced coagulation, by 
modification of hemodynamic effects and/or by causing endothelial injury. Nicotine may 
act by releasing free fatty acids, enhancing the conversion of VLDL (very low density 
lipoproteins) to LDL (low density lipoproteins), so impairing the clearance of LDL and/or 
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by accelerating the metabolism of HDL. Nicotine could also affect platelets by increasing 
the release of epinephrine, which is known to enhance platelet reactivity by inhibiting the 
production of the  anti-aggregatory hormone, prostacyclin,  which is normally secreted by 
endothelial cells, or perhaps by a direct action. Alternatively, by increasing heart rate and 
cardiac output and thereby increasing blood turbulence nicotine may promote endothelial 
injury.  
Amongst the other cardiac effects of nicotine it also facilitates AV nodal 
conduction which could result in an increased ventricular response during atrial 
fibrillation. Nicotine could aggravate peripheral vascular disease by constricting small 
collateral arteries and/or by inducing local thrombosis. Patients with coronary or peripheral 
vascular disease are likely to suffer some increase in risk when taken nicotine. Nicotine 
could contribute to the progression of chronic hypertension by aggravating 
vasoconstriction either in sympathetic activation or inhibition of prostaglandin synthesis.  
Based on its pharmacological actions, it is likely that nicotine plays a role in causing or 
aggravating acute coronary events. Finally, myocardial infarction can be due to one or 
more of these precipitating factors: excessive demand for oxygen and substrates; 
thrombosis and coronary spasm all of which are potentially induced by nicotine. Finally, 
nicotine by increasing heart rate and blood pressure stimulates myocardial oxygen 
consumption which in a myocardium where there are „restricted‟ vessels makes the 
problems even worse (Weber et al., 2001).  
These coronary effects of nicotine have been able to be more objectively studied 
over recent years as nicotine, consumed in the form of nicotine chewing gum, has been 
used in patients with and without coronary artery disease. Chewing gum containing 4mg of 
nicotine – usually used in those patients used to more than 20 cigarettes a day – when used 
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in „control‟ people who were without coronary artery disease, increased their myocardial 
contractility. However, in patients with coronary artery disease, nicotine gum decreased 
the contractility in the ischemic regions of the myocardium, consistent with aggravation of 
ischemia. In the most severe cases of coronary artery disease, overall contractility 
decreased after nicotine gum. This supports the idea that nicotine contributes to the 
induction of myocardial ischemia in susceptible smokers.  
Nicotine may also induce coronary spasm by sympathetic activation or inhibition 
of the vasodilatory effects of prostacyclin. This would agree with the findings that 
coronary spasm has been observed during cigarette smoking. Sudden cardiac death in 
smokers might result from ischemia, combined with the arrhythmogenic effects of 
increased amounts of circulating catecholamine released by nicotine. In addition to 
creating an imbalance between myocardial oxygen supply and demand, nicotine may 
actually promote thrombosis.   
4.02 Testing of nicotine and its metabolites. 
The problem with cigarette use is that although most of its effects may be attributed 
to nicotine it may be more complicated since this agent is metabolized by the liver into 
more than 20 compounds, which are excreted by the kidneys into the urine. The primary 
metabolite is cotinine, and this is widely distributed in the body. Consequently, cotinine is 
the major metabolite of nicotine and is usually the metabolite of choice to evaluate tobacco 
use or exposure to tobacco smoke in an individual, because it is stable and is only 
produced when nicotine is metabolized. Cotinine has a half-life in the body of between 7 
and 40 hours, while nicotine has a half-life of 1 to 4 hours. Blood and/or urine cotinine 
tests may be ordered along with nicotine tests. In some cases, other nicotine metabolites, 
such as nicotine-1´-N-oxide, trans-3´-hydroxycotinine, or nornicotine, or other tobacco 
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chemicals, such as anabasine in urine, may also be tested for but cotinine is the most 
commonly carried out. Clearly the presence of nicotine and/or cotinine in an individual‟s 
biological sample may indicate the use of tobacco products or exposure to environmental 
tobacco smoke. Testing may be used in a number of situations to evaluate the possible use 
of tobacco products such as in smoking cessation programs, prospective employment 
assessments and evaluations of applicants for health or life insurance (Weber et al., 2001; 
Nishi et al., 2008). 
Nicotine and cotinine testing may also be ordered in cases of suspected nicotine 
poisoning. Acute overdoses of nicotine, such as might happen if a child ingests nicotine 
lozenges or gum, are relatively rare but generally require immediate medical attention. 
Symptoms can include a burning mouth, nausea, abdominal pain, salivating (drooling), 
diarrhea, sweating, confusion, dizziness, agitation, increased heart rate, rapid or difficult 
breathing, convulsions, coma, and even death. All these are predictable from knowledge of 
the pharmacological properties of nicotine. 
4.03 Collection of samples for nicotine analysis 
A venous blood sample is obtained in the usual way by inserting a needle into a 
vein in the arm and/or a random urine sample is collected. Occasionally, a saliva sample 
may be obtained – directly or by soaking a collecting „cloth‟ or swab with saliva. Rarely, a 
hair sample may be collected.  In this study urine was the source used. 
4.04 Nicotine test requirement. 
In the blood, nicotine levels can rise within a few seconds of a puff on a cigarette. 
The quantity depends on the amount of nicotine in the cigarette and the manner in which a 
person smokes, such as how deeply they inhale. Test results are not interchangeable and 
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are complicated to interpret as concentrations will be higher in urine than in blood or saliva 
because of the rapid removal and metabolism of the agent. There is also some variability 
from person to person and some genetic differences in the rate that nicotine is metabolized 
and also in the rate that cotinine is cleared from the body. When someone stops using 
tobacco and nicotine products, it can take more than two weeks for blood levels of cotinine 
to drop to the level that a non-tobacco user would have and several weeks more for urine 
levels to decrease to very low concentrations (Henningfield et al., 2006). 
In general, high levels of nicotine or cotinine indicate active tobacco use or 
nicotine replacement use. Moderate concentrations indicate a tobacco user who has not had 
tobacco or nicotine for two to three weeks. Lower levels may be found in a non-tobacco 
user who has simply been exposed to „environmental smoke‟ sometimes known as 
„passive smoking‟. Very low to non-detectible concentrations are found in non-tobacco 
users who have not been exposed to „environmental smoke‟ or a tobacco user who has 
refrained from tobacco and nicotine for several weeks (Johnson et al., 1995; Linberg et al., 
1998). 
In Patients who have suffered a nicotine overdose, for whatever reason, the use of 
the nicotine or cotinine test is somewhat problematic as although the concentrations would 
be increased the levels do not necessarily correlate with the severity of a person‟s 
physiological symptoms. This makes prediction of the likely events, cardiac or otherwise, 
somewhat difficult if not impossible in cases of nicotine „overdosage‟. However nicotine 
or its primary metabolite, cotinine are most often tested for to measure/ evaluate tobacco or 
its replacement usage. This is useful as it is well documented as has been described above 
that the long term use of tobacco products can increase the risk of developing many 
diseases including lung cancer, COPD, stroke, heart disease, and respiratory infections, or 
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exacerbate asthma, and blood clot formation. Finally, in pregnant women, smoking can 
retard fetal growth and lead to low birth weight babies (Benowitz et al., 1983). 
Although the measurement of blood/urine levels of nicotine is somewhat 
controversial because the use of tobacco products can greatly affect the health of 
individuals, companies may use nicotine/cotinine testing to evaluate prospective 
employees tobacco use. Today, many health and life insurance companies test applicants 
for nicotine or cotinine as a part of their assessment for insurance cover.  
Nicotine and cotinine can both be measured qualitatively or quantitatively. 
Quantitative testing can help distinguish between active smokers, tobacco users who have 
recently quit, non-tobacco-users who have been exposed to significant environmental 
tobacco smoke, and non-users who have not been exposed (Hukkanen et al., 2005). 
Cotinine may also be measured in saliva and in hair, although hair testing is primarily used 
in a research setting, such as a study of non-smokers exposure to tobacco smoke. Blood or 
urine nicotine levels may be ordered by itself or along with cotinine if a doctor suspects 
that someone is experiencing a nicotine overdose.  
When a patient has reported that they are using nicotine replacement products but 
are no longer smoking, nicotine, cotinine, and urine anabasine measurements may 
sometimes be ordered. Anabasine is present in tobacco but not in commercial nicotine 
replacement products. If a sample tests positive for anabasine, then the person is still using 
tobacco products (Benowitz et al., 2004). Cotinine and/or nicotine may be ordered 
whenever an evaluation of tobacco use status or tobacco smoke exposure is required. 
When a person enters a smoking cessation program, blood or urine cotinine tests may be 
ordered to evaluate compliance. Urine, blood, or saliva testing may be performed as a 
screen for tobacco use when someone is applying for life or health insurance, or applying 
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for work with an employer that prohibits smoking. Testing may also be ordered by a court 
for child custody purposes. Since smoking can increase the risks of medical complications, 
testing may be performed prior to the start of some drug therapies or surgical procedures 
(Xinan et al., 2009). 
Against this background a series of experiments have been carried out in smokers to 
determine their urinary levels of nicotine. 
4.05 Experimental analysis 
Smoking is major health problem throughout the world and to know the exact 
consequences of smoking it is very important to collect the best and accurate data for 
experimental analysis because inaccurate, insufficient and poor source of analysis may 
lead towards to draw wrong conclusions (Fowler et al., 1998). Clinicians and 
epidemiologists often need an accurate assessment of whether and to what extent a person 
smokes or otherwise uses nicotine, as relying upon self-reporting by nicotine users 
regarding their nicotine habits is often inaccurate. In addition, clinicians and 
epidemiologists may require information concerning inhalation of secondary smoke by 
non-smokers as well as concerning other passive exposure to nicotine as a result of 
environmental conditions. It means some people who are not smokers but simply by living 
close to those people who smoke can develop the same symptoms which have been shown 
by smokers. 
 Various assays have been developed to independently obtain such information 
(Wullner et al., 2008). The most convenient way to analyse the amount or concentration of 
nicotine in the body of smoker, is to prepare and carry out an analysis of various samples 
of their urine. The amount of nicotine and/or its metabolites in the urine will reveal a clear 
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picture of their exposure to this chemical. High performance liquid chromatography 
(HPLC) has been used to specifically determine the level of a nicotine metabolite(s), in the 
urine of subjects as the technique will identify and quantify in the same procedure. 
 4.06 Objectives of using chromatography techniques for the analysis of nicotine and 
its metabolites. 
 The following are the objectives of chromatography methods for nicotine analysis as 
described by Weber et al., (2001). 
1. To differentiate active nicotine users from those who do not use nicotine.  
2. To differentiate heavy users of nicotine from light users.  
3. To detect passive exposure to nicotine such as by secondary smoke inhalation.  
4. To detect extremely low levels of nicotine and/or its metabolites in the urine or 
other body fluids.  
5. To detect nicotine and/or nicotine metabolites without the use of any complex 
instruments.  
6. To provide a colorimetric assay system whereby the presence of nicotine can be 
determined visually.  
7. To provide an assay system whereby the presence of nicotine and/or nicotine 
metabolites can be detected in unprocessed urine.  
4.07 Use of the assay for nicotine in subjects who smoke and the Bioavailability of 
Nicotine 
The rapid absorption of nicotine from cigarette smoke through the lungs occurs 
because of the huge surface area of the alveoli and small airways, and because of 
dissolution of nicotine at physiological pH (approximately 7.4) which facilitates transfer 
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across cell membranes. Chewing tobacco, snuff, and nicotine polacrilex gum are 
formulated at alkaline pH as a result of the selection of appropriate tobacco and/or 
buffering with additives by the manufacturers. The alkaline pH facilitates absorption of 
nicotine through mucous membranes (Nishi et al., 2008). Nicotine is a water and lipid 
soluble drug which, in the free base form, is readily absorbed via respiratory tissues, skin, 
and the gastrointestinal tract.  Nicotine may pass through skin or mucous membranes when 
in alkaline solution (in which nicotine is largely unionized).When tobacco smoke reaches 
the small airways and alveoli of the lung, the nicotine is rapidly absorbed (Newton et al., 
2006).  
After absorption, nicotine enters the blood where, at pH 7.4, it is about 70% 
ionized and binding to plasma proteins is less than 5%.  Studies showed that, after 
intravenous administration, the distribution of C14-labeled nicotine is immediate, reaching 
the brain of mice within 1 min. after injection. Similar findings based on positron emission 
tomography of the brain, were seen after injection of 11C-nicotine in monkeys Nicotine 
inhaled in tobacco smoke enters the blood almost as rapidly as after rapid I.V. injections. 
Because of delivery into the lung, peak nicotine levels may be higher and lag time between 
smoking and entry into the brain shorter than after IV injection. Consequently, after 
smoking, the action of nicotine on the brain is expected to occur very quickly (Benowitz et 
al., 1982; Henning Field et al., 2006) 
This rapid onset of effects after inhalation of cigarette smoke is believed to provide 
optimal reinforcement for the development of drug dependence. The intensity of the effect 
of nicotine declines as it is distributed to other tissues. The distribution half-life, which 
describes the movement of nicotine from the blood and other rapidly perfuse tissues, such 
as the brain, to other body tissues, is about 9 min. Distribution kinetics, rather than 
131 
 
elimination kinetics (half-life about 2hr) determine the time course of the CNS actions of 
nicotine after smoking a single cigarette. The apparent volume of distribution in animals is 
approximately 1.0 L/kg whereas in one clinical study it was 2.0 L/kg in smokers and 3.0 
L/kg in nonsmokers.  
The effective biological half-life of nicotine averaging 2 hours is useful in 
predicting the rate of accumulation of the drug in the body with repetitive dosing and the 
time course of decline after cessation of dosing. Consistent with a half-life of 2 hours, 
accumulation of nicotine over 6 to 8 hours during regular smoking and persistence of 
significant levels of nicotine in the blood for 6 to 8 hours after cessation of smoking, i.e. 
overnight, has been observed (Benowitz et al., 2004; Hukkanen et al.,2005). Thus, heavy 
cigarette smoking represents a situation where the smoker is exposed to significant 
concentrations and possibly pharmacological effects of nicotine for 24 hours a day. 
Apparent acute tolerance to nicotine, determined on the basis of observations of the 
relationship between venous blood levels and effects, may be due to distribution 
disequilibrium between venous and arterial blood; venous blood levels substantially 
underestimate concentrations of nicotine in arterial blood and at potential sites of action. 
True tolerance does, however, develop rapidly, with a half-life of development and 
regression of about 35 minutes (Xinan et al., 2009).  The kinetics of tolerance may be 
another determinant of cigarette smoking particularly when the smoker smokes his next 
cigarette.  
 
 
132 
 
4.08 Elimination of nicotine and the effect of other factors on the urinary level of this 
drug. 
Nicotine and its metabolites (cotinine and nicotine 1-N-oxide) are excreted in the 
urine. At a pH of 5.5 or less, 23% is excreted unchanged. At a pH of 8, only 2% is excreted 
in the urine. The effect of urinary pH on total clearance is due entirely to changes in renal 
clearance. Nicotine is secreted into saliva. Passage of saliva containing nicotine into the 
stomach, combined with the trapping of nicotine in the acidic gastric fluid and 
reabsorption from the small bowel, provides a potential route for enteric nicotine 
recirculation. This recirculation may account for some of the oscillations in the terminal 
decline phase of nicotine blood levels after IV nicotine infusion or cessation of smoking.  
As has been described above nicotine is an agonist at nicotinic receptors in the 
peripheral and central nervous system. In man, as in animals, nicotine has been shown to 
produce both behavioural stimulation and depression. Pharmacodynamic studies indicate a 
complex dose response relationship, due both to complexity of intrinsic pharmacological 
actions and to rapid development of tolerance (Nguyen et al., 2003; Walsh et al., 2008). 
As stated in the Objectives - the urinary levels were used as an index as to what 
level of nicotine can be currently found in smokers in Kuwait. 
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Methodology 
4.09 Experimental investigation of urine samples taken from patients in this study 
using a solid phase reactant system. 
These experiments used an analytical system for detecting nicotine and/or nicotine 
metabolites. The detection system includes a solid phase containing assay reagents 
including a color determinant, a buffer, a cyanogen releasing agent and a cyanogen halide 
forming agent (Pons et al., 2008; Xinan et al., 2009). Since this system, is relatively new, a 
description of the various stages will be given. The method is capable of assaying 
unprocessed urine from smokers for the presence of nicotine and/or nicotine metabolites 
(DeNoble et al., 1982).  
The term solid phase is intended to include any solid material that is capable of 
binding the assay reagents and allowing contact of these reagents with a test sample via 
capillary action. Examples of solid phases include paper, porous membranes, capillary 
tubes, resin bed (ionic and non-ionic type columns) and the like. The preferred solid phase 
is paper. Examples of „paper‟ which may be used for such a procedure can include 
cellulose, fiberglass and tuff glass. The preferred paper is 100% cellulose (Oshida, 1994). 
The solid phase is selected for various functions. The solid phase may be adapted to bind 
reagents that are applied to the solid phase in solutions. Preferably, the solid phase is 
adapted to permit movement of liquid through the solid phase by capillary action 
(Schwartz et al., 1982).  
A porous solid phase will capture and bind the assay reagents onto the solid phase, 
and also is adapted to facilitate movement of the reagents through the solid phase by 
capillary action. The solid phase is selected based on its capacity to hold the reagent 
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volumes applied and on its capillary action properties. (Gotti et al., 1982; Jean, 2001; 
Gilbert et al., 2001) This method entails contacting the liquid sample with a solid phase 
impregnated with assay reagents including a color determinant, a buffer, a cyanogen 
releasing agent and a cyanogen halide forming agent, and detecting the formation of color 
as indicative of the presence of nicotine and/or nicotine metabolites. The terms nicotine 
and/or nicotine metabolites, solid phase, impregnated, color determinant, buffer, cyanogen 
releasing agent and cyanogen halide forming agent are used as defined above (Chang et 
al., 1974). 
Application of the reagents. 
The reagents may be applied to the solid phase so that they are arranged in a 
sequence which maximizes production of the end product in the color reaction assay. The 
preferred sequences are: color determinant, buffer, cyanogen releasing agent and cyanogen 
halide forming agent, or color determinant, cyanogen releasing agent, buffer and cyanogen 
halide forming agent. In either of these arrangements, immersion of one end of the solid 
phase into a liquid test sample results in the liquid initially making contact with the color 
determinant (Reynolds et al., 1978; Hukkanen, 2005; Nishi et al., 2008). The liquid then 
sequentially passes through the other reagents in the order that they are present on the solid 
phase, by capillary action. If nicotine or nicotine metabolites are present in the liquid 
sample, the reactions described above take place, resulting in a colored end product.  
In order to achieve the maximal advantages of this experiment, the amount of 
sample applied to the strip and the manner in which the sample is applied to the strip are 
specified. It is preferable that the sample contact only a portion of the strip, with capillary 
action drawing the sample through the strip and into contact with the various reagents of 
the strip. In the preferred strip (see examples), the end of the strip containing the color 
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determinant is immersed in the sample with approximately 1/2 of the color determinant 
region being immersed. The remaining portions of the strip are not immersed. Also in the 
preferred assay (see examples), a sample of about 0.5 ml is contacted with the color 
determinant end of the strip. This is a sufficient volume to permit the sample to contact the 
reagents such that a color end product is produced, but not so much for example to reduce 
color intensity due to dilution, to reduce the effects of the buffer due to dilution, or to 
cause any of the reagents to be washed from the strip (Mansour et al., 1977). 
Color detection. 
The term detecting the formation of color is intended to include any process 
whereby the presence or absence of colour is determined. Such processes include visual 
detection and detection with instruments. The preferred method for detecting colour 
formation is visual detection. The formation of color can be detected on the solid phase or 
in the liquid test sample. Preferably, colour is detected on the solid phase. Depending upon 
the colour determinant that is selected for the reaction assay, a particular colour is formed 
if nicotine and/or nicotine metabolites are present in the test sample. When the preferred 
colour determinant, diethyl thiobarbiturate, is used in the reaction assay, the presence of 
nicotine and/or nicotine metabolites in the test sample results in the formation of a pink 
color (Conti-Tronconi et al., 1982). 
The assay can also be used as a qualitative assay, in that the formation of any color 
indicates the presence of nicotine and/or nicotine metabolites. The assay can also be used 
as a semi-quantitative or quantitative assay, in that the intensity of color formed on the 
solid phase is indicative of the amount of nicotine and/or nicotine metabolites present in 
the test sample (Hall, 1981). 
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This would be desirable for distinguishing between a light or heavy smoker. 
Preferably, the intensity of color formation from the reaction assay is compared to a 
standard in which a known quantity of nicotine and/or nicotine metabolites has been 
contacted with a duplicate solid phase. The term duplicate solid phase is ted reagents. The 
standard may be generated by performing an assay reaction with a solution containing a 
known concentration of nicotine and/or nicotine metabolites (Aceto et al., 1982). The 
standard may also be a reference color chart which is generated to simulate the intensity of 
color formed when an assay reaction with a solution containing a known concentration of 
nicotine and/or nicotine metabolites is performed. For example, a standard representing 5-
6 μg/ml and 12-15 μg/ml of nicotine and/or nicotine metabolites in urine can be used to 
identify light to moderate and heavy smokers, respectively. A negative control with 0 μg / 
ml of nicotine and or nicotine metabolites also may be included. Alternatively, a semi-
quantitative or quantitative determination of nicotine and/or nicotine metabolites may be 
made by measuring the optical densities in a spectrophotometer of the liquid test samples 
themselves, which also turn color as a result of the solid phase of this invention being 
immersed into the liquid test samples   (Abood et al., 1981). 
4.10 Use of this assay in non smokers. 
This assay is also capable of assaying urine for the presence of nicotine and/or 
nicotine metabolites from nonsmokers who have been exposed to secondary smoke 
inhalation/ingestion if their urine sample is concentrated prior to the assay reaction. The 
urine may be concentrated using any art-recognized concentration protocol (Tripathi et al., 
1982). For example, the urine may be concentrated using an XAD-2 resin column as 
described in Mule et al. (1971), Yamasaki et al., (1977) and Kullberg & Grodezky (1974).  
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4.11 Application of the samples. 
Application of the reagents is accomplished manually or mechanically. Preferably, 
the reagents are applied such that the reagents are arranged in the particular sequences as 
previously discussed. The term drying is intended to include air drying and any type of 
mechanical drying process. (Xinan et al., 2009) The dried solid phase is packaged in a 
moisture proof material in the form of polypropylene coated aluminum foil, polypropylene 
and polyethylene (Abood et al., 1980; Martin et al., 1981). 
4.12 Experiments on smoker’s urine for nicotine content for this thesis. 
Tests were performed on urine of samples from smokers who had developed an elevated 
blood pressure. 
1) A patient who was asked to smoke a cigarette had his urinary level of nicotine 
monitored over 0-4 hours which was used to establish the validity and sensitivity of the 
experimental procedure in the Kuwait laboratory. I carried out all these myself. 
2) Urine samples from groups of nonsmokers (n=8), light smokers (n=8) moderate 
smokers (n=9) and heavy smokers (n=10) were collected and tested within identical time 
frames for the presence of nicotine and/or nicotine metabolites. They were all volunteers, 
to whom the ethics of the tests were explained and were chosen at random from patients in 
the hospital. The samples from smokers were performed on those individuals who had 
developed an elevated blood pressure, so that their levels of nicotine in their urine could be 
compared to their blood pressure. The experiments I carried out were in conjunction with 
the hospital laboratories under the supervision of the appropriate technical and scientific 
staff. 
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The procedure was as described below: 
.  
4.13 Steps in the preparation of the paper strips. 
Step 1 - preparation of Paper Strips (see above for a sample of a strip)  
Absorbent Paper Grade 222 was cut to 7.5×25 cm size with letters "DG" printed at 
0.5 cm intervals along the length of the strip with an arrow pointing to the bottom of the 
7.5 cm length. STR1 this paper was then cut to 0.5×7.5 cm size strips using a sharp razor 
blade in a strip cutter. Only strips with sharp edges were used.  
Step 2 – preparation of the required reagents which were then applied to Paper 
Strips. 
The reagents were prepared in the following way. 
40% chloramine-T was prepared by dissolving 40 g of chloramine-T in warm water to 
make 100 ml final volume. This solution was kept warm at 65°-70° C. during dispensing. 
100% potassium thiocyanate was prepared by dissolving 100 g of potassium thiocyanate in 
water to make a final volume of 100 ml, while shaking under warm tap water. 
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2M citrate buffer was prepared by combining 23 ml of 2M citric acid with 27 ml of 2M 
trisodium citrate to give a pH of 4.2.  
2.5% diethyl thiobarbiturate was prepared by dissolving 2.5g of diethyl thiobarbiturate in 
100-80% ethanol to a final volume of 100 ml.  
The blank strips from step 1 were arranged on a strip support provided with 
shallow grooves to hold strips in place, with all the "DG" facing one side. Using an eight 
channel multipipetter, the reagents were applied onto the strips starting with chloramine-T, 
followed by potassium thiocyanate, citrate buffer, and finally, diethyl thiobarbiturate. The 
volumes of each of the reagents and the spacing of each on the strip were as follows: 40% 
chloramine-T-31.5 μl at the top end where "DG" was printed; 100% potassium 
thiocyanate-15 μl approximately 2 cm from the top; 2M citrate buffer pH 4.2- 20 μl 
approximately 4 cm from the top; and 2.5% diethyl thiobarbiturate--20 μl at the bottom 
end of the strip.  
After all the reagents were dispensed onto the strips, they were transferred onto a 
mesh tray and dried in a box attached with an exhaust fan. To enhance the drying process, 
warm air was blown into the box from the opposite end of the fan. The strips were dry in 
one hour. Since moisture is an important factor in the stability of the strips, they were 
generally dried for longer than 1.5 hours.  
Step 3 - Packaging of Paper Strips  
After the paper strips were dried, they were packaged individually in a moisture 
proof material such as polypropylene coated aluminum foil, polypropylene or 
polyethylene. The strips were packaged in small numbers, e.g., in sets of 5 per sleeve, each 
strip in its own pouch. Perforations were made between individual pouches so that single 
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strips could be used without affecting the rest of the strips. On the side of the box 
containing the above package, a panel of colors was included to indicate one negative and 
two positive control colors. One of the positive colors corresponded to light to moderate 
smoker urine and the second color corresponded to heavy smoker urine. The packaged 
strips remain stable in the original packaging for at least a year at refrigerator temperature.  
Step 4 - Use of paper strips for assaying urine samples for the presence of nicotine 
and nicotine metabolites. 
Approximately 0.5 ml of urine was pipetted into a 13×100 mm tube. The package 
containing the reagent impregnated paper strip was cut open at the top and the strip was 
taken out with forceps and dropped into the urine sample with the arrow pointing 
downwards. It was allowed to stand for 10-15 minutes. Any color changes were observed. 
Urine containing no nicotine or nicotine metabolites did not change the color of the strip. 
The presence of nicotine and its metabolites in a urine sample gave a pink color, both on 
the strip and in the solution. The presence or absence of a nicotine /metabolite was 
independently verified using an enzyme immunoassay (EIA). The color was stable for 
almost an hour, after which it started to fade. Closing the tubes with a cap improved the 
final color intensity slightly.  
4.14. ELISA assay method. 
Enzyme-linked immunosorbent assay (ELISA), also known as an enzyme 
immunoassay (EIA), is a biochemical technique used mainly in immunology to detect the 
presence of an antibody or an antigen in a sample. In simple terms, in ELISA, an unknown 
amount of antigen is affixed to a surface, and then a specific antibody is applied over the 
surface so that it can bind to the antigen. This antibody is linked to an enzyme, and in the 
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final step a substance is added that the enzyme can convert to some detectable signal, most 
commonly a colour change in a chemical substrate takes place. 
Performing an ELISA involves at least one antibody with specificity for a 
particular antigen. The sample with an unknown amount of antigen is immobilized on a 
solid support (usually a polystyrene or polyvinylchloride acts as binding site on solid 
phase) either non-specifically (via   adsorption to the surface) or specifically (via capture 
by another antibody specific to the same antigen, in a "sandwich" ELISA). After the 
antigen is immobilized, the detection antibody is added, forming a complex with the 
antigen. The detection antibody can be covalently linked to an enzyme or can itself be 
detected by a secondary antibody that is linked to an enzyme through bioconjugation. 
Between each step, the plate is typically washed with a mild detergent solution to remove 
any proteins or antibodies that are not specifically bound. After the final wash step, the 
plate is developed by adding an enzymatic substrate to produce a visible signal, which 
indicates the quantity of antigen in the sample (Engvall et al., 1971, Vrolix et al., 2010).  
It can be understood by following diagram (after Van Weemen et al., 1971). 
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(1)   Plate is coated with a capture antibody;  
(2)   Sample is added, and any antigen present binds to capture antibody;  
(3)   Detecting antibody is added, and binds to antigen;  
(4)   Enzyme-linked secondary antibody is added, and binds to detecting   
antibody; 
(5)  Substrate is added, and is converted by enzyme to a detectable form due to    
the formation of a complex which has a certain color which in case of nicotine is 
a pink color. 
Figure 17. Enzyme Immunoassy (ELISA) of nicotine from a urine sample.  
4.15 Statistics. 
The nicotine concentrations (g/ml) in the urine samples were compared between non 
smokers and the light, moderate and heavy smokers groups using the Mann Whitney U 
test. A P value of less than 0.05 was considered significant. 
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4.16 Results 
Results found from urine samples taken at various time intervals from a person who had 
smoked one cigarette are shown in Table 5. 
These results established that the method was both feasible and also sensitive and 
reproducible. Duplicate measurements were made and the results show the mean of these 
measurements. 
Table 5 - ELISA and paper strip analysis of a smokers urine after smoking a single 
cigarette. Nicotine values are expressed as microgrammes of nicotine per ml of urine and 
for the paper strip is reported as showing either (+) the presence or (-) the absence of 
detectable nicotine.  
Specimen No. Time Elapsed after 
Smoking 
Paper Strip Test ELISA Nicotine 
concentration 
(μg/ml) 
1   0 hour - 0.0 
2 Three hours - 0.23 
3 Four hours + 0.16 
4 Five and half hours + 0.12 
Samples from non smokers and different levels of smoking activity 
Urine samples from nonsmokers (n=8), light smokers (n=8), moderate smokers (n=9) and 
heavy smokers(n=10) were tested for the presence of nicotine and/or nicotine metabolites 
by using both a) Paper strip assays were performed as described in 4.18 and b) ELISA 
assays which were performed as described in 4.14. 
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4.17 Qualitative test in the paper strip assay. 
  The Light (L), Medium (M) and Heavy (H) designations were determined by 
observing the intensity of the pink colour which appeared during the analysis of nicotine in 
urine. The more intense the pink color developed on strip indicated that the smoker was a 
heavier smoker where as a light pink colour indicated that the smoker was a light smoker. 
An intensity of color lying somewhat between light and more intense pink color indicated 
that the smoker was a moderate smoker. 
4.18 Comparison of paper strip and ELISA Assays.  
These results were quantified using the very sensitive method of the ELISA assay. 
This comparison, on the same samples as used for the paper strip method helped to make 
comparison between light, moderate and heavy smokers far more accurate and without the 
subjective basis of colour estimation.  
The ELISA method used a Solid-phase immunoassay which involved fixing 
antibody to the antigen on a polyvinylchloride sheet, by putting on a drop of urine and 
washing off after the antigen-antibody complex has had time to form, and then adding a 
second labeled or fluorescent antibody, this time specific to a different epitope [specific 
region where change take place] of the antigen. The amount of the second antibody that 
binds is proportional to the amount of antigen present. This can convert a colorless 
substance which is non-fluorescent to a fluorescent product because the second antibody 
contains a fluorescent component. 
These results were quantified using the very sensitive method of the ELISA assay. 
This comparison (table 6) helped to make comparison between light, moderate and heavy 
smokers far more accurate and without the subjective basis of colour estimation. 
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Table 6 - Reagent impregnated paper strip test and ELISA nicotine levels (g/ml) in the 
urine of non-smokers and three types of smokers – light, medium and heavy smokers. Key: 
Known secondary smoke exposure L = light; M = moderate; and H = heavy.  
Subjects I 
Non Smokers 
II  
Light smokers 
III 
Moderate smokers 
IV  
Heavy Smokers 
Strip 
Test 
ELISA Strip 
Test 
ELISA Strip 
Test 
ELISA Strip Test ELISA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
0.08 
0.12 
0.028 
*0.07 
N.D 
0.07 
  0.0 
  0.0 
L 
L 
L 
L 
L 
L 
L 
L 
 
   0.70 
   2.20 
   0.64 
   0.20  
   2.00 
   1.20 
   0.70 
   1.40 
 
 
 
M 
M 
M 
M 
M 
M 
M 
M 
M 
 
  1.0 
  2.3 
  1.1 
  N.D. 
  1.1 
  1.6 
  1.4 
   2.0 
   2.3 
  
 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
  4.0 
  7.6 
  4.0 
  2.1 
  3.7 
  2.6 
  2.5 
  3.2 
  5.6 
  8.0 
 4 out of 8 subjects 
self reported. 
consumption of 3-5 
cigarettes /day 
6 out of 9 subjects self 
reported consumption 
of 1 pack/day 
8 out of 10 subjects 
self reported 
consumption of 1-2 
packs/day 
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The bar chart presented in Figure 18 which indicates the concentration of nicotine 
which was found in the urine of respective subjects. The subjects are grouped together in 
arbitrary groups of four to facilitate their presentation. They were not linked together in 
any other way. 
 
Figure 18. Bar chart of ELISA results for nicotine levels in the urine of non-smokers as 
compared to three levels of smoking activity namely - light, medium and high. Each bar 
represented the levels found in one individual arbitrarily grouped together in groups of 
four subjects. These groups are designated subject 1-10. 
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4.19. Discussion. 
The values of nicotine in the urine of patients who do not smoke and with those who had 
with different levels of smoking activity are shown in Figure 18. The findings showed 
some interesting effects. 
For Non smokers.  
In some of the non smokers, five out of eight of the subjects, there were actually 
detectable levels of nicotine in their urine. This value, since they stated they were non 
smokers, must have been obtained from either the diet (see above) or from passive 
smoking. The detection and quantification of such low levels clearly established the 
sensitivity of the assay which was used. 
Smokers groups. 
In the „smoking groups‟ the levels of urinary nicotine were clearly dependent on 
the individuals exposure to cigarettes.  
Light smoking group (n=8) designated as being 3-5 cigarettes a day. If the 
patterns of excretion are examined (Figure 18) for the light smoking group they had a 
median value of 0.85 g/ml with a range of 0.20 – 2.2g/ml. If these patterns of excretion 
are statistically compared (Figure 18) for the light smoking group versus the non smoking 
group they had a significantly (Mann Whitney U test, P<0.01), greater level of excretion 
than the non smokers. For the light smoking group their median value was 0.85 g/ml with 
a range of 0.20 – 2.2g/ml as compared to a median value of 0.07 g/ml for the non 
smokers with a range of 0 – 0.12 g/ml. This tenfold range of excretion suggested a 
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greater variability in this group than the other groups, perhaps reflecting different patterns 
of smoking than for the other groups.  
Moderate smokers (n=9) designated as up to 20 cigarettes a day. The moderate 
group smoked on average between four and six times the number of cigarettes than the 
light group but did not have four to six times the nicotine excretion in their urine. In fact, 
the median value was 1.6 g/ml with a range of 1.0 – 2.3g/ml. The range was therefore 
only a doubling, rather than a tenfold range seen in the light smokers. Although these 
levels were not significantly different from the light smokers (P>0.05) it may have been 
anticipated that the levels would have been much greater because they smoked up to 20 
cigarettes per day. This was not the case. There was however more uniformity in the levels 
which were found in the urine.  
Heavy smokers (n=10) designated as being between 20-40 cigarettes a day. In 
the final group – heavy smokers - the nicotine excretion was the greatest of the three 
groups measured and significantly different (P<0.01) from control, light and moderate 
smoker groups.. In this group the median was 3.85g/ml and the range was 2.1 – 
8.0g/ml. This fourfold range may reflect the differences between individuals smoking 
between 20 – 40 cigarettes per day. If these urine levels reflect plasma levels, then at this 
high consumption rate the individual may experience the profound pharmacological effect 
on the cardiovascular system and other systems of nicotine. 
There were differences between members of the same group which may be 
expected as each member of the group did not smoke exactly the same number of 
cigarettes and there method of smoking – the depth of inhalation and the rapidity of their 
use – were all variables which could not be controlled. Also the measurement occurred at 
different times after smoking cigarettes so the values were bound to be variable as it was 
149 
 
excretion which was measured rather than plasma values. However despite all these 
„uncontrollable variables‟ some interesting values were determined.  
4.20 Comments and general conclusions about the urinary levels of nicotine found in 
this study. 
The results of the strip test and assay were very informative. The sensitivity and 
correlation of the strip test with the ELISA assay show that the strip test could be used in a 
semi-quantitative way of low, medium and high cigarette consumption with some degree 
of certainty that the results were correct. The ELISA is of course a very precise, but far 
more complex and costly method to determine nicotine levels. It did however establish that 
the urinary levels were not simply related to the actually number of cigarettes smoked. 
This may simply be that urinary volume outputs vary between individuals so the 
calculation on a per ml basis would need to be extrapolated for 24 hour collections – but 
even then this assumes that the output would be constant which may be an unwarranted 
assumption. Perhaps the data which was obtained is sufficient without resorting to 
extremely complex urinary collection systems as it shows a number of findings. There is 
also the problem of the variability between individuals of the metabolic products of 
nicotine which this assay does not detect. 
General conclusions  
1. Nicotine absorption can occur in individuals exposed to passive smoking. 
2. Smoking 3-5 cigarettes a day produces measurable urinary levels of nicotine.  
3. Smoking 20 cigarettes gives only twice the urinary output of the light smokers. 
4. Smoking 20-40 cigarettes a day gave more than twice the output of those people 
who smoked 20 cigarettes a day perhaps indicating that metabolism may be 
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exceeded and more free nicotine is excreted unchanged or in this group there was a 
more diverse range of metabolic products in the individuals studied. 
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Chapter Five 
Investigation into the effectiveness of aspirin in reducing risks. 
5.01 A The objective of this part of the study I to investigate the effectiveness of 
asprin with regard to age of the person who is suffering from CHD. 
 
 
5.02 Methodology. 
 All aspects of this study were read by and approved by the authorites in 
Kuwait who give ethical approval for the such studies to be undertaken. 
 
All male patients who were admitted to the Chest Hospital in Kuwait at the time at 
which this trial was being undertaken (2009-2010) were screened for cardiovascular 
disease. In the time period of this screening, there were found to be 197 patients who were 
admitted to the hospital and who were smokers, and also had coronary heart disease of the 
severity required in the trial. 
 When these 197 patients were examined in greater detail, including:  their smoking 
behavior, systolic/diastolic pressures, cholesterol levels and coagulation factor levels, it 
was found that of the 197 patients only 150 patient were considered to be suitable for 
treatment with aspirin, as the other 43, although they had coronary heart diseases also had 
many other complicating factors such as because of their age they had a greater potential to 
bleed if taking aspirin and they were also receiving complex drug therapies for their 
hypertension which it was thought may have made the analysis of the effects of aspirin 
extremely difficult to determine. However this group of non aspirin treated patients were 
not simply rejected but rather used as a „control‟ for the aspirin treated group as they did 
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not receive the aspirin but did, as for the aspirin treated group have coronary vascular 
disease are were receiving their usually medications for their existing diseases. It was a 
very useful control to have. 
This meant they acted as a control against which the pharmacological effects of 
aspirin could be compared with those who did receive the drug as this was the only 
difference between the groups. This is a major complicating factor as the therapies in both 
groups included drug classes such ACE inhibitors, calcium channel blockers and/or beta-
blockers which, although treating their hypertension may actually lower the risk of 
recurrent myocardial infarction. For ethical reasons the patients could not be taken off their 
existing drugs despite the fact that this made interpretation of the results extremely 
complicated.  Nevertheless, the 150 patients who actually took aspirin also continued on 
their existing medications so the two groups were comparable in the terms of not changing 
their existing therapy. Simply, one group of patients suffering from coronary disease 
problems was compared to another group, the only additional factor in their treatment 
being the inclusion of low dose aspirin therapy.  
 
Grouping the patients 
To facilitate analysis it was necessary to put the patients into different age groups 
as it would have been „unfair‟ to compare the effects of aspirin in individuals who had 
been suffering their disease for 1 or 2 years as against those who had been suffering it for 
30+ years. 
The 150 patients were first of all divided into „age range groups‟ (Figure 19) in 
order to see if aspirin exerted an age related effect. The number in the first age range 45-49 
years out of a total number of screened coronary disease patients (n=197) was 28. 
However of these, only 14 patients were judged to be suitable for the trial. Similarly, 33 
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patients who belonged to age group 50-54 years were found on admission to the hospital to 
be suffering from coronary problems but of these only 26 patients of this group were 
actually included in the aspirin trial. Likewise 34 patients of age group 55 to 59 years were 
treated with aspirin out of a total number of 37 patients of this age group who had coronary 
heart disease. For patients with ages between 60-64 years, only 36 patients out of 55 
coronary heart patients were treated with aspirin. The last age group of patients were those 
in the 65-69 years group and of the 44 patients who were detected on admission the vast 
majority i.e. 40 patients, were considered suitable for treatment with aspirin despite their 
age and therefore included in this trial.  
 
Figure 19. Bar chart showing the age groups of patients who were used in which to study 
the effects of aspirin who were suffering coronary heart disease. In this chart the pink 
colored bar shows the number of patients in the five age groups at time they were admitted 
with coronary heart diseases before aspirin treatment and the blue colored bar for number 
of patients in five groups who actually received aspirin treatment (75mg/day). 
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This division of the total number of patients detected with coronary heart disease 
with respect to their age groups and those adjudged suitable for treatment with aspirin is 
shown in Table 7. 
 
5.03 Results 
The use of Table 7 attempts to show the effectiveness of aspirin in all the different 
age related groups. To show the effectiveness of the aspirin therapy the value for the 
relative risk has been used for all the groups. Briefly, in this experiment relative risk is the 
probability of an event occurring in the aspirin group as compared to the non aspirin 
treated group. This is the classical use of such an analysis where the risk of 
developing/making worse existing coronary disease in those receiving aspirin is compared 
against those non aspirin treated. A relative risk of 1 indicates there is no difference 
between the two groups. A value less than 1 means the event is less likely to occur in the 
treated group rather than the non aspirin treated group. A value greater than 1 indicates 
that the event is more likely to occur in the treated group rather than the non aspirin treated 
group. 
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Table 7. Age group distribution and the number of patients selected to receive aspirin 
involved in a study on its cardiovascular effects in patients with coronary heart disease as 
compared with non aspirin treated patients. The relative risk is shown in the last column.  
 
 
Examination of the relative risk values in Table 7 shows some interesting findings. 
In the first four groups the risk-ratios are all less than 1.  This indicates that for all these 
four groups the treatment with aspirin has reduced the risk of patients suffering 
complications of their coronary heart disease. The final age group 65-69 years - with a risk 
ratio value of 1.29 shows the aspirin treatment has in fact increased the risk of suffering 
the disease they were first diagnosed with.  
These results show that aspirin had been effective for the majority of the age 
groups studied, all of whom had at the beginning of the study, coronary heart disease. 
Clearly, aspirin benefited 110 patients in the trial. For the remaining 40, in the age group 
Age group 
(years) 
Total patient 
number - before 
selection for 
aspirin treatment 
(n=197) 
Selected for 
aspirin 
treatment 
(n=150) 
Relative risk (to show the 
benefit of aspirin treatment as 
compared with those who did 
not receive aspirin ) 
45-49 28 14 0.48 
50-54 33 26 0.77 
55-59 37 34 0.73 
60-64 55 36 0.61 
65-69 44 40 1.29 
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65-69 the results were not favourable for the use of aspirin. It is interesting to speculate 
and give possible reasons for the lack of aspirin‟s effect in the final group. 
 
5.04 Discussion/Conclusion 
International statistics provide ample evidence that the number of patients who 
have problems due to coronary heart disease increases with age. This is said to be the 
major disease of the century in the majority of countries around the world, including 
Arabic nations. This means that within any group of males as their age increases the 
chances of coronary heart diseases also increases. Consequently, the aspirin treatment may 
reflect the finding that in the age group 65-69, where the coronary problems would be 
expected to be at a high level, the use of aspirin which provided a relative risk of 1.29, 
perhaps reflects the inability of aspirin to reverse a cardiovascular condition(s) which had 
gone untreated for many years prior to the trial and/or their existing treatment simply 
maintained rather than reversed. This is not a failure of the aspirin to bring about changes 
but rather a reflection that changes to the coronary arteries and indeed other vascular 
components in such patients may have reached a level where reversing the future potential 
for increased risk is simply impossible.  
The main conclusion is that aspirin should be started as early as possible in 
younger age groups to avoid such a problem of the lack of a suitable repsonse occurring. 
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5.05. Part B. The objective of this part of the study were to investigate  
 ‘Does aspirin bring about its beneficial effects by modification of diastolic blood 
pressure’? 
 
5.06 Methodology. 
To try and find out why the aspirin had exerted such a beneficial effect seen in Part 
A, some of the major risk factors which contribute to the risk of heart attacks and strokes 
were examined in the subjects who took part in the trial in more detail. 
 The first of these was to determine if their diastolic pressure had been modified 
during their treatment with aspirin. 
To examine the effect of aspirin over the whole range of diastolic blood pressures, 
the same cohort of patients (n= 150) were placed into three groups made according to their 
limits of diastolic blood pressure. This rather arbitrary grouping was not expected to 
produce identical numbers in each group but was rather to make comparisons between non 
aspirin treated and aspirin treated patients more comparable – in terms of one factor – 
diastolic pressure.  
Of the 152 patients, those patients whose diastolic pressure was 70mmHg or less 
numbered 56 of which 35 were patients were included in the trial of aspirin (Figure 20).  
The next group was those in which the diastolic pressure was between 70-80 mmHg. In 
this group of patients (n=57) 40 patients were treated with aspirin. The final group of 
patients (n=79) were those who had a diastolic blood pressure greater than 80 mmHg and 
these patients have been categorized due to its severity as being in Stage 1  or Stage 2 
hypertension.  Of these 79 patients, 77 received aspirin therapy. The effectiveness of the 
aspirin as compared to non treated aspirin for a seven day dosing period (75mg/day) in 
these three groups are shown in Table 7 
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5.07 Results. 
Table 8. The distribution of patients into three „levels of diastolic pressures‟, and the 
numbers treated by aspirin (75mg/day for 7days) from the total number which was studied. 
The differences between the total number of patients and the treated group are shown in 
the table. 
Diastolic blood 
pressure 
(mm Hg) 
Total patients 
(n= 192) 
Aspirin treated 
(n= 152) 
Relative risk (to show 
the benefit of aspirin 
treatment) 
≤70 56 35 0.55 
70-80 57 40 0.75 
≥80 79 77 0.94 
 
Figure 20. Bar chart of the numbers of subjects in each group as defined by their 
diastolic pressures ≤ 70mmHg, 70-80 mmHg and ≥ 80mmHg.  
The number of subjects who received either aspirin (the blue block) or non treated 
(the pink block) for each of the three diastolic pressure groups which were studied. The 
aspirin treated groups received 75mg which was given for7 days.  
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5.08 Discussion/conclusion. 
From this data it can be seen that the relative risk is favourable for aspirin therapy 
at all levels of diastolic pressure. It could be argued that the first two diastolic levels are 
more successful than the third levels, namely over 80mmHg. Again this may be possible to 
explain as these patients have usually had cardiovascular disease for a longer period of 
time and the reversal of long standing problems may be simply too great for the aspirin to 
overcome.  
After observing such improvement these patients were followed up for the next 30 
days and after that aspirin is suggested on a regular basis and they were advised to 
continue use low dose of aspirin  
 
5.09 Part C. The objective of this part of the study was to investigate ‘ Does aspirin 
bring about its beneficial effects by modification of plasma cholesterol 
concentrations?’ 
 
5.10 Aims and methodology. 
 
The aim of this study was to determine the effectiveness or otherwise of aspirin 
treatment the 186 patients who were divided into smokers and non smokers and then 
divided into three groups made on the basis of their original plasma cholesterol 
concentration. The patients were placed into three groups namely:  a) ≥5.9, b) 5.9-6.7 and 
c) ≥6.7 mmol/L. This resulted in the number of patients who smoked in each of these 
groups being, 48, 39 and 58 respectively. 
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The total number of patients used in this part of the study was 186 (Figure 21) of 
whom 145 were smokers. These are a different study group to those reported in Part A and 
B. 
5.11 Results. 
Figure 21. Bar chart of the numbers of subjects in each group as defined by their plasma 
cholesterol concentration of i) ≥5.9, ii) 5.9-6.7 and iii) ≥6.7 mmol/L. The number of 
subjects who received aspirin is shown as blue blocks and the number of patients before 
aspirin treatment as shown pink block for each of the three cholesterol plasma level groups 
which were studied.  In this experiment based on the results found in Part B The aspirin 
treated groups received 75mg per day for one and half months (45 days). 
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Table 9. The distribution of patients into three „plasma cholesterol levels‟, and the 
numbers treated by aspirin (75mg/day for 45 days). The difference between the total 
number of patients and the treated group are those that have received aspirin treatment. 
 
Plasma cholesterol 
concentration 
(mmol/L) 
Total patients 
(n=186) 
Aspirin treatment 
(n=145) 
Relative risk (to 
show the  benefit of 
aspirin treatment) 
≤5.9 53 48 0.96 
5.9-6.7 63 39 0.55 
≥6.7 70 58 0.95 
 
Of the 48 patients who smoked and had a cholesterol concentration of less than 5.9 
mmol/L, the aspirin treatment brought about a very small reduction in the plasma 
concentration and this was reflected in a relative risk of 0.96 (see Table 9). In the second 
group, of 39 patients who had a cholesterol concentration between 5.9mmol/L to 
6.7mmol/L, aspirin brought about an even greater reduction in plasma cholesterol levels 
which altered their risk of cardiovascular problems as shown by the relative risk factor of 
0.55. In the final group the 58 patients treated with aspirin and whose initial cholesterol 
concentration was greater than 6.7 mmol/L a similar relative risk to those below5.9 
mmol/L was recorded.  
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5.12 Discussion/Conclusion 
Perhaps the last finding indicates that the changes induced by a high plasma 
cholesterol concentration are such, that reversal of the long lasting effect of cholesterol, in 
terms of cardiac risk factors, is extremely difficult to overcome simply by the use of 
aspirin. 
 Plasma cholesterol levels are considered to be one of the major risk factors along 
with high blood pressure to make heart attacks and strokes more likely to occur. The 
finding that aspirin can reduce this level in the group 5.9 – 6.7 mmol/L is potentially of 
great significance. 
 
5.13 Part D The objective of this part of the study is to investigate the effects of 
aspirin on patients and its placebo equivalent with respect to the age of the patients./ 
 
5.14 Methodology. 
In Part A of these studies it was found that on detailed examination of the data 
from 150 patients who took aspirin it had a range of measurable effects on the relative risk 
of suffering cardiovascular events. During this detailed examination of all the patients who 
had taken both aspirin and placebo it was found that 26 patients who took the placebo 
treatment had actually benefitted from the placebo in terms of their coronary problems. 
These individuals are shown in Table 10. 
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5.15 Results 
Table 10. Age group distribution and the number of patients selected to receive aspirin 
involved in the study and those who had the same age but only (Non aspirin) received 
placebo. Please note - The number of patients in each age range who positively responded 
to the placebo was variable.  
Age 
(years) 
Aspirin 
(n=150) 
Placebo treated with a 
positive outcome (n=variable 
depending on age group) 
The 
effectiveness of 
placebo 
treatment as 
compared to 
aspirin 
treatment  
45-49 14 1 NIL 
50-54 26 0 NIL 
55-59 34 11 0.40 
60-64 36 9 0.99 
65-69 40 5 0.59 
 
Although a positive placebo effect was seen in four out of the five groups the 
numbers in some of the study groups were very small. However in one group, the 55-59 
there was placebo response of 11 out of 34 patients (see Figure 22).  
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Figure 22. Bar chart of the numbers of subjects in the age ranges shown who were treated 
with aspirin (pink bars) and the number of subjects who positively responded to the 
placebo or non aspirin treatment (blue bars). 
 
 
5.16 Discussion/Conclusion. 
These results show some positive effects with the placebo. This may be by a 
chance observation but this age group might be favorably stimulated to „look after 
themselves‟ during the study period as this age group should be aware of the serious 
consequences of their cardiovascular disease. They may have started to eat more wisely, 
take more exercise or even reduce their consumption of cigarettes but these factors were 
not recorded in this study. It would be interesting to study what steps people take when on 
a trial to get the maximum benefit for themselves. 
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5.17 Part E The objective of this part of the study is to investigate the effect of 
placebo with respect to diastolic blood pressure. 
 
5.18 Methodology  
Again it was observed when the data was being collected that in patients receiving the 
placebo there were changes in some of their diastolic pressures. In total 26 patients were 
found to be in this group spread throughout all three diastolic pressure groups. The details 
are shown in Table 10.   
 
5.19 Results. 
Table 11. Diastolic blood pressure distribution and the number of patients selected to 
receive aspirin involved in the study and those who in the same diastolic pressure range 
but received (non aspirin) only the placebo. Please note - The number of patients in each 
age range who positively responded to the placebo was variable.   
 
Diastolic blood 
pressure 
(mm Hg) 
Aspirin 
(n=152) 
Positive Placebo 
responders 
(  n=26) 
Relative risk (to 
show the benefit of 
aspirin treatment 
compared to 
placebo treatment) 
≤70 35 6 0.41 
70-80 40 10 0.21 
≥80 77 10 1.42 
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Figure 23. Bar chart of the numbers of subjects in the diastolic blood pressure ranges 
shown who were treated with aspirin (pink bars) and the number of subjects who 
positively responded to the placebo (blue bars). 
 
 
 
 
5.20 Discussion/Conclusion. 
The implications for the findings made in this part of the study are very interesting. 
Although there was a measurable placebo response which is not too unexpected the effect 
of aspirin was quite pronounced. What was unexpected was the high rate of placebo effect 
in the higher diastolic ranges. In the diastolic range 70-80 mmHg aspirin had a measurable 
effect which was different to the other two groups. The higher risk in the group over 
80mmHg is unexpected and perhaps worrying and may reflect the problem that pre 
existing coronary vascular disease has caused a lack of response to the aspirin. 
Whatever the reason(s) it is certainly worth further investigations. 
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5.21 Part F The objective of this part of the study is to investigate the effect of Aspirin 
and Placebo with respect to Cholesterol concentration (m mol/L) 
 
5.22 Methodology. 
The data for 145 patients treated with aspirin into the three arbitrary plasma levels 
groups were found to have variable responses to aspirin (See Table 8 above). When the 
placebo results were studied it was found that some could be classified as „positive placebo 
responders‟ (See Table 13).  
  
5.23 Results 
Table 12. Plasma cholesterol concentrations and the number of patients selected to receive 
aspirin involved in the study and those who in the same cholesterol range but received 
(non aspirin) only the placebo.  
Cholesterol 
concentration 
(mmol/L) 
Aspirin 
(n=145) 
Positive Placebo 
responders 
(n=26) 
Relative risk(to 
show the benefit of 
aspirin treatment 
compared to 
placebo) 
≤5.9 48 12 0.20 
5.9-6.7 39 8 0.90 
≥6.7 58 6 1.53 
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Figure 24. Bar chart of the numbers of subjects in the plasma cholesterol levels in the 
ranges shown who were treated with aspirin (pink bars) and the number of subjects who 
positively responded to the placebo (blue bars). 
 
 
 
5.24 Discussion/Conclusion 
The greatest placebo effect was seen at the lowest plasma levels i.e. below 5.9 
mmol/L. Perhaps this reflects that the people who took part in the trial may have over the 
months of the trial period changed their behavior in terms of smoking and diet. If they 
changed both these factors then the lipid levels may well reduce and such an effect is not 
just a psychological effect but rather a real effect brought about by behavioral changes. 
This of course will never be known as it dependent on patients in the trial maintaining a 
constant behavioral and dietary pattern. This shows how complex a trial lasting over this 
length of time actually turns out to be.   
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5.25 Part G The objectives of this study was to investigate any additional factors stu 
for studying the role of aspirin in controlling diastolic blood pressure. 
 
5.26 Methodology 
In this study 239 patients who were having regular disturbances in their diastolic 
blood pressure were physically examined and their blood pressure measured. On 
examination it was observed that these patients all had some form of coronary artery 
problems and/or other heart problems. These changes it was thought were affecting their 
control of diastolic pressure. It was decided to carry out a study in which these patients 
received aspirin (75mg/day) to determine if it could be beneficial for the control of 
diastolic pressure. When the 239 patients were screened for the use of aspirin, as might 
perhaps be expected, not all were suitable because of the risk of gastric haemorrhage and 
so the actual number which received the drug was 189.   
The patients who were to receive aspirin were divided into three diastolic ranges, 
the same as which had been used in the previous studies i.e. ≤ 70mmHg, 70-80 mmHg and 
≥ 80 mmHg.(Figure 25) 
 
5.27 Results 
 When the data was examined (See Table 13) it was observed that those patients 
who had a diastolic blood pressure greater than 80mmHg did not benefit from the aspirin 
treatment. The other 90 subjects did however benefit from the treatment to a significant 
degree (See Table 13). 
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Table 13. This table shows the results which have been formulated about those people 
who when treated with aspirin who have actually developed some form of  coronary heart 
diseases, combined in some cases with heart stock due to changes in the diastolic blood 
pressure. 
 
Diastolic blood 
pressure 
(mm Hg) 
Total patients 
before aspirin 
treatment 
(n=239) 
Aspirin treatment 
(n=189) 
Relative risk (to 
show the benefit of 
aspirin treatment) 
≤70 64 42 0.59 
70-80 64 48 0.68 
≥80 111 99 1.08 
 
Figure 25. Bar chart of the numbers of subjects in the diastolic blood pressure ranges 
shown who were not treated with aspirin (pink bars) and the number of subjects who 
positively responded to the aspirin treatment  (blue bars). 
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5.28 Conclusion 
The effect of aspirin seems to have been more marked on the lower levels of 
diastolic pressure rather than the levels above 80 mmHg. This is similar to other findings 
where the lower diastolic values seem to respond to aspirin therapy whereas the higher 
levels do not. This may reflect that the hypertension in the third group has simply existed 
for a longer period of time and may be associated with structural and/or humoural changes 
which it is impossible in the short term to reverse with aspirin treatment. It would be of 
great interest to carry out the study for much longer and determine if with longer term 
treatments there are any more successful results.  
 
Overall conclusions 
 
These results show the effectiveness of aspirin in reducing the risks caused by 
those cardiovascular conditions which are both complex and potentially very serious in 
outcome resulting from of a number of different possible diseases. The effectiveness of 
aspirin appeared to increase as the diastolic blood pressure increased but only to a certain 
limits. The possible limitations of aspirin therapy with the higher levels of diastolic 
pressure. is a point which may limit the widespread use of the drug in all severities of 
hypertension. However for the lower diastolic values the treatment looks as though there is 
a distinct possibility and this may result in a greater number of hypertensive patients 
getting relief of their cardiovascular problems by the use of a simple, cheap therapy. 
Similar results were obtained with systolic blood pressure when we studied the range of 
blood pressure from greater than 130mm Hg and less than 145mm Hg. 
There is of course a worry about the widespread use of aspirin in all age groups as 
during this treatment the major dominant side effect of aspirin was reported to be gastric 
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irritation and some bleeding due to the well known antiplatelet effect which in some 
individuals caused small scale blood coagulation problems. 
However as was demonstrated in Part A of this study, aspirin should be started as 
early as possible in younger age groups to avoid CHD developing. 
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Chapter Six 
An investigation of aspirin on ambulatory blood pressure of hypertensive 
smokers and non smokers. 
6.01 Objectives. 
The objective of this part of the thesis was firstly to establish the ambulatory blood 
pressure of hypertensive, non-smokers and smokers. They would then be divided into two 
groups. One group would receive placebo or non aspirin treated and another, 75mg/day of 
aspirin. Their blood pressure would be monitored throughout a 24 hour period. The effects 
of aspirin and placebo would then be determined over two study periods namely – daytime 
(7am and 11pm) - and night time (11pm – 7am). 
6.02 Background. 
It has been reported that smoking causes a temporary rise in blood pressure levels 
for both hypertensive and normotensive individuals. Individuals can be assessed by an 
isolated blood pressure measurement technique according to the recommendations of 
national and international guidelines (JNC 7, ESH 4, and I V DBHA) and these are the 
guidelines which have been used in this study. They have previously been used and 
validated by other workers for the determination of blood pressure in smokers. (Cristal-
Boneh etal., 1997; Kumar .,etal. 2004)  
It has been observed that smokers when submitted to ambulatory blood pressure 
monitoring (ABPM) present a higher mean blood pressure reading than in non-smokers. 
Consequently, this technique provides a better understanding of  
a) The 24-hour effect of smoking on the hour by hour blood pressure trends,  
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b) The actual systemic blood pressure which is produced, 
c) By extrapolation of these values the impact which these may have on organs 
which are known to be „targeted‟ by elevated blood pressure.  
Ambulatory blood pressure monitoring (ABPM) is the non-invasive diagnostic tool 
which provides the basis for this type of analysis, and also provides a profile which 
indicates the variations in blood pressure within the whole 24-hour period. 
Consequently, this test provides a better understanding of hypertension for both 
diagnosis and for treatment purposes. The object of this study was to determine the effects 
on blood pressure caused by smoking throughout 24 hour periods - day and night so the 
whole cycle of ambulatory blood pressure parameters could be determined. The 
effectiveness of aspirin was also designed to be investigated in these hypertensive patients. 
6.03 Methods 
At the beginning of this study 200 hypertensive patients volunteered to take part in 
the research project and these included both men and women. These two hundred 
ambulatory blood pressure monitoring tests were „self selected‟ from a wider population of 
patients.  Their blood pressures were measured and any measurements which produced 
„substandard tests‟ were repeated in order to ensure the accuracy of the measurements 
made. The study group of 200 patients included 147 non-smokers and 53 smokers. 
However, despite their initial willingness of both males and female patients to 
participate in the study, very unfortunately all the women, 48 in number, were reluctant to 
follow through with their agreement to participate in the full study, due to many family 
pressures in the Islamic country of Kuwait. Consequently 152 males remained but of these 
the final number who agreed to all aspects of the study was eventually only 72. 
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These 72 patients were then classified as smokers or non-smokers according to the 
information given when the device was fitted. Anyone who smoked one or more cigarettes 
per day was classified as a smoker (Kawasaki et al., 1996). These 72 males were then 
divided into two groups – smokers and non-smokers.  Their ambulatory blood pressure 
(ABPM) was monitored over a 24 hour period in which the following parameters were 
considered and calculated: 
1- Changes in both daytime and night time systolic and diastolic blood pressure readings. 
2- The changes in systolic and diastolic pressures during the night time as compared to the 
day time. 
3- The data from the patients was then classified in eight further sub-groups according to 
whether or not they received aspirin (75mg/day). 
The following ABPM parameters were analyzed 
1- Change in the average daytime and night time systolic and diastolic blood pressure 
readings.  
2- The variations in systolic and diastolic pressures during the night time. 
These measurements were carried out using the Dyna-MAPA 24-hour oscillometric 
ABP-Monitor which has previously been validated by the American Association for the 
Advancement of Medical Instrumentation (AAMI) and the British Hypertension Society 
(BHS). The programming and report generation software was also Dyna-MAPA. The 
program automatically produced the statistical report without calculation/interpretation by 
any professional. (Walker et al. 2001: Diretrizes, 2001) 
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The patients were fitted with the device during normal day time working hours by a 
trained technician. Each patient wore the device for 24-hours and returned to the clinic the 
following day for removal and the downloading of the data. The monitoring was 
performed on a week day that was thought to reflect the patient's normal daily activities. 
The cuff was placed on the non-dominant arm two fingers widths above the elbow crease. 
Adequate sized cuffs according to arm circumference were always used. A previously 
established set of instructions was given to the patient when the device was fitted. (Leon et 
al. 2000) 
The electronics within the device measured data every 15 minutes during the day 
and every 20 minutes during the night. The normal daily activities of patients, including 
what medicines they take, both during the day time and night time were also noted by the 
patient. (Kool M., et al. 1993) 
Information about medicines was thought to be central to the study and the patients 
were asked to record the time they took their aspirin, the dosage actually taken and the 
time(s) they were taken. Additionally they were asked to record if they had any unexpected 
symptoms and they were to record such events, noting the hour of onset and the time at 
which they became absent. Day time was considered as the period between 7a.m. and 
11p.m.- a sixteen hour period- and night time between 11p.m. and 7a.m – an eight hour 
period following the recommendations of the 2
nd
 
 
Brazilian Consensus for ABPM.
 
So, 
initially the test sample was divided into two groups smokers and non-smokers, these two 
groups were then further subdivided into smokers taking aspirin and non-smokers taking 
aspirin or not taking aspirin as follows (Poulter N.,etal.,1999). By virtue of the numbers 
involved, the total for each group was such that comparisons could be made. The groups 
were: 
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Group 1 with aspirin treatment:
 Night time systolic BP (n=9)
 
Group 2 without aspirin treatment:
 Day time systolic BP (n=9)
 
Group 3 with aspirin treatment:
 Day time systolic BP (n=9)
 
Group 4 without aspirin treatment:
 
Night time systolic BP (n=9)
 
Group 5 without aspirin treatment:
 Daytime diastolic BP (n=9)
 
Group 6 with aspirin treatment:
 Daytime diastolic BP (n=9)
 
Group 7 without aspirin treatment:
 Night time diastolic BP (n=9)
 
Group 8 with aspirin treatment:
 Night time diastolic BP (n=9)
 
To express the data in the most suitable way the median and the minimum, and 
maximum i.e. the range - were calculated as were the arithmetic mean and standard 
deviation. To show the nature of the numerical results the values were calculated and used 
for expressing all the values found in the data recordings. Since such a study has not been 
carried out in Kuwait patients it was thought both essential and appropriate to calculate 
this data in terms of both non parametric and parametric data. This could then be used to 
provide a comparison between the groups and to determine the best sort of values to use. It 
should be stressed that the values in the tables are the summary data for an individual 
throughout either the day or night time. No attempt is made to provide hour by hour values 
as it was thought to be valuable to show the summary data. 
Univariate analysis was used for comparing the smoking and nonsmoking groups, 
the significantly different variables from the groups were selected using multivariate 
analysis details of which can be found. 
Minimum, maximum, median, mean and standard deviation values were used for 
expressing all variables. The Mann Whitney U test was used for the analysis of comparing 
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the smoking and non-smoking groups, the significantly different variables from the groups 
were determined (Chernoff et al. 1954). 
6.04 Results 
Please note   
All the bar charts presented below show the mean values for an individual for the 
time period under study – day time or night time. They are presented in terms of ascending 
numerical order as members of the group are paired only in terms of ascending numerical 
order. The pairs were not matched for any other value except the rank order of value for 
the blood pressure. This somewhat unusual choice of presentation has been made as it 
shows perhaps in a very simple, yet informative way, the variability within the group, and 
the comparison of mean values for each individual in the group and the span of values 
found for each group can be easily seen. 
6.05 Figures tables and calculations 
6.06 Group 1. Patients who smoked and non-smokers who received Aspirin treatment -
Night time Systolic BP 
From the bar chart (Figure 26) it can be seen that the mean systolic blood pressure 
for individuals was variable within the groups of both smokers and non-smokers. No two 
patients actually had the same mean pressure and so a range of nine values can be seen for 
each group. These values are perhaps best seen in Table 14 where the individual values are 
shown as is the standard deviation. The trend appears to be that the non smokers had a 
lower overall systolic pressure that the smokers. However when the median values were 
compared using the Mann Whitney U test then there was found to be no significant 
difference (P>0.05) between them. 
179 
 
 
Figure 26. Mean systolic night time blood pressure of male, smokers and non-smokers 
over an 8 hour period (11pm-7am), who received 75mg of aspirin on a daily basis. 
 
 
 
Table14. Numerical values from which Figure 26 was constructed. For both Aspirin and 
placebo treatment the figures represent the mean night time systolic BP mmHg.  
 
 Mean Night time systolic BP 
 mmHg 
Mean 
mmHg 
Median 
mmHg 
Standard 
deviation 
Non 
smokers 
114,115,118,123,127,129,132,133,139 125 127 8.239 
Smokers 119,122,124,128,132,138,144.148,150 
 
133.8 132 10.9 
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Specimen Calculations 
 Mean (non-smokers) =114+115+118+123+127+129+132+ 133+139/9=1130/9 =125 
mmHg 
Mean (smokers) =119+122+124+128+132+138+144+148+156/9=1205/9 =133.8 mmHg 
Standard deviation calculation 
Step 1-find the standard deviation of each number from the mean, 
For non-smokers                                                            For smokers 
114-125= -11                                                         119-133.8= -14.8 
115-125= -10                                                         122-133.8= - 11.8 
118-125= -7                                                           124-133.8= - 9.8 
123-125= -2                                                           128-133.8= -5.8 
127-125= 2                                                            132-133.8= -1.8 
129-125= 4                                                            138-133.8=   4.2 
132-125= 7                                                            144-133.8= 10.2 
133-125= 8                                                            148-133.8= 14.2 
139-125= 14                                                          150-133.8= 16.2 
For smokers 
Step 2-square each of the deviations, which amplifies large deviations and makes negative 
values positive 121, 100, 49, 4, 4, 16, 49, 64, 196                 
Step 3-find the mean of those squared deviations, 
=121+100+49+4+4+16+49+64+196/9 = 611/9 =67.89 
Step 4-take the non-negative square root of the quotient (converting squared units back to 
regular units), 
=√67.89 =8.239 So, the standard deviation of the calculated was 8.23 
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For non smokers 
Step 2  -square each of the deviations, which amplifies large deviations and makes 
negative values positive 
219.04, 139.24, 96.04, 33.64, 3.24, 17.64, 104.04, 201.64, 262.44 
Step 3 - find the mean of those squared deviations 
=219.04+139.24+96.04+33.64+3.24+17.64+104.04+201.64+262.44/9 
=1076/9 =119 
Step 5 - Take the non-negative square root of the quotient (converting squared units back 
to regular units), =√119  = 10.9  
So, the standard deviation of the set was 10.9 
6.07 Group 2 Patients who smoked and non-smokers who received placebo treatment - 
day time Systolic BP 
Patient smokers and non-smokers in this group received placebo rather than aspirin 
treatment and their mean daytime systolic BP is shown in (Figure 27). Again the values 
have been paired simply for graphical presentation, the actually values, mean, median and 
standard deviation is shown in Table 15. 
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Figure 27. Patients‟ daytime (7am-11pm) systolic blood pressure in those male patients 
smokers and non-smokers who received placebo rather than aspirin treatment.  
 
 
Table 15. Patients on placebo or (non aspirin) therapy (mean day time systolic BP) 
    day time systolic BP mmHg Mean 
mmHg 
Median 
mmHg 
Standard 
deviation 
Non-
smokers 
 
100,116,120,123,127,132,135,139,141 125 127 12.20 
Smokers 
 
 
112,118,125,131,137,143,147,150,156 135 137 14.18 
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Specimen calculations 
Mean (non-smokers) =100+116+120+123+127+132+135+139+141/9 
                                 =1133/9 =125mmHg 
Mean (Smokers) =112+118+125+131+137+143+147+150+156/9 
                             =1219/9 =135mmHg  
Standard deviation calculation – 
Step 1 - Find the deviation of each number from the mean 
For non-smokers                                                             For smokers 
100-125= - 25                                                                     112-135= -23                                                                                     
116-125= -9                                                                        118-135= -17 
120-125= -5                                                                        125-135= -10 
123-125= -2                                                                        131-135= - 4 
127-125= 2                                                                         137-135= 2 
132-125= 7                                                                         143-135= 8 
135-125= 10                                                                       147-135=12 
139-125= 14                                                                       150-135= 15    
141-125= 16                                                                       156-135=21 
For non-smokers 
Step 2 -Square each of the deviations, which amplifies large deviations and makes 
negative values positive, 625, 81, 25, 4, 4, 49, 100, 196, 256          
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Step 3.Find the mean of those squared deviations 
=625+81+25+4+4+49+100+196+256/9 = 1340/9  = 148.8 
Step 4. Take the non-negative square root of the quotient (converting squared units back to 
regular units), 
=√148, 8 =12.20. So, the standard deviation of the set is 12.20 
For smokers 
Step 2. Square each of the deviation, which amplifies large deviations and makes negative 
values positive 
529, 289, 100, 16, 4, 64, 144, 225, 441 
Step 3. Find the mean of those squared deviations, 
=529+289+100+16+4+64+144+225+441/9 =1812/9 =201 
Step 4. Take the non-negative square root of the quotient (converting squared units back to 
regular units) 
=√201 =14.18  The standard deviation of the set is 14.1 
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6.08  Group 3 Patients who smoked and non-smokers who received aspirin treatment - 
day time Systolic BP. 
With Aspirin treatment the daytime systolic BP From the bar chart (Figure 28) it 
can be seen that the mean systolic blood pressure for individuals was variable within the 
groups of both smokers and non-smokers. No two patients actually had the same mean 
pressure and so a range of nine values can be seen for each group. These values are 
perhaps best seen in Table 15 where the individual values are shown as mean, median and 
the standard deviation. The trend appears to be that the non smokers had a lower overall 
systolic pressure than the smokers. However when the median values were compared using 
the Mann Whitney U test then there was found to be no significant difference (P>0.05) 
between them. 
 
Figure 28. Effect of aspirin on day time systolic blood pressure of smokers and non 
smokers. 
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Table 16. Effect of aspirin on day time systolic blood pressure of smokers and non 
smokers. 
 
  day time systolic BP  Mean                Median Standard 
deviation 
Non-
smokers 
 
90,94,98,104,108,112,114,118,126 107 108 11 
Smokers 
 
 
100,108,114,116,119,127,134,138,140 121 119 13 
 
Mean (non-smokers) =90+94+98+104+108+112+114+118+126/9 
                                 =964/9 =107 
Mean (Smokers) =100+108+114+116+119+127+134+138+140/9 
                             =1096/9 =121 
Standard deviation calculation 
Find the deviation of each number from the mean 
For non-smokers                                                           For smokers 
90-107= - 17                                                                    100-121= -21                                                                                          
94-107= -13                                                                     108-121= -13 
98-107= -9                                                                       114-121= -7 
104-107= -3                                                                      116-121= -5 
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108-107= 1                                                                        119-121= -2 
112-107= 5                                                                        127-121= 6 
114-107= 7                                                                        134-121=13 
118-107= 11                                                                      138-121=17    
126-107= 19                                                                      140-121=19 
For non-smokers – the steps are the same as used above for both non-smokers and smokers 
for all the caluclitons shown below.. 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive, 
289, 169, 81, 9, 1, 25, 49, 121, 361         
Find the mean of those squared deviations 
=289+169+81+9+1+25+49+121+361/9 =1105/9 =122.7 
Take the non-negative square root of the quotient (converting squared units back to regular 
units) 
=√122.7 =11. So, the standard deviation of the set is 11 
For smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive 
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441, 169, 49, 25, 4, 36, 169, 289, 361 
find the mean of those squared deviations, 
=441+169+49+25+4+36+169+289+361/9 =1543/9 =171 
 Take the non-negative square root of the quotient (converting squared units back to 
regular units), 
=√171 =13. So, the standard deviation of the set is 13  
6.09 Group 4 Without Aspirin treatment Night time systolic BP 
 
Figure 29. Night time systemic blood pressure (mmHg) of smokers and non smokers. 
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Table 17. Patient without Aspirin treatment (night time systolic BP mmHg)) 
 
 night time systolic BP mmHg 
 
Mean 
mmHg 
Median 
mmHg 
Standard 
deviation 
Non-
smokers 
96,99,105,108,111,114,120,123,125 111 111 9.68 
Smokers 
 
100,108,111,113,115,124,135,145,159 123.3 115 18.215 
 
Mean (non-smokers) =96+99+105+108+111+114+120+123+125/9 
 
                             =1001/9 =111 
 
Mean (Smokers) =100+108+111+113+115+124+135+145+159/9 
 
                             =1110/9 =123.3 
  
Standard deviation calculation 
Find the deviation of each number from the mean, 
For non-smokers                                                                 For smokers 
96-111= -15                                                                         100-123.3= -23.3                                                                                       
99-111= - 12                                                                        108-123.3= -15.3 
105-111= -6                                                                         111-123.3= -12.3 
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108-111= - 3                                                                        113-123.3= - 10.3 
111-111= 00                                                                        115-123.3= - 8.3 
114-111= 3                                                                           124-123.3= 0.7 
120-111= 9                                                                           135-123.3=11.7 
123-111= 12                                                                         145-123.3= 21.7   
125-111= 14                                                                         159-123.3=35.7 
For non-smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive, 
225, 144, 36, 9, 00, 9, 81, 144, 196       
find the mean of those squared deviations 
=225+144+36+9+00+9+81+144+196/9 = 844/9 =93.77 
Take the non-negative square root of the quotient (converting squared units back to regular 
units), 
=√93.77 =9.68. So, the standard deviation of the set is 9.68 
For smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive 
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542.89, 234.09, 151.29, 106.09, 68.89, 0.49, 136.89, 470.89, 1274.5 
Find the mean of those squared deviations, 
=542.89+234.09+151.29+106.09+68.89+0.49+136.89+470.89+1274.5/9 
=2986.1/9 =331.79 
Take the non-negative square root of the quotient (converting squared units back to regular 
units) =√331.79 =18.215. So, the standard deviation of the set is 18.215 
6.10 Group 5 Without Aspirin treatment Daytime Diastolic BP 
Figure 30. Day time diastolic blood pressure(mmHg)  of smokers and non smokers. 
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Table 18. Patient without Aspirin treatment (mean day time diastolic BPmmHg) 
 
 Mean daytime Diastolic 
BP 
Mean Median Standard 
deviation 
Non-
smokers 
68,72,76,79,82,84,86,87,90 70.88 82 4.35 
Smokers 72,74,78,82,86,88,90,94,100  84.88 86 8.746 
 
Mean (non-smokers) =68+72+76+79+82+84+86+87+90/9 = 638/9 =70.88 
 
Mean (Smokers) =72+74+78+82+86+88+90+94+100/9  = 764/9 =84.88 
Standard deviation calculation 
Find the deviation of each number from the mean 
For non-smokers                                                                      For smokers 
68-70.88= -2.88                                                                      72-84.88= -12.88                                                                                        
72-70.88= 1.12                                                                        74-84.88= -10.88 
76-70.88= 5.12                                                                        78-84.88= -6.88 
79-70.88= 8.12                                                                         82-84.88= - 2.88 
82-70.88= 11.12                                                                       86-84.88= 1.12 
84-70.88= 13.12                                                                       88-84.88= 3.12 
86-70.88= 15.12                                                                        90-84.88=5.12 
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87-70.88= 16.12                                                                        94-84.88= 9.12   
90-70.88= 19.12                                                                        100-84.88=15.12 
For non-smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive, 
8.294, 1.254, 26.214, 65.934, 123.65, 172.13, 228.614, 259.854, 365.574 
Find the mean of those squared deviations 
=8.294+1.254+26.214+65.934+123.65+172.13+228.614+259.854+365.574/9 
= 1251.5/9 =139 
Take the non-negative square root of the quotient (converting squared units back to regular 
units) 
=√139 =4.35 So, the standard deviation of the set is 4.35 
For smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive 
165.589, 118.374, 47.334, 8.294, 1.254, 9.734, 26.214, 83.174, 228.614 
Find the mean of those squared deviations, 
=165.589+118.374+47.334+8.294+1.254+9.734+26.214+83.174+228.614/9 
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=688.6/9 =76.509 
 Take the non-negative square root of the quotient (converting squared units back to 
regular units), 
=√76.509 =8.746. So, the standard deviation of the set is 8.746 
6.11 Group 6 With Aspirin treatment Daytime Diastolic BP. 
Figure 31. Effect of aspirin treatment on day time diastolic blood pressure (mmHg)  of 
smokers and non smokers. 
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Table 19. Patient with aspirin treatment (mean day time diastolic BPmmHg) 
 
  daytime Diastolic BP Mean Median Standard 
deviations 
Non-
smokers 
70,74,76,78,81,82,83,84,88 79.55 81 5.25 
Smokers 72,76,80,84,87,90,92,94,96 85.66 87 7.83 
 
 
Mean (non-smokers) =70+74+76+78+81+82+83+84+88/9 = 716/9 =79.55 
 
Mean (Smokers) =72+76+80+84+87+90+92+94+96/9  = 771/9 =85.66 
 
Standard deviation calculation 
Find the deviation of each number from the mean, 
For non-smokers                                                                    For smokers 
70-79.55= - 9.55                                                                     72-85.66= -13.66                                                                                          
74-79.55= -5.55                                                                       76-85.66= -9.66 
76-79.55= -3.55                                                                        80-85.66= -5.66 
78-79.55= -1.55                                                                        84-85.66= - 1.66 
81-79.55= 1.45                                                                         87-85.66= 1.34 
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82-79.55= 2.45                                                                          90-85.66= 4.34 
83-79.55= 3.45                                                                          92-85.66=6.34 
84-79.55= 4.45                                                                          94-85.66= 8.34    
88-79.55= 8.45                                                                           96-85.66=10.34 
For non-smokers 
square each of the deviations, which amplifies large deviations and makes negative values 
positive, 
91.202, 30.802, 12.602, 2.402, 2.102, 6.002, 11.902, 19.802, 71.402 
Find the mean of those squared deviations 
=91.202+30.802+12.602+2.402+2.102+6.002+11.902+19.802+71.402/9 
=248.218/9 =27.548 
Take the non-negative square root of the quotient (converting squared units back to regular 
units), 
=√27.548 =5.25. So, the standard deviation of the set is 5.25 
For smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive 
186.595, 93.315, 32.035, 2.755, 1.795, 18.835, 40.195, 69.555, 106.915 
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Find the mean of those squared deviations, 
=186.595+93.315+32.035+2.755+1.795+18.835+40.195+69.555+106.915/9 
=551.995/9 =61.33 
 Take the non-negative square root of the quotient (converting squared units back to 
regular units), =√61.33 =7.83. So, the standard deviation of the set is 7.83 
6.12 Group 7. Without aspirin treatment (mean night time diastolic BP) 
 
Figure 32. Night time Diastolic blood pressure (mmHg)  of smokers and non smokers 
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Table 20. Without aspirin treatment (mean night time diastolic BPmmHg) 
 
 Mean night time 
Diastolic BP 
Mean Median Standard 
deviation 
Non-
smokers 
61,64,65,66,68,70,72,74,76 68.44 68 4.669 
Smokers 67,69,71,72,74,78,80,86,92 76.55 74 7.8 
 
Mean (non-smokers) =61+64+65+66+68+70+72+74+76/  = 616/9 =68.44 
Mean (Smokers) =67+69+71+72+74+78+80+86+92/9 = 689/9 =76.55 
Standard deviations 
Find the deviation of each number from the mean, 
Non-smokers                                                                                      smokers 
61-68.44= -7.44                                                                                67-76.55= -9.55 
64-68.44= -4.44                                                                                69-76.55= -7.55 
65-68.44= -3.44                                                                                71-76.55= -5.55 
66-68.44= -2.44                                                                                72-76.55= -4.55   
68-68.44= -0.44                                                                                74-76.55= -2.55 
70-68.44= 1.56                                                                                 78-76.55=1.45 
72-68.44=3.56                                                                                  80-76.55= 3.45 
74-68.44=5.56                                                                                  86-76.55=9.45 
76-68.44=7.56                                                                                  92-76.55=15.45 
 
 
 
199 
 
For non-smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive, 
55.354, 19.714, 11.834, 5.954, 0.194, 2.434, 12.674, 30.914, 57.154 
Find the mean of those squared deviations 
=55.354+19.714+11.834+5.954+0.194+2.434+12.674+30.914+57.154/9 
=196.226/9 =21.803 
Take the non-negative square root of the quotient (converting squared units back to regular 
units), 
=√21.803= 4.669. So, the standard deviation of the set is 4.669 
Smokers 
Square each of the deviation, which amplifies large deviations and makes negative values 
positive, 
91.202, 57.002, 30.802, 20.702, 6.502, 2.102, 11.902, 89.302, 238.702 
Find the mean of those squared deviations 
=91.202+57.002+30.802+20.702+6.502+2.102+11.902+89.302+238.702/9 
=548.218/9 =60.913 
Take the non-negative square root of the quotient (converting squared units back to regular 
units), 
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=√60.913 =7.8 So, the standard deviation of the set is 7.8 
6.13 Group 8 With Aspirin treatment night time Diastolic BP. 
 
Figure 33. Effect of aspirin on night time diastolic blood pressure (mmHg)  of smokers 
and non smokers. 
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Mean (non-smokers) =61+63+65+67+69+71+72+75+76= 619/9 = 68.77 
Mean (Smokers) =68+70+71+73+75+77+79+81+83/9  = 677/9 =75.22 
  
Standard deviation calculation 
Find the deviation of each number from the mean, 
For non-smokers                                                                   For smokers 
61-60.33= 0.67                                                                         68-75.22= -7.22                                                                                           
63-60.33=2.67                                                                          70-75.22= -5.22 
65-60.33=4.67                                                                           71-75.22= -4.22 
67-60.33= 6.67                                                                          73-75.22= -2.22 
69-60.33= 8.67                                                                          75-75.22= -0.22 
71-60.33= 10.67                                                                         77-75.22=1.78 
72-60.33= 11.67                                                                         79-75.22=3.78 
75-60.33= 14.67                                                                          81-75.22= 5.78    
76-60.33= 15.67                                                                          83-75.22=7.78 
For non-smokers 
Square each of the deviations, which amplifies large deviations and makes negative values 
positive, 
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0.449, 7.129, 21.809, 44.489, 75.169, 113.849, 136.189, 215.209, 245.549 
Find the mean of those squared deviations 
=0.449+7.129+21.809+44.489+75.169+113.849+215.209+245.549/9 
=859.84/9 =95.537 
Take the non-negative square root of the quotient (converting squared units back to regular 
units) 
=√9.774 =9.774 So, the standard deviation of the set is 9.774 
For smokers 
Square each of the deviations, which amplifies large deviations and makes negative values 
positive 
52.128, 27.248, 17.808, 4.928, 0.0484, 3.168, 14.288, 33.408, 60.528 
Find the mean of those squared deviations, 
=52.128+27.248+17.808+4.928+0.0484+3.168+14.288+33.408+60.528/9 
=213.553/9 = 23.728 
 Take the non-negative square root of the quotient (converting squared units back to 
regular units), 
=√23.728 = 4.871  So, the standard deviation of the set is 4.87 
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6.14. Comparison between the groups of patients treated with aspirin (75mg/day) and 
the placebo controls (no aspirin) 
Table 22. Comparison between the groups of patients treated with aspirin (75mg/day) and 
the placebo controls (no aspirin). 
 
For all the groups shown there were 9 values determined. The statistical comparisons 
between groups were made using the Mann Whitney U test. 
The data shown in table above are the actual mean values recorded for all the 
patient groups using the constant 24 hour monitoring device. If the values in each of the 
Group 
Blood pressure in 
day/night period 
Smokers 
Mean ±SD 
mmHg 
Non-Smokers 
Mean ±SD 
mmHg 
 Aspirin                   No Aspirin Aspirin               No Aspirin 
Day time systolic 
BP 
121±13                        134±14 107±11                    125±12 
Day time diastolic 
BP 
85.6±7.8                         84±8.7 79.55±5.25            70.8±4.35 
Night time systolic 
BP 
133.8±10.9                   123±18 125±8.2                   111±9.7 
Night time 
diastolic  
BP 
75.22±4.8                   76.55±7.8 
 
  ( n=9)                            (n=9) 
60.3±9.7                  68.4±4.7 
 
   (n=9)                         (n=9) 
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individual columns are examined the mean blood pressure both systolic and diastolic are 
shown for the day and night periods.  
If this figures are closely examined  it may for  the reader be surprising that none of 
the values show blood pressure readings which are normally classed as being hypertensive. 
This is because the patients in all groups were receiving effective antihypertensive 
therapy and this study was focused on determining if the addition of aspirin had a further 
beneficial effect on blood pressure reduction.  
6.15. Experimental tests used during analysis  
Experimental tests used Comparing the mean systolic and diastolic pressure 
measurements, the mean daytime systolic and diastolic blood pressure measurements as 
mentioned in Table 22 were significantly higher for the smokers. The rise in blood 
pressure is a clear indication that smoking causes the elevation of blood pressure. There 
was also a clear indication of controlling blood pressure by aspirin. It has also been noted 
that the use of aspirin during nighttime as far more effective than daytime.  
Multivariate analysis - is based on the statistical principle of multivariate 
statistics, which involves observation and analysis of more than one statistical variable at a 
time. In design and analysis, the technique is used to perform studies across multiple 
dimensions while taking into account the effects of all variables on the responses of 
interest. (Chernoff et al., 1954) 
The variables that presented a significant difference in the univariate analysis between the 
groups of smokers and non-smokers were used in the multivariate analysis.  
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Univariate analysis - the ABPM parameters were expressed as minimum, 
maximum, median, mean and standard deviation values. Univariate analysis was 
conducted using the smoking variable for the groups that used and did not use aspirin. The 
data with a statistical significance of p less than 0.05 (p < 0.05) were selected. 
 Mean systolic and diastolic blood pressure measurements, the mean daytime 
systolic and diastolic blood pressure measurements (as mentioned in above graphs) were 
significantly higher for the smokers which have been shown in above given data. The 
rising in blood pressure is clear indication that smoking causes the rising in blood pressure. 
There was also clear indication of controlling of blood pressure by aspirin. It has also been 
note that use of aspirin during night time is far effective then day time. What real 
mechanism is involve in this is not clear but assumption is this that during day time body's 
almost all function are active and may be effective absorption of aspirin is reduced due to 
complex activities during day time. In resting condition during night time, many activities 
of body may ceased or slow down, and when we take aspirin in resting condition we are 
stimulating only active absorption of aspirin to blood. 
The mean daytime systolic and diastolic blood pressure measurement was 
significantly higher for the smokers and the smokers which don‟t use aspirin.    
 In the group of patients that did not use aspirin, the daytime diastolic blood 
pressure load was significantly higher (p = 0.0107) in the smokers. Similarly in the group 
of patients that did not use aspirin, the day time systolic blood pressure load was 
significantly higher (p< 0.0001) in the smokers. 
Mean daytime systolic and diastolic blood pressures were both significantly higher 
in the smokers. Mean 24-hour systolic blood pressure readings were significantly higher in 
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the smokers; Blood pressure loads were consistently and significantly higher in the 
smokers. 
The non-smoker which already has blood pressure, it has been observed in that 
group a great reduction in blood pressure as result of use of aspirin. 
 The smokers which did not have symptoms of blood pressure before smoking, 
they have blood pressure as result of regular smoking, their blood pressure has been 
controlled effectively after use of aspirin. 
Summary of findings. 
i) mean daytime systolic and diastolic pressures were both significantly higher in  
smokers 
ii) mean 24 hour  
iii) blood pressure loads 
iv) the non smoker group who already suffered from blood pressure showed a great 
reduction in blood pressure as a result of the use of aspirin 
v) the smoker group which did not have symptoms of blood pressure before 
smoking developed blood pressure as a result of regular smoking but their blood pressure 
was controlled effectively after the use of aspirin. 
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6.16 Discussion. 
For diagnostic purposes as well as therapeutic and prognostic evaluation 
monitoring 24hrs blood pressure, ABPM analysis is powerful tool. Mean systolic and 
diastolic blood pressure measurements are essential data for this study. The variables that 
are more closely related to cardiovascular events such as acute myocardial infarction and 
encephalic stroke were the mean night time systolic blood pressure followed by the mean 
24-hour systolic blood pressure and the mean daytime blood pressure measurements (See 
Table 23). 
Table 23. Division of the group into non-smokers and smokers with placebo or aspirin 
treatment. 
 
The results (Table 22) showing that the mean daytime systolic and diastolic blood 
pressure measurements were significantly higher in smokers, particularly, systolic blood 
pressure were found to be higher in night time as compare to diastolic blood pressure. 
It is a known fact that smoking one cigarette increases the heart rate by 14% and 
blood pressure by 6%. This reaction is probably caused by the increased plasma 
concentrations of adrenaline and noradrenaline while smoking (Yugar etal., 2002). 
  Group 1 with aspirin 
                                      
Group without aspirin 
A non-smokers                120                     83 
 B smokers                 35                     39 
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Norepinephrine levels progressively increase within a 12.5 minute period and peak 
after 15 minutes before returning towards initial levels after a further 30 minutes. This 
alteration causes a maximum blood pressure increase which although it reduces towards 
the previous level after 30 minutes, the level does remain higher than the values registered 
before smoking (Barua et al., 2002). 
 This may result in a „staircase effect‟ when cigarettes are smoked in quick 
succession. These effects are not irreversible however as it has been recorded that in 
patients during the first week after they had quit smoking that there a significant decrease 
in these variables. These patients also demonstrated a significant decrease in the plasma 
and urinary levels of norepinephrine and epinephrine after one week of not smoking 
(Mikkelsen et al., 1997). 
The effects of smoking are obviously complex. A previous reported study 
evaluated in ten normotensive smokers who smoked one cigarette every fifteen minutes 
during an hour and demonstrated that blood pressure and heart rate increased immediately 
after smoking the first cigarette and remained at that level while the other three cigarettes 
were smoked. This of course is not a classical „staircase effect‟ but rather some complex 
process of elevation of a level which is then maintained.  The initial blood pressure 
increase was approximately 12 mmHg for the systolic reading and 15 mmHg for the 
diastolic reading. The pressure effect caused by smoking decreased during an hour 
demonstrated that blood pressure changes caused by smoking probably is affected due to 
an unknown compensatory mechanism. In this same study, six other normotensive 
smokers smoked one cigarette every thirty minutes during eight hours and once again there 
was an increase in blood pressure and heart rate soon after smoking the first cigarette and 
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they remained elevated during the entire period of exposure to tobacco. The greatest blood 
pressure variations for both groups occurred while they smoked (Whincup et al., 1995). 
Chronically, nicotine diminishes the sensitivity of baroreceptors which are neural 
receptors located in both the aortic arch and carotid sinuses. They detect the systolic blood 
pressure and if the pressure is too high, as is the effect of circulating catecholamines, this 
causes these receptors cause the vasomotor centre to be stimulated which brings about the 
vasodilatation in both arterioles and veins causing a fall in the overall pulse pressure. 
There is also an increased parasympathetic activity and a decrease in the 
cardioacceleratory centre which both reduce the heart rate and so effectively lower the 
systemic blood pressure. The baroreceptors are an example of a short term blood pressure 
regulation mechanism. Baroreceptors detect the amount of stretch of the blood vessel 
walls, and so act as mechanoreceptors sending their signals to the central nervous system 
in response to this stretch. Baroreceptor sensitivity and stimulation also increases the 
production of thromboxane A2, a powerful vasoconstrictor. This increase in TxA2 
production has been detected, not directly because of its very short half life but rather by 
measuring the levels of thromboxane B2, the metabolite of TxA2, which have been found 
in hypertensive smokers
.
 It has also been demonstrated that smoking increases angiotensin 
II production (Berecek  et al., 1982) the potent vasoconstrictor effect of which is widely 
documented. In contrast to the stimulation of vasoconstriction, nicotine inhibits the 
synthesis of endothelin, an extremely potent vasoconstrictor which is a potential beneficial 
effect on the cardiovascular system. Paradoxically, nicotine also inhibits the production of 
nitrous oxide by endothelial cells which acts as a local vasodilator, which could add to the 
vasoconstrictor response. This last effect is very curious as the reduction of nitrous oxide is 
not specifically related to the number of cigarettes smoked.  
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Contrary to the results of the study in which normotensive patients, monitored by 
ABPM, were submitted to the effects of nicotine smokers, did not have the same effects on 
the cardiovascular system.  
The smokers presented lower mean day time systolic BP and diastolic BP mean 
readings. It has been suggested that this outcome is caused by an adaptive effect in the 
sympathetic nervous system after numerous years of exposure to nicotine. They also report 
that smokers are less affected by "white coat" hypertension and confirm that the chronic 
stimulation by nicotine and its metabolites eliminate the power of any other stimuli to 
provoke further reaction. The authors emphasize that smoking also helps to reduce stress, 
which could be associated with the lowering of blood pressure. (Lida et al., 2006) 
 For smokers their mean night time diastolic blood pressure did not present a 
significant difference between the groups in relation to smoking, as seen previously in 
other studies with both normotensive
 
and hypertensive patients.  
However, the mean night time systolic blood pressure was significantly higher in 
the smokers that did not use aspirin. It is believed that the acute pressure effect caused by 
smoking does not exist during the night when most individuals are sleeping and therefore 
justifies the similar blood pressure measurements of smokers and non-smokers. For both 
normotensive aspirin taking patients and those who were hypertensive, the physiological 
blood pressure trend has a circadian rhythm, which reaches lower levels when the person is 
sleeping and returns to higher levels when the person wakes up. 
Most of the ambulatory devices, including those used in this study, register night 
time hours as the period between 11p.m. and 7 a.m.. This obviously this could lead to 
inaccurate results for any patients that do not strictly abide by these hours for going to 
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sleep and waking up. There is a device called the „Timepiece‟ which is just a concept at 
the moment –it is called Escape Clock and features a black finish and big red digits. When 
you want to go back to sleep for a while, simply give it a good hit with your fist. 
Figure 34. The timepiece – which is just a concept at the moment – is called Escape Clock 
and features a black finish and big red digits (website. 2008) 
                                             
  
Encouraging the patients to use the sleep/activity button could result in more 
accurate data for hours of sleep. However, we have observed that some patients become 
confused when they have to adjust the device distorting the registers. Sleep quality could 
interfere in the physiological decrease and this information should also be recorded on the 
test report. 
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The most interesting and evident fact of this study is that blood pressure levels for 
smokers increase during the day. If we continue to exclusively use simple in-office blood 
pressure measurements for smokers it is possible that regular evaluations could be made 
that do not reflect the actual systemic blood pressure and inadequately estimate the 
homodynamic effect of target organ lesions. Some theories try to explain the 
epidemiological findings of blood pressure levels in smokers that are less than or equal to 
the casual blood pressure measurement. The theory with the highest acceptance rate is that 
there is a reduction of the acute effect which has been caused by smoking due to tobacco 
abstinence for a few minutes or hours before the office measurement. Another attempt to 
explain this phenomenon is that the prolonged and chronic use of tobacco increases heart 
rate that would lead to a decrease in left ventricular end-systolic volume and consequently 
lower blood pressure. The use of ABPM exclusively during the daytime can be a valid 
consideration of future studies for both diagnostic purposes and the assessment of aspirin 
in smokers. 
An alternative to ABPM for smokers could be the repetitive in-home blood 
pressure measurements taken over a period of a few days using validated equipment. This 
method has been recommended, since it helps in treatment adherence and is superior to the 
casual measurements taken at the doctor's office in regard to target organ lesions. In 
comparison to both the in-office measurements and the in-home blood pressure 
measurements the ABPM offers a greater number of readings, better reproducibility and 
data storage in the unit's memory chip. However, a greater number of more economical 
units need to be validated and specific diaries should be created for these patients to 
perhaps understand the data which they collect. A series of in-home readings recording the 
times of cigarette smoking can be useful for these patients, avoiding interpretations based 
on unreal situations like a programmed abstinence from smoking. 
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All hypertensive patients are advised to quit smoking as a control measure for 
cardiovascular risk factors. This advice is part of the non-medicinal hypertension treatment 
that is being incorporated which also includes a low sodium diet, moderate alcohol 
consumption, weight loss and periodic physical activity. 
Short-term longitudinal studies using ABPM to evaluate patients that have quit 
smoking reveal that the blood pressure measurements of these patients are substantially 
lower than when they were smoking. These observations suggest a possible 
aetiopathogenic link between the effect of smoking and hypertension. Prospective studies 
with long-term follow-up and the control of variables such as weight gain may be able to 
confirm and quantify this effect. 
It appears that the smoking population is a special group in which ABPM is the 
most adequate method for blood pressure assessment, avoiding the isolated measurement 
at the doctor's office, a procedure which could incorrectly diagnose hypertensive patients 
or under medicate patients using aspirin, the ABPM is a reallu useful technique to 
eliminate changes on a minute by minute to those over a 24 hour cycle and so provided 
evidence for a much better rational basis of treatment.  
6.17 Valid Conclusion for future studies 
It should be stressed that the mean daytime systolic and diastolic blood pressure 
readings were consistently higher in the smokers when compared to non-smokers. The low 
dose aspirin was effective treatment in controlling blood pressure of smokers for sysytloic 
in the daytime and diastolic in the nighttime. So, perhaps instead of using the more 
conventional and perhaps more expensive treatment using antihypertensive drugs aspirin 
could have a central role in the therapy of hypertension. 
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Chapter 7 
General conclusions 
 Bringing together the conclusions of the individual studies within this thesis, 
highlights the following key points:- 
 Passive smoking results in a measurable absorption by non smokers perhaps 
indicating the potential hazards of this process. Any absorbed nicotine has to be both 
metabolised and excreted in both smokers and non smokers and the level of nicotine in the 
body reflects the abilities of these two systems. This has been considered in chapter 4. 
 It is considered that aspirin should be introduced as early as possible into a 
hypertensives‟ treatment so as to prevent the onset of CHD. This has been considered in 
chapter 5. 
 Aspirin lowers the systolic daytime BP and diastolic night time BP of smokers and 
this is a really interesting finding and is considered at length in Chapter 6. 
However, this investigation proved to be both challenging and interesting for a 
number of reasons. The first challenge was the scale and the diverse nature of the world 
literature on hypertension. It was major challenge to „ get to grips‟ with the wealth of detail 
which was available. But after a comprehensive reading of the literature it could be clearly 
established that cardiovascular disease and hypertension in particular is not limited to any 
one country and there were problems with its treatment.. For example in 2003 the WHO 
considered in the WHO/ISH Hypertension guidelines that:  
Hypertension is already a highly prevalent cardiovascular risk factor worldwide because of 
increasing longevity and prevalence of contributing factors such as obesity. Whereas the 
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treatment of hypertension has been shown to prevent cardiovascular diseases and to extend 
and enhance life, hypertension remains inadequately managed everywhere. (my italics) 
Furthermore two other the findings from the literature were that smokers had twice as high 
a mortality than non smoking hypertensives and that intensive blood pressure treatment was 
beneficial to all but the smoking hypertensives ( Lund-Johassen, 2003). This provides a clear focus 
for this thesis to try and develop a better strategy for drug treatment of this sub group of 
hypertensives. So the strategy for the thesis had clear and obvious aims and objectives which have 
been achieved.  
Another complicating factor is that most studies on hypertension have been carried 
out in North America and Europe and the results extrapolated to the rest of the world. 
When this is considered for Kuwait then there are many differences illustrated by different 
– genetics, diet, physical activity, and the use of medical guidelines. 
A further complicating factor is of course the cigarettes which are available in 
Kuwait are similar to those elsewhere in the world and it is interesting to note that:  
The nicotine content in several major brands is reportedly on the rise. Harvard University 
and the Massachusetts Health Department revealed that between 1997 and 2005 the amount of 
nicotine in Camel, Newport, and Doral cigarettes may have increased by as much as 11 percent.   
The American brands Marlboro, Kool, Camel and Kent own roughly 70% of the global 
cigarette market.  
30 Fascinating Cigarette Smoking Facts- http://listverse.com/2009/01/11/30-
fascinating-cigarette-smoking-facts/ 
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The unexpected findings that aspirin showed a hypotensive effect in hypertensives 
is of great interest. In a publication the atypical response of hypertensives who smoked 
was briefly described as: 
 „ the results of the smoking cohort are puzzling in many respects and some are not 
easy to explain. (Lund-Johansen, 2003) 
These hypertensives failed to respond to normal antihypertensive therapy and were 
resistant to the conventional therapy:  
The new subanalysis showed that the incidences of death and cardiovascular events per 
1000 patient-years were much higher in the aggressive treatment groups. When the two 
treatment goal groups (intensive versus less intensive) were compared, the relative risk 
(RR)was increased in the most intensively treated group for total death, cardiovascular 
death, sudden death, major cardiovascular diseases, and stroke (RR of 2.03, 2.67, 2.93, 
1.74 and 2.44, respectively).  The baseline characteristics in the different treatment 
groups were super imposable. 
This makes the effects of aspirin look even more interesting as the drug can hardly 
be classed as „aggressive‟ and was more active in the less severe forms of hypertension 
which suggests that as for conventional therapy the aspirin cannot modify whatever 
„centre‟ is responsible for the increased mortality of the severe hypertensives who smoke. 
One possible explanation is suggested in the paper: 
It is well established that smoking induces pathological alterations in the thrombogenic 
mechanism, and that fibrinogen increases, platelet adhesiveness is increased and 
fibrinolysis is impaired. Interestingly, some of the same type of  abnormalities are seen 
in hypertensive patients. Thus, the combination of hypertension and smoking could be 
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particularly harmful for the high pressure compartment vessels, making them more 
sensitive to reductions in perfusion pressure than in subjects with just moderate 
hypertension. 
 
From the audit data presented in Appendix 1 it is clear that Kuwait uses a 
considerable quantity of aspirin in its hospital dispensaries. The strength of the 
tablets establishes that it not for analgesic doses but rather for its anti-thrombotic 
effects. Perhaps the use of aspirin could be extended due to the evidence from this 
study. This would of course necessitate the study of aspirin in hypertensives who 
do not smoke but that could be done by someone else as a useful project.  
 
Future studies 
Future studies could be undertaken to develop the findings made in the individual 
studies of this thesis and produce useful and interesting data to extend them. 
1. extend the prophylactic use of aspirin in hypertensives who are non-smokers 
2. target recently diagnosed hypertensives both smokers and non-smokers and 
monitor them using ambulatory methods to plot the development of their 
hypertension. 
3. study the effect of aspirin in women as well as men 
4. determine the exact levels of nicotine in the cigarettes commonly sold in Kuwait 
to establish their relative risk to the smoking population 
5. try and introduce the NICE guidelines for the cessation of smoking so as to 
reduce one of the risk factors in the hypertensive patient which may reduce 
thrombotic events 
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Future clinical pharmacy developments (Appendix 4) which may impact on the 
role of clinical pharmacy in the treatment of hypertension in the State of Kuwait, 
could consider these as a course of action. 
 
The study contained a limitation which should also be mentioned. 
 The culture of Kuwait does not allow contact between a male and a female who are 
not related and so inclusion of women in this study was not therefore possible. This is 
unfortunate as the effect of aspirin in women would be a very interesting aspect to study to 
see if the effect was male gender specific or not. 
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Appendix 1 
Reported effects of tobacco products in both men and women (Placezek et al., 2004). 
Disease Consequences Conclusion  
Cancers   
Bladder cancer "Smoking cause of bladder cancer."  
"The evidence is sufficient to infer 
a causal relationship between 
smoking and bladder cancer." 
Cervical cancer "Smoking increase cervical cancer." 
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and cervical cancer." 
Esophageal cancer "Smoking cause esophageal cancer."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and cancers of the 
esophagus." 
Kidney cancer 
"Smoking is factor in the development of 
kidney cancer."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and renal cell, and renal 
pelvis cancers." 
Laryngeal cancer 
"Smoking is cause cancer of the lung, larynx, 
oral cavity, and esophagus.'' 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and cancer of the larynx." 
Leukemia 
"Leukemia has recently been implicated as a 
smoking-related disease."  
 
"The evidence is sufficient to infer 
a causal relationship between 
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Disease Consequences Conclusion  
smoking and acute myeloid 
leukemia." 
Lung cancer "Smoking causes lung cancer."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and lung 
 
 
 
Oral cancer 
 
 
 
"Smoking cause oral cancers."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and cancers of the oral 
cavity and pharynx." 
Pancreatic cancer 
"Smoking reduces the risk of pancreatic 
cancer, compared with continued smoking."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and pancreatic cancer." 
Stomach cancer 
"Data on smoking and cancer of the stomach 
are unclear."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and gastric cancers." 
Cardiovascular diseases   
Abdominal aortic 
aneurysm 
"Death more common in cigarette smokers."  
"The evidence is sufficient to infer 
a causal relationship between 
smoking and abdominal aortic 
aneurysm." 
 
Atherosclerosis 
 
"Smoking the most common factor to 
atherosclerotic peripheral vascular disease."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and subclinical 
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Disease Consequences Conclusion  
atherosclerosis." 
Cerebrovascular 
disease 
"Smoking is a major cause of cerebrovascular 
disease (stroke)."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and stroke." 
Coronary heart 
disease 
"Smoking is cause coronary heart disease." 
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and coronary heart 
disease." 
Respiratory diseases   
Chronic obstructive 
pulmonary disease 
"Smoking is the most important of the causes 
of chronic bronchitis."  
"The evidence is sufficient to infer 
a causal relationship between active 
smoking and chronic obstructive 
pulmonary disease morbidity and 
mortality." 
Pneumonia 
"Smoking cessation reduces rates of 
respiratory symptoms such as cough, sputum 
production, and wheezing, and respiratory 
infections such as bronchitis and pneumonia, 
compared with continued smoking."  
 
"The evidence is sufficient to infer 
a causal relationship between 
smoking and acute respiratory 
illnesses, including pneumonia, in 
persons without underlying 
smoking-related chronic obstructive 
lung disease." 
Respiratory effects in 
utero 
"In utero exposure to maternal smoking is 
associated with reduced lung function among 
infants.'' 
 
"The evidence is sufficient to infer 
a causal relationship between 
maternal smoking during pregnancy 
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Disease Consequences Conclusion  
and a reduction of lung function in 
infants." 
Respiratory effects in 
childhood and 
adolescence 
"Cigarette smoking during childhood and 
adolescence produces significant health 
problems among young people, including 
cough and phlegm production, an increased 
number and severity of respiratory illnesses, 
decreased physical fitness, an unfavorable lipid 
profile, and potential retardation in the rate of 
lung growth and the level of maximum lung 
function.'' 
 
"The evidence is sufficient to infer 
a causal relationship between active 
smoking and impaired lung growth 
during childhood and adolescence." 
"The evidence is sufficient to infer 
a causal relationship between active 
smoking and the early onset of lung 
function decline during late 
adolescence and early adulthood. 
The evidence is sufficient to infer a 
causal relationship between active 
smoking and respiratory symptoms 
in children and adolescents, 
including coughing, phlegm, 
wheezing, and dyspnea. The 
evidence is sufficient to infer a 
causal relationship between active 
smoking and asthma-related 
symptoms (i.e., wheezing)." 
Respiratory effects in 
adulthood 
"Cigarette smoking accelerates the age-related 
decline in lung function that occurs among 
never smokers. With sustained abstinence from 
smoking, the rate of decline in pulmonary 
function among former smokers returns to that 
of never smokers."  
 
 
"The evidence is sufficient to infer 
a causal relationship between active 
smoking in adulthood and a 
premature onset of and an 
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Disease Consequences Conclusion  
accelerated age-related decline in 
lung function." 
"The evidence is sufficient to infer 
a causal relationship between 
sustained cessation from smoking 
and a return of the rate of decline in 
pulmonary function to that of 
persons who had never smoked." 
Other respiratory 
effects 
"Smoking cessation reduces rates of 
respiratory symptoms such as cough, sputum 
production, and wheezing, and respiratory 
infections such as bronchitis and pneumonia, 
compared with continued smoking."  
 
 
"The evidence is sufficient to infer 
a causal relationship between active 
smoking and all major respiratory 
symptoms among adults, including 
coughing, phlegm, wheezing, and 
dyspnea." 
"The evidence is sufficient to infer 
a causal relationship between active 
smoking and poor asthma control." 
  
Other Diseases   
Reproductive 
effects 
  
Fetal death and 
stillbirths 
"The risk for prenatal mortality both stillbirth 
and neonatal deaths and the risk for sudden 
infant death syndrome (SIDS) are increased 
among the offspring of women who smoke 
"The evidence is sufficient to infer a causal 
relationship between sudden infant death 
syndrome and maternal smoking during 
and after pregnancy." 
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Other Diseases   
during pregnancy."  
Fertility 
"Smoke has increased risks for conception delay 
and for both primary and secondary infertility."  
"The evidence is sufficient to infer a causal 
relationship between smoking and reduced 
fertility in women." 
 
 
Low birth weight 
 
 
"Smoke during pregnancy has a lower average 
birth weight."  
 
 
"The evidence is sufficient to infer a causal 
relationship between maternal active 
smoking and fetal growth restriction and 
low birth weight." 
Pregnancy 
complications 
"Smoking during pregnancy is associated with 
increased risks for preterm premature rupture of 
membranes, abruptio placentae, and placenta 
previa, and with a modest increase in risk for 
preterm delivery."  
 
"The evidence is sufficient to infer a casual 
relationship between maternal active 
smoking and premature rupture of the 
membranes, placenta previa, and placental 
abruption." 
"The evidence is sufficient to infer a causal 
relationship between maternal active 
smoking and preterm delivery and 
shortened gestation." 
Other effects   
Cataract 
"Women who smoke have an increased risk for 
cataract.'' 
"The evidence is sufficient to infer a causal 
relationship between smoking and nuclear 
cataract." 
Diminished health 
status/morbidity 
"Relationships between smoking and cough or 
phlegm are strong and consistent; they have 
been amply documented and are judged to be 
causal.'' 
 
"The evidence is sufficient to infer a causal 
relationship between smoking and 
diminished health status that may be 
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Other Diseases   
"Consideration of evidence from many different 
studies has led to the conclusion that cigarette 
smoking is the overwhelmingly most important 
cause of cough, sputum, chronic bronchitis, and 
mucus hyper secretion."  
manifest as increased absenteeism from 
work and increased use of medical care 
services." 
"The evidence is sufficient to infer a causal 
relationship between smoking and 
increased risks for adverse surgical 
outcomes related to wound healing and 
respiratory complications." 
Hip fractures 
"Women who currently smoke have an 
increased risk for hip fracture."  
"The evidence is sufficient to infer a causal 
relationship between smoking and hip 
fractures." 
 
 
 
Low bone density 
 
 
"Postmenopausal women who currently smoke 
have lower bone density than do women who do 
not smoke."  
 
 
 
"In postmenopausal women, the evidence 
is sufficient to infer a causal relationship 
between smoking and low bone density." 
Peptic ulcer 
disease 
 
"The relationship between cigarette smoking 
and death rates from peptic ulcer, especially 
gastric ulcer, is confirmed. In addition, 
morbidity data suggest a similar relationship 
exists with the prevalence of reported disease 
from this cause."  
"The evidence is sufficient to infer a causal 
relationship between smoking and peptic 
ulcer disease in persons who are 
helicobacter pylori positive." 
 
Appendix 2 
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Instructions for patients on how to take low dose aspirin are shown by the following 
examples  
For example, „briefly mention and you can take aspirin to help you during a heart attack. 
After you call 911 or other emergency services, chew 1 adult-strength aspirin (325 mg) if you 
are not allergic to aspirin and if there is no other reason that you can't take aspirin. Aspirin 
slows blood clotting, so a blood clot that is causing the heart attack stays smaller.‟  
„You may also take low-dose aspirin (81 mg) every day to help lower the risk of a heart 
attack or stroke.  
Low-dose aspirin may be used:‟ 
After a heart attack, to prevent another one.  
By people who have coronary artery disease.  
By people with stable angina.  
By people with unstable angina.  
After bypass surgery or angioplasty.  
By people who have had a stroke and or transient ischemic attack (TIA).  
After surgery to prevent a stroke (carotid endarterectomy).  
By healthy men over age 40 who have one or more risk factors for heart disease, as 
long as their blood pressure is controlled and the benefits of aspirin are greater than the risks. 
By healthy women over age 65, or women under 65 who have one or more risk factors for 
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heart disease as long as their blood pressure is controlled and the benefits of aspirin are 
greater than the risks.  
If you have atrial fibrillation and cannot take or choose not to take warfarin, you may 
take an adult-strength aspirin (325 mg) every day to help lower the risk of a stroke.  
Aspirin protects you from having a clot-related stroke in the same way it protects you 
from having a heart attack.  
Aspirin slows the blood's clotting action by reducing the clumping of platelets. 
Platelets are cells that clump together and help to form blood clots. Aspirin keeps platelets 
from clumping together, thus helping to prevent or reduce blood clots. 
During a heart attack, blood clots form in an already-narrowed artery and block the 
flow of oxygen-rich blood to the heart muscle (or to part of the brain, in the case of stroke). 
When taken during a heart attack, aspirin slows clotting and decreases the size of the forming 
blood clot. Taken daily, aspirin's anti-clotting action helps prevent a first or second heart 
attack. 
Aspirin should not be taken if you think you are having a stroke, because not all 
strokes are Aspirin should not be taken by people who are at risk for or who have had a 
hemorrhagic stroke, which is a type of stroke that is not caused by a blood clot but rather by 
bleeding into and around the brain. Aspirin can trigger asthma attacks in some people who 
have sensitivity to it. Also, don't take aspirin without first talking to your doctor if you're 
already taking prescribed blood thinners, such as Coumadin. The combined effect could 
cause bleeding problems.  
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Aspirin should not be taken with many prescription and over-the-counter drugs, 
vitamins, herbal remedies, and supplements. So, before you start aspirin therapy, talk to your 
doctor about all the drugs and other remedies you take. Because aspirin reduce your blood's 
ability to clot, your doctor may want you to stop taking aspirin at least 5 days before any 
surgery or dental procedure that may cause bleeding. Do not suddenly stop taking aspirin 
without talking to your doctor first. Talking to your doctor first is especially important if you 
have had a stent placed in a coronary artery.  
Tell your doctor if you notice that you bruise easily, have bloody or black stools, or 
have prolonged bleeding from cuts or scrapes. 
Although nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and 
naproxen, relieve pain and inflammation much like aspirin does, they do not affect blood 
clotting in the same way that aspirin does. Do not substitute NSAIDs for aspirin because they 
will not decrease your risk of another heart attack.  
So, information is available to patient from many sources to give them an insight as to 
how aspirin should be taken and its possible consequences. 
Finally here is a comment about what patients should do if they have take analgesics as 
well as aspirin. 
 If both aspirin and a pain reliever every day have been used, doctor's suggestion about 
what pain reliever should take must be considered. If we take uncoated aspirin and ibuprofen 
at the same time, the aspirin may not work as well to prevent a heart attack. We may be able 
to use acetaminophen instead of ibuprofen to treat our pain. But if ibuprofen is our only 
option, avoid taking it during the 8 hours before and the 30 minutes after our aspirin dose. 
For example, we can take ibuprofen 30 minutes after our aspirin dose. If we take ibuprofen 
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once in a while, it does not seem to cause problems. Experts do not know if NSAIDs other 
than ibuprofen interfere with uncoated aspirin. Also, experts do not know if people who take 
a daily coated aspirin should be concerned about ibuprofen or other NSAIDs interacting with 
the aspirin (Thomas et al., 2006). 
 
 
. 
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Appendix 3 
An audit of drugs used to treat hypertension and other cardiovascular diseases 
Objective: 
To audit the current use of aspirin and a range of categories of cardiovascular drugs in the 
state of Kuwait hospitals in order to contribute to the clinical pharmacy developments of the 
country 
Background 
 Data has been obtained from the centralized official records of the pharmaceutical 
supply system of Kuwait for the period January 2007 – January 2011. Written permission to 
both obtain and use this data was granted by Dr Omar A. Al-Sayed Omar Assistant 
Undersecretary for Drugs and Medical Supplies Affairs. A copy of this official permission is 
shown in Appendix 4. 
Methodology 
This data was examined for the quantities of aspirin tablets of 100mg strength which 
had been used in this time period and the quantities of this drug were compared with other 
drugs used for a variety of conditions for both anticoagulation and cardiovascular conditions. 
Results 
The current use of aspirin in the state of Kuwait hospitals in comparison to other anti-
platelet drugs. 
The first group to be studied was to compare low dose aspirin usage against the 
widely used standard treatment for an extension of blood clots in those patients who have an 
increased risk of blood coagulation, namely warfarin. The relative quantities are shown in 
Figure A with the actual data being shown in Table A.  It can be seen that the total use is in 
millions of tablets – approximately 18 million warfarin tablets have been used in this four 
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year period  as compared with aspirin where 131 536 400 tablets were used. This means that 
7.2 times more aspirin has been used than all strengths of warfarin combined. This may 
reflect the actual prophylaxtic use of aspirin as against the use in warfarin in proven greater 
risk – for example in atrial fibrillation or to inhibit the extension of a clot which has already 
formed. |It could be argued the use of aspirin may have prevented the problems of blood clots 
otherwise the use of warfarin would have been even greater. 
  
265 
 
  
Figure A. The comparative use of 100mg aspirin as compared against three 
formulations of warfarin – 1, 2 and 5mg tablets during the time period 2007-2011.  The 
actual figures are shown in the table A below. 
Medical Group: anticoagulation 
 
 
Table A -Actual numbers of tablets dispensed by the central medical stores in the time 
period January  2007 – January  2011 for three strengths as warfarin – 1, 2 and 5mg 
and the 100mg strength of aspirin. 
 
 
 
 
 
 
The 
Basic Description  Unit Quantity 
Subclass: Anti Coagulants warfarin   
WARFARIN  1MG TAB 5 540 500 
WARFARIN  2MG TAB 7 148 100 
WARFARIN  5MG TAB 5 448 500 
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next comparison which was made was between two other drugs used to modify platelet 
function so as to decrease the potential of platelet activation and subsequent clot formation.  
The drugs in this class were clopidogrel 75mg (Plavix) and dipyridamole 75mg 
(Persantin). From Figure B and table B it can be seen that the use of both these agents are 
orders of magnitude less than that for aspirin. They are often prescribed for patients who have 
an aspirin allergy or are intolerant of aspirin which usually means that the gastric irritation is 
too serious to warrant further use of the drug.  
Figure B. The comparative use of 100mg aspirin against two well established drugs 
clopidogrel and dipyridamole, both of 75mg strength, during the time period 2007-2011. The 
actual figures are shown in table B below. 
 
Table B. Actual numbers of tablets dispensed by the central medical stores in the time period 
January 2007 – January 2011 for clopidogrel and dipyridamole and the 100mg strength of 
aspirin. 
 
 
 
 
 
 
Subclass: Anti platelet 
ACETYL SALICYLIC ACID 100MG TAB 131 536 400 
CLOPIDOGREL 75MG(PLAVIX) TAB 6 577 788 
DIPYRIDAMOLE (PERSANTIN) 
75MG 
TAB 7 740 200 
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The figures suggest that 9.2 times more aspirin has been used that the other anti-
platelet drugs. This would suggest that the aspirin is not used in simple combination with the 
other two drugs but rather as the primary treatment for conditions in which platelets are 
involved and in which it exert a prophylactic effect. 
 
The comparative use of aspirin compared to a range of other cardiovascular drugs . 
Digoxin 
The first comparison is the use of aspirin against formulations of digoxin (Figure C 
and Table C). This is rather a difficult comparison to make as the drug is used for its positive 
inotropic effects and reduce conductivity within the atrioventricular node rather than an 
antiplatelet effect and the drug is usually used for controlling the ventricular response in 
persistent and permanent atrial fibrillation rather than a specific effect on platelets. However 
atrial fibrillation is known to stimulate platelets to be pro-coagulant which is one of the 
reasons that warfarin is used in this condition to prevent the occurrence of emboli forming 
which may lead to vascular occlusions causing myocardial infarctions and  stroke. 
Interestingly, the use of warfarin is greater than for the use of digoxin showing that the 
warafrin is used for other conditions rather than potential atrial fibrillation which is treated by 
digoxin. The data shown below provides the relative usage of this drug and shows its use to 
be small, as would perhaps be expected for a drug which has therapeutic limitations due to its 
narrow therapeutic index. 
 
 
Figure C. The comparative use of three strengths of digoxin, 0.0625, 0.0125 and 0.25mg   as 
compared with the use of 100mg aspirin tablets both of 75mg strength, during the time period 
2007-2011. The actual figures of usage are shown in the table below. 
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Table C. The three strengths of Lanoxin which are used in the hospital services in Kuwait 
and 
their 
numb
er in 
the 
period Jan 2007 – Jan 2011. 
 
 
 
 
 
 
Diuretics 
 
Diuretics used in the treatment of Hypertension 
Subclass: Positive inotropic drugs 
LANOXIN 0.0625MG (DIGOXIN) TAB 1 268 900 
LANOXIN 0.0125 (DIGOXIN) TAB 2 491 500 
LANOXIN 0.25MG (DIGOXIN) TAB 1 829 600 
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In the treatment of cardiovascular disease, especially hypertension, the use of 
diuretics is in most guidelines of the world as the first line in therapeutic treatments after an 
increase in exercise and restrictions of salt intake and abolition of smoking. The most 
frequent drug of choice in most of the international guidelines is to use bendroflumethazide 
2.5 mg. 
 The data shown in Figure D and Table D below do not feature this drug at all. The 
four major drugs actually dispensed during the period 2007 – 2011 were in terms of their rank 
order and the quantities used were:  
Furosemide (Lasix) 21 047 600,  
Indapamide SR (Natrilix), 13 202 010, 
 Amiloride + hydrochlorothiazide (Moduretic) 7 011 760   
 Spironolactone, 6 544 500 
This rank order is perhaps surprising, as the commonest was a high ceiling diuretic, 
namely furosemide which is usually added to existing therapy of hypertension to achieve 
better control with those who prove to have „resistant hypertension‟ rather than a first line 
drug. It is true, that the drug is also used for hypertensives that also have impaired renal 
function or heart failure but the numbers of patients in this group will be limited in any 
national group of essential hypertensives.  
Indapamide is chemically related to the diuretic chlortalidone and is claimed to lower 
blood pressure especially in diabetic subjects where it causes less metabolic disturbance. This 
is a very useful function and perhaps may reflect the problem mentioned in earlier sections 
that many causes of hypertension in Kuwait are present in patients who also have diabetes. 
This may explain perhaps its popularity. 
The use of the combination of amiloride and hydrochorothiazide is interesting since it helps 
compliance to have the two drugs in one preparation and of course. The conservation of 
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potassium is facilitated by this combination but one dangerous problem is that when this drug 
is used in combination with ACE inhibitors of angiotensin II receptor antagonists it may 
cause severe hyperkaleamia 
The extensive use of spironolactone is perhaps surprising. In the UK the guidelines 
for the use of this drug are limited to the treatment of oedema and ascites in liver cirrhosis in 
addition to malignant ascites, nephrotic syndrome, congestive heart failure and primary 
hyperaldosteronism. In the UK its use is restricted because of a suggested risk of one of the 
metabolic products of the drug being a potential carcinogen. This has only been proved in 
rodents and its risk in man in unknown. In the elderly it can cause hyperkalaemia to occur 
which of course can cause serious cardiac problems. There is also the problem that it 
potentiates the effects of thiazide and loop diuretics by antagonising the effect of aldosterone 
and so acts as a potassium sparing diuretic. Low doses of spironolactone are also used in the 
treatment of severe heart failure which again is a very restricted group of this large 
utilization. 
 
 
 
 
 
Figure D. The comparative use of a range of diuretics during the time period 2007-2011. The 
actual figures of usage are shown in Table D below. 
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Table D. The diuretics and their respective strengths which were used in the hospital services 
in Kuwait and the total number dispensed in the period Jan 2007 – Jan 2011. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subclass: Diuretics  
BUMETANIDE (BURINEX) 1 MG TAB 117 964 
BUMETANIDE + POT. CHLORIDE 
(BURINEX K) 
TAB 26 356 
CHLOROTHIAZIDE (SALURIC) 
500MG 
TAB 164 400 
CHLOROTHIAZIDE (HYGROTON) 
50MG 
TAB 668 260 
FRUSEMIDE 40MG (LASIX) TAB 21 047 600 
FRUSEMIDE 500MG (LASIX) TAB 335 364 
HYDROCHLOROTHIAZIDE 
(ESIDREX) 25MG 
TAB 506 820 
INDAPAMIDE(NATRILIX) SR TAB 13 202 010 
MODURETIC TAB 7 011 760 
SPIRONOLACTONE 
(ALDACTONE) 100MG 
TAB 19 450 
SPIRONOLACTONE 
(ALDACTONE) 25MG 
TAB 6 544 500 
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Anti Arrhythmic Drugs  
The treatment of cardiac arrhymias is both complex and difficult. It first of all 
requires a very accurate diagnosis of the type of arrhythmia and to do this usually requires 
some form of ECG analysis. The arrhythmia can be due some times to heart failure and so 
this requires treatment in addition to the arrhythmia which makes overall treatment complex.  
The commonest drug in this classification used for this purpose was Telmisartan 
(Micardis) 40mg, 4 626 636. This was followed by Moxonidine (Physiotens) 0.2mg Tablets, 
3 427 636. This was followed by Bisoprolol 5mg 1 383 810 and then Amiodarone 200mg, 1 
331 250. 
If the drugs are examined in the official data for this group some interesting 
observations can be made.  
Some of these drugs in this listing are not usually included in a group labeled „Anti 
Arrhythmic Drugs‟ (Figure E and Table E). 
For example, Telmisartan is an angiotensin II receptor antagonist and is usually used 
for the treatment of hypertension. It can be used for the treatment of heart failure or diabetic 
nephropathy but not as an anti Arrhythmic Drug. 
Another unusual drug to include is monoxidine. This drug is usually classed as a 
centrally acting antihypertensive which in the UK is licensed for use in mild to moderate 
essential hypertension and has a useful role when thiazides, calcium channel blockers, ACE 
inhibitors and beta blockers have not controlled the blood pressure or are simply 
inappropriate.  
Bisoprolol can be used for the treatment of hypertension, angina, as an adjunct to 
severe heart failure but not as an anti Arrhythmic Drug. In Table Ethere are two beta blockers 
which can be used as anti arrhythmic drugs. These drugs do belong in this classification as 
there are anti arrhythmic drugs because they can attenuate the effects of stimulation of the 
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sympathetic nerves to the heart by a combination of reducing conductivity and automaticity 
within the cardiac tissues.  
Finally there is Amiodarone which is a drug which is clearly used for arrhythmias. 
According to the current BNF, (March 2010) it can be used for all forms of arrhythmias 
including paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation 
and flutter, and ventricular fibrillation. The formulation given in Table E is the oral form and 
this has a very long half life and the attainment of a steady state plasma concentration may 
require several weeks or even months.   
Some of the other drugs in the list are clearly used as anti arrhythmic drugs.  
Flecainide – this drug is usually reserved for the treatment of serious symptomatic 
ventricular arrhythmias. It belongs to the same class as lidocaine and can also be used for the 
treatment of what is termed „junctional re-entry tachycardia‟ and for paroxysmal atrial 
fibrillation. Sometimes it has the unwanted effect of actually causing arrhythmias to occur. 
Propanfenone - can slow atrial flutter and can be used along with beta blocker, 
diltiazem, or verapamil. It can be used in a prophylactic way and also as a form of treatment 
for ventricular arrhythmias and for some forms of supraventricular arrhythmias. It does have 
as well some beta blocking properties which make it useful for such a treatment. 
 
 
 Figure E. The frequency of use of drugs, over the period Jan 2007 – Jan 2011, which were 
classified on the central computer of the medical stores as anti - arrhythmic drugs. 
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Table E. The anti arrhythmic drugs and their respective strengths which were used in the 
hospital services in Kuwait and the total number dispensed in the period Jan 2007 – Jan 2011. 
 
AMIODARONE HCL (CORDARON) 
200MG 
TAB 1 331 250 
BISOPROLOL FUMARATE (CONCOR) 
5MG 
TAB 1 383 810 
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Beta adrenoceptor blocking drugs 
In cardiovascular medicine the use of beta blockers has saved an untold number of lives and 
it is clear from the data provided by the central medicine stores that Kuwait uses a range of 
these drugs in considerable quantities. This is not unsurprising and unlike the table for „anti-
arrhythmic drugs‟ the vast majority of those included in the list are beta blockers (Figure F 
and Table F). 
Figure F. The frequency of use of beta blocking drugs, over the period January 2007-January 
2011, which were classified on the central computer of the medical stores as beta blockers. 
 
BISOPROLOL FUMARATE (CONCOR) 
10MG 
TAB 550 680 
FLECAINIDE ACET. 100MG 
(TAMBOCOR) 
TAB 447 060 
MOXONIDINE (PHYSIOTENS) 0.2MG TAB 3 427 636 
MOXONIDINE (PHYSIOTENS) 0.4MG TAB 576 184 
PROPAFENONE (RYTMONORM) 150MG TAB 173 850 
PROPAFENONE (RYTMONORM) 300MG TAB 42 450 
QUINIDINE BISULPHATE (KINIDIN) TAB 2 000 
SOTALOL 40MG TAB 1 540 
TELMISARTAN (MICARDIS) 40MG TAB 4 626 636 
TRIMETAZIDINE D1 HCL 20MG 
(VASTAREL) 
TAB 180 
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Table F. The frequency of use of beta blocking drugs, over the period Jan 2007 – Jan 2011, 
which were classified on the central computer of the medical stores as beta adrenoceptor 
blocking drugs.  
 
Subclass: Beta Adrenoceptor Blocking Drugs 
ATENOLOL (TENORMIN) 100MG TAB 18 770 900 
ATENOLOL (TENORMIN) 50MG TAB 40 080 300 
BOSENTAN 125MG (TRACLEER)* TAB 39 872 
BOSENTAN 62.5MG (TRACLEER) TAB 17 304 
CARVEDILOL (DILATREND) 
25MG 
TAB 2 294 460 
CARVEDILOL (DILATREND) 
6.25MG 
TAB 3 368 820 
LABETALOL HCL (TRANDATE) 
100MG 
TAB 488 300 
LABETALOL HCL (TRANDATE) 
200MG 
TAB 1 292 800 
METOPROLOL TARTRATE 
(LOPRESOR) 100MG 
TAB 2 613 680 
METOPROLOL TARTRATE 
(LOPRESOR) 50MG 
TAB 15 813 120 
NADOLOL (CORGARD) 80 MG TAB 5 544 
PROPRANOLOL 10MG (INDERAL) TAB 10 594 000 
PROPRANOLOL 40MG (INDERAL) TAB 2 948 000 
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Key *Bosentan 
– is not a beta 
blocker but 
rather a 
vasodilator antihypertensive drug 
 
The beta blocker which seems to be used above all others is atenolol whether alone or in 
combination with the diuretic chlortalidone. In fact 84 078 200 tablets were dispensed in the 
period Jan 2007 – Jan 2011 for a population is about 2 million. Of the other beta blockers the 
most commonly used was metoprolol – approximately 17 million tablets - which because of 
its relatively cardioselective action has merits over the other non selective beta blockers of 
which propranolol was the next most commonly used. The combined preparations of 
propranolol amounted to 13.5 million tablets. 
It is impossible from the collective data to know exactly what percentage of the total 
was used for different conditions. However the combined use for antihypertensive effects, 
anti-anginal effects as well as for its anti-arrhythmic effects is a substantial number of tablets 
and yet still does reach the total for the aspirin tablets taken which was 131 536 400. This 
may indicate that since the aspirin was once a day the majority of sufferers of these 
PROPRANOLOL LA (INDERAL 
LA) 160MG 
CAP 350 
PROPRANOLOL LA (INDERAL 
LA) 80MG 
CAP 3 878 
SOTALOL 160MG TAB 2 452 
SOTALOL 80MG TAB 497 252 
TENORETIC ( Atenolol 
+chlortalidone)  
TAB 25 228 000 
VISKALDEX (Pindolol + clopamide) TAB 27 840 
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cardiovascular diseases received aspirin in addition to their antihypertensive, and all the other 
therapies for cardiovascular disease. 
 
Drugs affecting the renin-angiotensin system - either as ACE inhibitors or as 
angiotensin receptor antagonists. 
 
 This well used and understood group of drugs is well documented in the data which 
was available (Figure G and Table G). Some are of an earlier date of introduction with 
limitations to effective half life in contrast to the later introductions. From the data the most 
frequently used ACE inhibitor captopril – 100 million doses in total – which is one of the 
older group of agents. Of all the other drugs lisinopril is the next most commonly used drug. 
It is interesting to note that the angiotensin receptor antagonist valsartan was dispensed for 18 
million tablets. This perhaps was due to the problems of persistent cough or intolerance to an 
ACE inhibitor. Some of these doses would have been taken along with aspirin if the risk 
factors in hypertension were such as to merit its use.  
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Figure G. The frequency of use of ACE inhibitors or as angiotensin receptor antagonists, 
over the period Jan 2007 – Jan 2011, which were classified on the central computer of the 
medical stores as rennin –angiotensin drugs. 
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Table G. The frequency of use of renin-angiotensin drugs, over the period Jan 2007 – Jan 
2011, which were classified on the central computer of the medical stores as drug affecting 
renin – angiotensin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Affecting the Renin-angiotensin  
CANDESARTAN (ATACAND) 
8MG ** 
TAB 5 889 400 
CAPTOPRIL (CAPOTEN) 25MG* TAB 59 240 200 
CAPTOPRIL (CAPOTEN) 50MG* TAB 39 282 000 
CILAZAPRIL (INHIBACE) 2.5MG* TAB 522 340 
LISINOPRIL (ZESTRIL) 10MG* TAB 16 216 844 
LISINOPRIL (ZESTRIL) 20MG* TAB 13 952 512 
LISINOPRIL (ZESTRIL) 5MG* TAB 11 468 184 
PERINDOPRIL (COVERSYL) 
4MG* 
TAB 3 027 810 
VALSARTAN (DIOVAN ) 160MG 
** 
TAB 1 425 760 
VALSARTAN (DIOVAN ) 80MG ** CAP 17 404 520 
ZESTORETIC 20MG *** TAB 11 121 152 
 
Key * ACE inhibitor  ** Angiotensin receptor antagonist  ***ACE 
inhibitor plus hydrochlorothiazide 
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Vasodilator drugs 
 
Drugs in this class are usually based on some form of „nitrate‟ from the simple 
glyceryl trinitrate structure to the more complex isosorbide structure. They have a major role 
in the treatment of anginas as they are potent coronary vasodilators. Their major function 
seems to be to reduce venous return which as a consequence reduces left ventricular work 
and so reduces the oxygen demand of the heart. This allows blood flow which may be 
compromised by atherosclerotic vessels to be able to allow the heart to receive sufficient 
blood flow for its needs. 
 
Glyceryl trinitrate 
 
Isosorbide
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The range order of use for the nitrate derivatives was Glyceryl trinitrate at 29 733 000 
was greater than isosorbide 10mg (19 002 000) followed by 40mg (9 284 250) and 60mg 
(5 560 800) of isosorbide. Both drugs are used sublingually where the gylceryl trinitrate 
achieves a quicker effect than the isosorbide although the later has a longer duration of action 
(Figure H and Table H). 
 
Figure H. The frequency of use of vasodilatory drugs, over the period Jan 2007 – Jan 2011, 
which were classified on the central computer of the medical stores as vasodilators as 
compared with the use of low dose aspirin tablets. 
 
 
 
 
 
 
Table H. The frequency of use of vasodilatory drugs, over the period Jan 2007 – Jan 2011, 
which were classified on the central computer of the medical stores as drug affecting renin – 
angiotensin. 
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Trimetazidine is an anti-anginal agent which is currently unlicensed in UK, so perhaps a few 
words about this drug may be useful. 
Marzilli stated in 2001: It has been recently demonstrated that trimetazidine, known 
for years to be an effective antianginal agent, shifts cardiac energy metabolism from fatty 
acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl 
coenzyme A thiolase. By decreasing fatty acid oxidation, trimetazidine stimulates glucose 
utilization, restoring coupling between glycolysis and carbohydrate oxidation and leading to 
adenosine triphosphate production with lesser oxygen consumption. The antianginal 
properties of this agent are independent of haemodynamic changes, and dramatically improve 
recovery of mechanical function after ischaemia. Several studies have tested the efficacy of 
trimetazidine and have demonstrated this agent to be at least as effective as and better 
Subclass: Nitrates  
GLYCERYL TRINITRATE  0.5MG TAB 29 733 000 
ISOSORBIDE DINITRATE 
(ISORDIL) 10MG 
TAB 19 002 000 
ISOSORBIDE DINITRATE 
(ISORDIL) 40MG 
TAB 9 284 250 
ISOSORBIDE DINITRATE 
(ISORDIL) 5MG 
TAB 81 000 
ISOSORBIDE MONONITRAE 
(IMDUR) 60MG 
TAB 5 560 800 
TRIMETAZIDINE 35MG 
(VASTAREL MR) 
TAB 12 480 540 
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tolerated than haemodynamic agents. In stable effort angina, trimetazidine improves exercise 
tolerance and elevates the ischaemic threshold to an extent comparable with beta-blockers 
and calcium channel blockers. The combination of trimetazidine and a beta-blocker appears 
more effective than the combination of nitrates and a beta-blocker, and the addition of 
trimetazidine improves symptoms in patients resistant to diltiazem (Marzilli et al.
 
, 2001). 
 
 
Sympathomimetics 
 
Etilefrine is an α-agonist agent with a potent vasoconstrictor effect, which is 
potentially useful in preventing vasovagal syncope by reducing venous pooling and/or by 
counteracting reflex arteriolar vasodilatation. This drug is not licensed for use in the UK. 
A study carried out by Raviele et al., in 1999 perhaps shows why the product was not 
licensed in the UK. They stated that: 
The main finding of the VASIS trial is the lack of superiority of etilefrine over placebo 
in preventing spontaneous syncopal recurrence. Indeed, the 63 patients treated with 
etilefrine at the dosage of 25 mg 3 times a day showed exactly the same recurrence rate 
during the first year following enrolment as did the 63 patients treated with placebo 
(24%). Furthermore, the time to the first syncope after the start of treatment, as well as 
the incidence and the number of presyncopal episodes, were not significantly different 
between the 2 study groups.   
 
 
Figure I. The frequency of use of Etilefrine, over the period Jan 2007 – Jan 2011, as 
compared to aspirin usage over the same time period. 
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Table I. The number of tablets of Etilefrine against the use of aspirin for the period Jan 2007 
– Jan 2011. 
 
 
 
 
 
Anti Fibrinolytic Drugs and Haemostatic 
ETILEFRINE HYDROCHLORIDE 
(EFFORTIL) 
TAB 104 560 
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These drugs both affect problems in the cardiovascular system. The number of drugs 
in this class is very small, namely two – tranexamic acid and etamsylate (Figure J and Table 
J). 
Tranexamic acid is an inhibitor of fibrinolysis brought about by plasmin. It is 
generally considered to be a plasmingogen inhibitor. Its uses usually limited to bleeding 
associated with excessive fibrinolysis as classically seen in operations on the prostate gland, 
operations on the urinary bladder and in some individuals after dental extractions who suffer 
haemophilia. It is also used in the management of menorrhagia and for epistaxis. Because of 
these selective uses it would not be expected to be used in any condition where platelets 
would be directly involved with fibrinolysis. The relative use is only 0.48% that of the 
aspirin. 
 
Etamsylate. This drug again has very uses for specific cardiovascular conditions but 
have some involvement with platelets. It acts as a haemostatic agent and is said to reduce 
capillary bleeding in the presence of a normal number of platelets. It does not require the 
mechanisms of fibrin stabilisation but may act via correcting normal platelet adherence. 
There is some controversy as to whether the drug is modified in the presence of aspirin but 
they seem to work by very different mechanisms. 
 
Figure J. The frequency of use an anti fibrinolytic drug and a haemostatic over the period 
Jan 2007 – Jan 2011, as compared to aspirin usage over the same time period. 
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Table J. The number of tablets of anti fibrinolytic drug and haemostatics against the use of 
aspirin for the period Jan 2007 – Jan 2011. 
 
 
 
 
 
 
 
Lipid lowering drugs 
 
The final group of drugs for which data is available is collectively known as the lipid 
lowering drugs. These drugs have a history behind them as they were developed over many 
years and so it is no surprise to find seven different types listed. See Figure 46 for the full 
display of all the drugs found in the data (Figure K and Table K). 
 
Subclass: Anti Fibrinolytic Drugs and Haemostatics  
ETAMSYLATE 500MG 
(DICYNONE) 
TAB 271 060 
TRANEXAMIC ACID 
(CYCLOKAPRON) 500MG 
TAB 575 880 
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As perhaps may be expected in 2011 the most commonly used drug turned out to be 
one of the statins, and that it was Atorvastatin is also no surprise as this is the biggest selling 
„lipid lowering drug‟ in the world in 2011. If the drug is treated as a single entity, although 
two different strengths were used then over 65 million doses were used in the period Jan 2007 
– Jan 2011. The fibrates as a group then followed, namely Bezafibrate, Fenofibrate and 
Gemfibrozil. In terms of numbers of usage they were collectively even greater than for the 
statins. 
Figure K. The frequency of use Lipid lowering drugs over the period Jan 2007 – Jan 2011, as 
compared to aspirin usage over the same time period. 
 
 
Table K. The number of tablets of lipid lowering drugs against the use of aspirin for the 
period Jan 2007 – Jan 2011. 
 
Subclass: Lipid Lowering Drugs 
ATORVASTATIN  10MG 
(LIPITOR) 
TAB 28 389 990 
ATORVASTATIN  20MG TAB 42 031 710 
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The important finding in the graph is that when the dose of Atorvastatin is increased 
from 10mg to 20 mg, its effectiveness in „dissolving the lipids‟ which are deposited within 
the arterial walls may enhance and so the passage of flow of blood increases. Simvastatin is 
least effective among these selected agents of this sub class and this shown by it limited use.  
 
 
 
Conclusions 
In conclusion, the data for drug consumption allows us to see that aspirin is very 
widely used, perhaps it is the most commonly prescribed drug of any in the entire formulary 
of Kuwait. Its widespread use would suggest all prescribers are aware of its very useful 
(LIPITOR) 
BEZAFIBRATE  200MG (BEZALIP) TAB 23 367 350 
FENOFIBRATE 100MG 
(LIPANTHYL) 
CAP 28 113 200 
GEMFIBROZIL 600MG (LOPID) TAB 3 053 460 
OMEGA-3 FISH OIL CAP 3 419 110 
SIMVASTATIN (ZOCOR) 20MG TAB 14 258 356 
SIMVASTATIN (ZOCOR) 40MG TAB 1 661 760 
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potential to decrease the risk of stroke in those who have elevated risk factors, including 
those people who smoke or who used to smoke. 
It is hoped this analysis will facilitate the new directions which are planned for the 
Pharmacy in Kuwait.  
 
 
 
 
 
 
 
 
